SIRP1A and CD40L-based chimeric proteins

A chimeric protein combining CD172a and CD40L domains enhances tumor immunotherapy by blocking immunosuppressive signals and stimulating immune activation, addressing the limitations of current cancer treatments by improving efficacy and safety.

JP2024544972AInactive Publication Date: 2024-12-05SHATTUCK LABS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024527845
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-08-11
Filing Date
2022-11-11
Publication Date
2024-12-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current cancer immunotherapy treatments, such as those targeting checkpoint molecules like CTLA-4 and PD-1/L1, have limited efficacy in a small percentage of patients and are hindered by side effects, necessitating improved dosing strategies that account for individual patient factors and tumor characteristics.

Method used

Development of a chimeric protein comprising the extracellular domain of CD172a (SIRPα) linked to the extracellular domain of CD40L through a hinge-CH2-CH3 Fc domain, which blocks immunosuppressive signals and stimulates immune activation, enhancing tumor cell phagocytosis and adaptive immune responses.

Benefits of technology

The chimeric protein effectively increases immune cell populations and cytokine levels in the tumor microenvironment, leading to enhanced antitumor activity and improved treatment outcomes by simultaneously blocking inhibitory and stimulating signals, overcoming limitations of monotherapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544972000001_ABST
    Figure 2024544972000001_ABST
Patent Text Reader

Abstract

The present disclosure relates, in part, to compositions and methods comprising chimeric proteins that can be used in the treatment of diseases, such as in the immunotherapy of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present technology relates in particular to compositions and methods comprising chimeric proteins for use in the treatment of diseases, such as in the immunotherapy of cancer, including doses, dosing regimens comprising biphasic administration, or dosing regimens comprising three cycles.

[0002] Priority This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 278,567, filed November 12, 2021, and U.S. Provisional Application No. 63 / 371,083, filed August 11, 2022, the contents of each of which are incorporated by reference in their entirety herein.

[0003] Sequence Listing This application contains a Sequence Listing that has been submitted in XML format via EFS-Web. The contents of the XML copy entitled "SHK-055PC_116981-5055_Sequence_Listing", created on November 9, 2022, is 82,547 bytes in size, and is hereby incorporated by reference in its entirety. [Background technology]

[0004] The field of cancer immunotherapy has grown exponentially in the last few years. This has been driven primarily by the clinical efficacy of antibodies targeting the family of checkpoint molecules (e.g., CTLA-4 and PD-1 / L1) in many tumor types. However, despite this success, only a small number of patients (10–45% for a variety of solid tumors) demonstrate clinical responses to these agents as monotherapy, and these treatments are hampered by side effects.

[0005] Rational dose selection and optimization of dosing regimens are clinically important and are prerequisites for increasing patient compliance and obtaining maximum clinical benefit. Development of dosing regimens usually relies on pharmacokinetic / pharmacodynamic studies performed in animal models. However, because immunotherapy is expected to exploit tumor immunity rather than exerting a direct antiproliferative effect on cancer cells, some animal studies generally use mouse surrogates and pharmacokinetic / pharmacodynamic studies are not available. In addition, physicians may change the dosing regimen of immunotherapy based on the immunogenicity, disease stage, and physical condition of the patient's tumor. Thus, new strategies for dosing and regimen development are needed. Summary of the Invention

[0006] Thus, in various aspects, the present disclosure provides compositions and methods useful for developing strategies for developing doses and administration regimens for cancer immunotherapy.The present disclosure is based in part on the discovery that CD80+ cells, CD8+ cells, granzyme B+ cells, CD68+ cells, Ki67+ cells, and PD-L1+ immune cells are increased in the tumor microenvironment (TME) after administration of SIRPα-Fc-CD40L chimeric protein, that B cells and / or CD40+ cells migrate from peripheral blood within hours after administration and return to peripheral blood within days, and that after administration of SIRPα-Fc-CD40L chimeric protein, the levels of certain serum cytokines increase within hours after administration and decrease within days.

[0007] One aspect of the disclosure is a method of treating cancer in a human subject. In an embodiment, the method includes (i) administering to the human subject a first dose of a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L). In an embodiment, a background level of cells in a pre-administration biological sample taken from the subject prior to administration of the first dose is measured, and the marker is selected from one or more of CD80+ cells, CD8+ cells, Granzyme B+ cells, CD68+ cells, Ki67+ cells, and PD-L1+ immune cells. In some embodiments, the method further comprises administering a second dose of the chimeric protein to the human subject when the level of the cells after administration is higher than the background level of the cells. In some embodiments, the second dose is administered at least about 48 hours after the administration of the first dose. In some embodiments, the biological sample is a biopsy or a surgical specimen. In some embodiments, the biological sample is a tumor biopsy or a tumor surgical specimen. In some embodiments, the level of the cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescent activated cell sorting (FACS), or a combination thereof.

[0008] One aspect of the disclosure is a method of treating cancer in a human subject. In an embodiment, the method comprises (i) administering to the human subject a first dose of a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L). In an embodiment, the background level and / or activity of B cells and / or CD40+ cells in a first biological sample taken from the subject prior to administration of the first dose is measured. In an embodiment, the level and / or activity of B cells and / or CD40+ cells N hours after administration is measured in a second biological sample taken from the subject after administration of the first dose. In some embodiments, N is a number between 1 and 24. In some embodiments, the level and / or activity of B cells and / or CD40+ cells N hours after administration is lower than background level and / or activity of B cells and / or CD40+ cells. In some embodiments, the level and / or activity of B cells and / or CD40+ cells M days after administration is measured in a third biological sample taken from the subject after administration of the first dose. In some embodiments, M is a number between 1 and 28. In some embodiments, the method further comprises (ii) administering to the human subject a second dose of the chimeric protein if the level and / or activity of B cells and / or CD40+ cells M days after administration is at least about 50% higher than the level and / or activity of B cells and / or CD40+ cells N hours after administration. In some embodiments, the second dose is administered at least about 48 hours after administration of the first dose. In some embodiments, the first biological sample, the second biological sample, and the third biological sample are blood.In one embodiment, the level and / or activity of B cells and / or CD40+ cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

[0009] One aspect of the disclosure is a method of treating cancer in a human subject. In an embodiment, the method comprises (i) administering to the human subject a first dose of a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L). In an embodiment, the background amount and / or activity of a cytokine selected from CCL2, CXCL9, CXCL10, IFNα, IL15, IL23, IL-12, MCP-1, MIP-1β, MIP-1α, and MDC is measured in a first biological sample obtained from the subject prior to administration of the first dose. In some embodiments, the amount and / or activity of the cytokine is measured N hours later in a second biological sample taken from the subject after administration of the first dose. In some embodiments, N is a number between 1 and 24. In some embodiments, the amount and / or activity of the cytokine N hours after administration is higher than the background amount and / or activity of the cytokine. In some embodiments, the amount and / or activity of the cytokine is measured M days later in a third biological sample taken from the subject after administration of the first dose. In some embodiments, M is a number between 1 and 28. In some embodiments, the method further comprises (ii) administering a second dose of the chimeric protein to the human subject if the amount and / or activity of the cytokine M days after administration is at least about 30% lower than the amount and / or activity of the cytokine N hours after administration. In some embodiments, the second dose is administered at least about 48 hours after administration of the first dose. In some embodiments, the first biological sample, the second biological sample, and the third biological sample are blood. In certain embodiments, the amount and / or activity of cytokines is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

[0010] One aspect of the present disclosure is a method for evaluating the efficacy of a cancer treatment in a subject suffering from cancer and in need of the cancer treatment. In an embodiment, the method includes (i) obtaining a biological sample taken from a subject receiving a first dose of a chimeric protein. In an embodiment, the chimeric protein has a general structure of N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L). In an embodiment, the background level and / or activity of cells in the biological sample taken from the subject prior to administration of the first dose is measured. In some embodiments, the cells are selected from one or more of CD80+ cells, CD8+ cells, Granzyme B+ cells, CD68+ cells, Ki67+ cells, and PD-L1+ immune cells. In some embodiments, the method further comprises (ii) measuring the post-administration level and / or activity of the cells in the biological sample. In some embodiments, the method further comprises (iii) determining that the chimeric protein is efficacious if the post-administration level and / or activity of the cells is higher than the background level and / or activity of the cells. In some embodiments, the biological sample is a tumor biopsy or tumor surgical specimen. In some embodiments, the level and / or activity of the cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

[0011] One aspect of the present disclosure is a method for selecting a subject for a cancer treatment. In an embodiment, the method includes (i) obtaining a biological sample from a subject receiving a first dose of a chimeric protein. In an embodiment, the chimeric protein has a general structure of N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L). In an embodiment, the background level and / or activity of cells in the biological sample from the subject prior to administration of the first dose is measured. In some embodiments, the cells are selected from one or more of CD80+ cells, CD8+ cells, Granzyme B+ cells, CD68+ cells, Ki67+ cells, and PD-L1+ immune cells. In some embodiments, the method further comprises (ii) measuring the post-administration level and / or activity of the cells in the biological sample. In some embodiments, the method further comprises (iii) selecting the subject for treatment with the chimeric protein if the post-administration level and / or activity of the cells is higher than the background level and / or activity of the cells. In some embodiments, the biological sample is a tumor biopsy or tumor surgical specimen. In some embodiments, the level and / or activity of the cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

[0012] One aspect of the present disclosure is a method for evaluating the efficacy of a cancer treatment in a subject suffering from cancer and in need of the cancer treatment. In an embodiment, the method includes (i) obtaining a first biological sample taken from a subject receiving a first dose of a chimeric protein. In an embodiment, the chimeric protein has a general structure of N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L). In an embodiment, the method further includes measuring the background level and / or activity of B cells and / or CD40+ cells in the first biological sample. In some embodiments, the method further comprises (iii) obtaining a second biological sample from the subject N hours after the administration, where N is a number between 1 and 24. In some embodiments, the method further comprises measuring the level and / or activity of B cells and / or CD40+ cells in the second biological sample N hours after the administration. In some embodiments, the method further comprises (iv) obtaining a third biological sample from the subject M days after the administration, where M is a number between 1 and 28. In some embodiments, the method further comprises measuring the level and / or activity of B cells and / or CD40+ cells in the third biological sample M days after the administration. In one embodiment, the method further includes (v) determining that the chimeric protein is effective if the level and / or activity of B cells and / or CD40+ cells N hours after administration is lower than the background level and / or activity of B cells and / or CD40+ cells and / or if the level and / or activity of B cells and / or CD40+ cells M days after administration is at least about 50% higher than the level and / or activity of B cells and / or CD40+ cells N hours after administration. In one embodiment, the first biological sample, the second biological sample, and the third biological sample are blood.In one embodiment, the level and / or activity of B cells and / or CD40+ cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

[0013] One aspect of the present disclosure is a method for selecting a subject for treatment with a cancer therapy. In an embodiment, the method includes (i) obtaining a first biological sample from a subject receiving a first dose of a chimeric protein. In an embodiment, the chimeric protein has a general structure of N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L). In an embodiment, the method further includes measuring background levels and / or activity of B cells and / or CD40+ cells in the first biological sample. In an embodiment, the method further includes (iii) obtaining a second biological sample from the subject N hours after administration, where N is a number between 1 and 24. In some embodiments, the method further comprises measuring the level and / or activity of B cells and / or CD40+ cells in the second biological sample N hours after administration. In some embodiments, the method further comprises (iv) obtaining a third biological sample from the subject M days after administration, where M is a number between 1 and 28. In some embodiments, the method further comprises measuring the level and / or activity of B cells and / or CD40+ cells in the third biological sample M days after administration. In some embodiments, the method further comprises (v) selecting the subject for treatment with the chimeric protein if the level and / or activity of B cells and / or CD40+ cells N hours after administration is lower than background level and / or activity of B cells and / or CD40+ cells and / or if the level and / or activity of B cells and / or CD40+ cells M days after administration is at least about 50% higher than the level and / or activity of B cells and / or CD40+ cells N hours after administration. In certain embodiments, the first biological sample, the second biological sample, and the third biological sample are blood.In one embodiment, the level and / or activity of B cells and / or CD40+ cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

[0014] One aspect of the present disclosure is a method for evaluating the efficacy of a cancer treatment in a subject suffering from cancer and in need of the cancer treatment. In an embodiment, the method includes (i) obtaining a first biological sample taken from a subject receiving a first dose of a chimeric protein. In an embodiment, the chimeric protein has a general structure of N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L). In an embodiment, the method further includes (ii) measuring the background amount and / or activity of a cytokine in the first biological sample. In some embodiments, the cytokine is selected from CCL2, CXCL9, CXCL10, IFNα, IL15, IL23, IL-12, MCP-1, MIP-1β, MIP-1α, and MDC. In some embodiments, the method further comprises (iii) obtaining a second biological sample from the subject N hours after administration, where N is a number between 1 and 24. In some embodiments, the method further comprises measuring the amount and / or activity of the cytokine in the second biological sample N hours after administration. In some embodiments, the method further comprises (iv) obtaining a third biological sample from the subject M days after administration, where M is a number between 1 and 28. In some embodiments, the method further comprises measuring the amount and / or activity of the cytokine in the third biological sample M days after administration. In one embodiment, the method further includes (v) determining that the chimeric protein is effective if the amount and / or activity of the cytokine N hours after administration is higher than the background amount and / or activity of the cytokine and / or if the amount and / or activity of the cytokine M days after administration is at least about 50% lower than the amount and / or activity of the cytokine N hours after administration. In one embodiment, the first biological sample, the second biological sample, and the third biological sample are blood.In certain embodiments, the amount and / or activity of cytokines is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

[0015] One aspect of the present disclosure is a method for selecting a subject for treatment with a cancer therapy. In an embodiment, the method includes (i) obtaining a first biological sample from a subject receiving a first dose of a chimeric protein. In an embodiment, the chimeric protein has a general structure of N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L). In an embodiment, the method further includes (ii) measuring the background amount and / or activity of a cytokine in the first biological sample. In some embodiments, the cytokine is selected from CCL2, CXCL9, CXCL10, IFNα, IL15, IL23, IL-12, MCP-1, MIP-1β, MIP-1α, and MDC. In some embodiments, the method further comprises (iii) obtaining a second biological sample from the subject N hours after administration, where N is a number between 1 and 24. In some embodiments, the method further comprises measuring the amount and / or activity of the cytokine in the second biological sample N hours after administration. In some embodiments, the method further comprises (iv) obtaining a third biological sample from the subject M days after administration, where M is a number between 1 and 28. In some embodiments, the method further comprises measuring the amount and / or activity of the cytokine in the third biological sample M days after administration. In one embodiment, the method further includes (v) selecting the subject for treatment with the chimeric protein if the amount and / or activity of the cytokine N hours after administration is higher than the background amount and / or activity of the cytokine and / or if the amount and / or activity of the cytokine M days after administration is at least about 50% lower than the amount and / or activity of the cytokine N hours after administration. In one embodiment, the first biological sample, the second biological sample, and the third biological sample are blood.In certain embodiments, the amount and / or activity of cytokines is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

[0016] In some embodiments, the first domain is capable of binding to a CD172a (SIRPα) ligand. In some embodiments, the first domain comprises substantially all of the extracellular domain of CD172a (SIRPα). In some embodiments, the first domain comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:57.

[0017] In some embodiments, the second domain is capable of binding to the CD40 receptor. In some embodiments, the second domain comprises substantially the entire extracellular domain of CD40L. In some embodiments, the second domain comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:58.

[0018] In certain embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from IgG4. In certain embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from human IgG4. In certain embodiments, the linker comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

[0019] In one embodiment, (a) the first domain comprises the amino acid sequence of SEQ ID NO:57, (b) the second domain comprises the amino acid sequence of SEQ ID NO:58, and (c) the linker comprises an amino acid sequence at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In one embodiment, the chimeric protein further comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:7. In one embodiment, the chimeric protein further comprises the amino acid sequences of SEQ ID NO:5 and SEQ ID NO:7.

[0020] In certain embodiments, the chimeric protein comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61.

[0021] In some embodiments, the first dose of the chimeric protein ranges from about 0.03 mg / kg to 10 mg / kg, hi some embodiments, the first dose is about 0.003, or about 0.01, or about 0.03, or about 0.1, or about 0.3, or about 1, or about 2, or about 3, or about 4, or about 6, or about 8, or about 10 mg / kg.

[0022] In an embodiment, the method of any aspect disclosed herein further comprises a second dose of chimeric protein. In an embodiment, the second dose is administered at least about 3 days, or at least about 4 days, or at least about 5 days, or at least about 6 days, or at least about 7 days, or at least about 8 days, or at least about 9 days, or at least about 10 days, or at least about 14 days, or at least about 21 days, or at least about 28 days after administration of the first dose. In an embodiment, the second dose of chimeric protein is in the range of about 0.03 mg / kg to 10 mg / kg. In an embodiment, the second dose is about 0.003, or about 0.01, or about 0.03, or about 0.1, or about 0.3, or about 1, or about 2, or about 3, or about 4, or about 6, or about 8, or about 10 mg / kg.

[0023] This patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [Brief description of the drawings]

[0024] [Figure 1] Schematic diagram of SIRPα-Fc-CD40L chimeric protein (SL-172154). SL-172154 (SIRPα-Fc-CD40L) is a hexameric bifunctional fusion protein consisting of SIRPα (which has a binding affinity for CD47 of 0.628 nM) linked via an Fc linker protein to CD40L (which has a binding affinity for CD40 of 4.74 nM). [Diagram 2] Dose escalation with modified toxicity probability interval (mTPI-2) design (N=15) is shown. Planned dose escalation is half-log escalation. At least 3 subjects were enrolled at successive dose levels (DL) and assessed for dose-limiting toxicity (DLT) during the first cycle of treatment. Subjects will receive SL-172154 intravenously (IV) according to Schedule 1 or Schedule 2 until disease progression, unacceptable toxicity, or withdrawal of consent. [Diagram 3]Tumor response and duration of treatment are shown. iUPD=unconfirmed progressive disease (iRECIST) NE=not evaluable, PD=progressive disease, SD=unchanged [Figure 4] Figure 1 shows reproducible increases in serum cytokines following repeated administration of SL-172154. Changes in levels of CCL2 (MCP-1) (A), CCL4 (MIP-1β) (B), CCL3 (MIP-1α) (C), and CCL22 (MDC) (D) are shown. [Figure 5A] 1 shows a dose-dependent and reproducible increase in serum IL-12. Subject levels of interleukin 12 (IL-12), a mediator of TH1 proinflammatory responses, over time are shown, which are representative of the cyclic effector cytokine responses observed in test subjects. [Figure 5B] 1 shows a dose-dependent and reproducible increase in serum IL-12. The median response upon the first infusion (horizontal bar) is shown and appears preliminarily to be dose-dependent. [Figure 6] Figure 1 shows that SL-172154 preferentially binds to CD47 on leukocytes but not RBCs. A shows CD47 receptor occupancy (RO) on both red blood cells (RBCs) and white blood cells (WBCs, white blood cells) assessed by fluorescence-activated cell sorting (FACS) analysis using whole blood. One hour post-infusion on cycle 1, day 1 (C1D1), the median CD47 RO on leukocytes (horizontal bar) is approximately 80%. B shows that CD47 RO on erythrocytes is less than 5% at all dose levels. [Figure 7A] Figure 1 shows that SL-172154 stimulates B cell bordering and activation in a dose-dependent manner. A dose-dependent increase in the median frequency of bordering cells is shown (horizontal bars). Receptor engagement is approximately 100% at all dose levels (data not shown). [Figure 7B] We show that SL-172154 stimulates B cell margination and activation in a dose-dependent manner, with median B cell frequencies returning to pre-infusion levels by the next infusion and maintaining a cyclical pattern of release and return with each infusion cycle. [Figure 7C]We show that SL-172154 stimulates B cell margination and activation in a dose-dependent manner, and that returning B cells show increased expression of the costimulatory marker CD86 and maturation marker CD95, suggesting that SL-172154 can induce phenotypic changes. [Figure 8A] Figure 1 shows distinct profiles of TNFα and interleukin-6 (IL-6) compared to CD40 mAb. Induction of TNFα with various doses of CP-870,893 (left panel) or SL-172154 (right panel) is shown. Data for CP-870,893 are taken from Vonderheide et al., J Clin Oncol 25:876-883 (2007). [Figure 8B] Figure 1 shows distinct profiles of TNFα and interleukin-6 (IL-6) compared to CD40 mAb. Induction of IL-6 with various doses of CP-870,893 (left panel) or SL-172154 (right panel) is shown. Data for CP-870,893 are taken from Vonderheide et al., J Clin Oncol 25:876-883 (2007). [Figure 9] Figure 1 shows that SL-172154 induces an innate immune response in the tumor microenvironment (TME). A, Immunohistochemistry analysis of biopsy samples from patient A before and after SL-172154 treatment. Monocytes were detected by staining for CD68, a protein highly expressed on monocytic cells. B, Upregulation of activation markers CD40 and MHC class II in the TME in tumor biopsies after treatment with SL-172154 compared to pre-treatment biopsies. [Figure 10] SL-172154 induces adaptive immune responses in the tumor microenvironment (TME). A shows CD8+ cells, granzyme B+ cells, CD68+ cells, and Ki67+ cells in biopsy samples from patient A before and after administration of SL-172154. Compared to the pre-treatment biopsy sample, the post-treatment biopsy sample has an increase in CD8+ cells, granzyme B+ cells, CD68+ cells, and Ki67+ cells. B shows a graph comparing tumor proportion score (TPS) and combined positive score (CPS). [Figure 11] 1 shows the planned clinical development strategy for SL-172154, including trials of SL-172154 monotherapy in ovarian cancer, SL-172154 + liposomal doxorubicin combination therapy in ovarian cancer, SL-172154 + azacitidine + venetoclax combination therapy in AML, SL-172154 + azacitidine combination therapy in HR-MDS, and SL-172154 + azacitidine combination therapy in TP53 mutant AML. [Figure 12] 1 shows an increase in CD80+ cell abundance and / or CD80 expression in tumors following administration of SL-172154. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] The present disclosure is based in part on the discovery that CD80+ cells, CD8+ cells, granzyme B+ cells, CD68+ cells, Ki67+ cells, and PD-L1+ immune cells are increased within the tumor microenvironment (TME) following administration of a SIRPα-Fc-CD40L chimeric protein, which is well tolerated without DLT or evidence of anemia, thrombocytopenia, liver dysfunction, cytokine release syndrome, or pneumonia. The present disclosure also provides a method for the detection of B cells and / or CD40 cells within hours of administration of a SIRPα-Fc-CD40L chimeric protein. + Cells migrate from the peripheral blood, levels of innate and adaptive serum cytokines such as CCL2, CXCL9, CXCL10, IFNα, IL15, IL23, IL-12, MCP-1, MIP-1β, MIP-1α, and MDC increase, and B cells and / or CD40 cells are activated within approximately 1 day after administration of the SIRPα-Fc-CD40L chimeric protein. + The present invention is based in part on the discovery that cells home to the peripheral blood and levels of innate and adaptive serum cytokines such as CCL2, CXCL9, CXCL10, IFNα, IL15, IL23, IL-12, MCP-1, MIP-1β, MIP-1α, and MDC are reduced. +The levels of cells, as well as innate and adaptive serum cytokines such as CCL2, CXCL9, CXCL10, IFNα, IL15, IL23, IL-12, MCP-1, MIP-1β, MIP-1α, and MDC, approach background levels within 1 or 2 days after administration of the SIRPα-Fc-CD40L chimeric protein.

[0026] Importantly, the chimeric proteins of the present disclosure can provide an anti-tumor effect by two different pathways, since they can (by binding the extracellular domain of CD172a (SIRPα) to its receptor / ligand on the cancer cell) disrupt, block, reduce, inhibit, and / or sequester the delivery of immunosuppressive signals, for example, from cancer cells attempting to evade phagocytosis and / or destruction, and (by binding CD40L to its receptor) enhance, increase, and / or stimulate the delivery of immunostimulatory signals to anti-cancer immune cells, and this dual action is likely to provide any anti-tumor effect to the patient and / or provide an enhanced anti-tumor effect to the patient. Moreover, because such chimeric proteins can act through two different pathways, they can be at least effective in patients who are poor responders to therapies that target one of the two pathways. Thus, patients who are poor responders to therapies that act through one of the two pathways can achieve therapeutic benefit by targeting multiple pathways.

[0027] Chimeric Proteins The chimeric protein of the present invention contains the extracellular domain of CD172a (SIRPα) and the extracellular domain of CD40L, and by combining these, it is possible to simultaneously block immunosuppressive signals and stimulate immunoactivating signals.

[0028] An embodiment of the present disclosure provides a chimeric protein comprising the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of CD172a (SIRPα), (b) is a linker flanking the first domain and the second domain, e.g., a linker comprising at least one cysteine ​​residue capable of forming a disulfide bond and / or comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of CD40L, the linker connecting the first domain and the second domain.

[0029] In some embodiments, the first domain comprises substantially all of the extracellular domain of CD172a (SIRPα). In some embodiments, the first domain can bind to a CD172a (SIRPα) ligand. In some embodiments, the first domain can bind to a CD172a (SIRPα) ligand (e.g., CD47) expressed on the surface of a cancer cell. In some embodiments, the first domain can inhibit binding of a CD172a (SIRPα) ligand (e.g., CD47) to a CD172a (SIRPα) protein located on bone marrow and hematopoietic stem cells and neurons. In some embodiments, the first domain can inhibit an immunosuppressive signal. In some embodiments, the first domain can inhibit an immunosuppressive signal. In some embodiments, the first domain can inhibit a macrophage checkpoint or a "do not eat me" signal. In one embodiment, therapy with a SIRPα-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61) stimulates macrophages to phagocytose tumor cells and effectively presents tumor antigens from the phagocytosed tumor cells to T cells.

[0030] In some embodiments, the second domain is capable of binding to the CD40 receptor. In some embodiments, the second domain comprises substantially all of the extracellular domain of CD40L. In some embodiments, the second domain is capable of activating an immunostimulatory signal.

[0031] In some embodiments, the chimeric protein is a recombinant fusion protein, e.g., a single polypeptide having an extracellular domain as disclosed herein, e.g., in some embodiments, the chimeric protein is translated as a single unit in a prokaryotic, eukaryotic, or cell-free expression system.

[0032] In certain embodiments, the chimeric proteins of the present invention can be produced in mammalian host cells as a single, secretable, fully functional polypeptide chain.

[0033] In certain embodiments, a chimeric protein refers to a recombinant protein of multiple polypeptides, e.g., multiple extracellular domains disclosed herein, that are combined (via covalent or non-covalent bonds), e.g., in vitro, to generate a single unit (e.g., with one or more synthetic linkers disclosed herein).

[0034] In some embodiments, the chimeric protein is chemically synthesized as a single polypeptide, or each domain is chemically synthesized separately and then combined, in some embodiments, the chimeric protein is partially translated and partially chemically synthesized.

[0035] In some embodiments, the extracellular domain refers to a portion of a transmembrane protein that can interact with the extracellular environment. In some embodiments, the extracellular domain refers to a portion of a transmembrane protein that is sufficient to bind a ligand or receptor and is effective in transmitting a signal to a cell. In some embodiments, the extracellular domain is the entire amino acid sequence of a transmembrane protein that is normally present on the outside of a cell or cell membrane. In some embodiments, the extracellular domain is the portion of the amino acid sequence of a transmembrane protein that is required for signal transduction and / or ligand binding, as it is present on the outside of a cell or cell membrane and can be assayed using methods known in the art (e.g., in vitro ligand binding and / or cell activation assays).

[0036] A transmembrane protein usually consists of an extracellular domain, one or a series of transmembrane domains, and an intracellular domain. Without wishing to be bound by theory, the extracellular domain of a transmembrane protein is involved in interaction with a soluble receptor or ligand or a membrane-bound receptor or ligand (i.e., the membrane of an adjacent cell). Without wishing to be bound by theory, the transmembrane domain(s) serve to localize the transmembrane protein to the plasma membrane. Without wishing to be bound by theory, the intracellular domain of a transmembrane protein serves to coordinate interactions with intracellular signaling molecules to coordinate intracellular responses with the extracellular environment (or vice versa).

[0037] There are two general types of single-pass transmembrane proteins: type I transmembrane proteins with an extracellular amino terminus and an intracellular carboxy terminus, and type II transmembrane proteins with an extracellular carboxy terminus and an intracellular amino terminus. Type I and type II transmembrane proteins can be either receptors or ligands. For type I transmembrane proteins (e.g., CD172a (SIRPα)), the amino terminus of the protein faces the outside of the cell and thus contains the functional domain involved in the interaction with other binding partners (either ligands or receptors) in the extracellular environment. For type II transmembrane proteins (e.g., CD40L), the carboxy terminus of the protein faces the outside of the cell and thus contains the functional domain involved in the interaction with other binding partners (either ligands or receptors) in the extracellular environment. Thus, these two types of transmembrane proteins have opposite orientations to each other with respect to the cell membrane.

[0038] The description of CD47 as a "do not eat me" signal in a wide range of cancers prompted exploration of what combinations of "eat me" signals could enhance antitumor immunity in the setting of CD47 blockade. Willingham et al., The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109:6662-6667 (2012); Jaiswal et al., CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138:271-285 (2009); Weiskopf et al., Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341:88-91 (2013). Preclinical combinations of CD47 blocking agents and ADCP-reactive antibodies such as rituximab and trastuzumab enhance tumor phagocytosis.Kauder et al.,ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS One 13:e0201832(2018);Chao et al.,Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142:699-713(2010);Chao et al.,Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2:63ra94(2010);Advani et al.,CD47 Blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma. N Engl J Med 379:1711-1721(2018);Zhao et al.,CD47-signal regulatory protein-alpha(SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA 108:18342-18347(2011). At least 50% of patients with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma treated with Hu5F9-G4, a humanized IgG4 isotype CD47 blocking mAb, in combination with rituximab, show objective responses. Advani et al.,CD47 Blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma. N Engl J Med 379:1711-1721(2018).CD47 blockade enhances antigen presentation in immune-neglected tumors (Tseng et al., Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci USA 110:11103-11108(2013)), however, only sporadic clinical responses have been observed when CD47 / SIRPα blockers were used as monotherapy or in combination with PD-1 / L1-blocking antibodies.

[0039] Blockade of CD47 binding to SIRPα has emerged as a promising immunotherapeutic strategy for advanced cancers by enhancing antibody-dependent cellular phagocytosis (ADCP) of targeted antibodies. Preclinically, CD47 / SIRPα blockade induces antitumor activity by increasing phagocytosis of tumor cells by macrophages and enhancing cross-presentation of tumor antigens by dendritic cells to CD8+ T cells, both of which processes are enhanced by CD40 signaling. Herein, we generated a novel bilateral fusion protein, termed SIRPα-Fc-CD40L, incorporating the extracellular domains of SIRPα and CD40L adjacent to a central Fc domain. As shown herein, the SIRPα-Fc-CD40L chimeric protein bound with high affinity to CD47 and CD40 and activated CD40 signaling in the absence of Fc receptor cross-linking. No evidence of hemolysis, hemagglutination, or thrombocytopenia was observed in vitro or in cynomolgus monkeys. Moreover, as shown herein, SIRPα-Fc-CD40L chimeric protein outperformed CD47-blocking and CD40-agonistic antibodies in a murine CT26 tumor model and synergized with PD-1 and CTLA4 immune checkpoint blockade. SIRPα-Fc-CD40L activated type I interferon responses in macrophages and enhanced the activity of ADCP-responsive targeting antibodies both in vitro and in vivo. These data indicate that CD47 / SIRPα inhibition can enhance tumor cell phagocytosis, while CD40-mediated activation of type I interferon responses provides a bridge between macrophage- and T cell-mediated immunity, thereby significantly enhancing sustained tumor control and rejection.

[0040] The chimeric protein of the present invention comprises the extracellular domain of CD172a (SIRPα) and the extracellular domain of CD40L. Thus, the chimeric protein of the present disclosure comprises at least a first domain comprising the extracellular domain of CD172a (SIRPα), which is connected, directly or via a linker, to a second domain comprising the extracellular domain of CD40L. When the domains are linked in an amino-terminal to carboxy-terminal orientation, the first domain is located on the "left" and "outward" of the chimeric protein, and the second domain is located on the "right" and "outward" of the chimeric protein.

[0041] Other configurations of the first and second domains are envisioned, e.g., the first domain faces outward and the second domain faces inward, the first domain faces inward and the second domain faces outward, the first and second domains both face inward. If both domains are "inward-facing", the chimeric protein will have an amino- to carboxy-terminal configuration that includes the extracellular domain of CD40L, a linker, and the extracellular domain of CD172a (SIRPα). In such a configuration, it may be necessary for the chimeric protein to include extra "slack", as described elsewhere herein, to allow the binding domains of the chimeric protein to bind to one or both of its receptors / ligands.

[0042] The constructs can be generated by cloning nucleic acids encoding the three fragments (the extracellular domain of CD172a (SIRPα), followed by a linker sequence, followed by the extracellular domain of CD40L) into a vector (plasmid, virus, or other), with the amino terminus of the complete sequence corresponding to the "left" of a molecule containing the extracellular domain of CD172a (SIRPα) and the carboxy terminus of the complete sequence corresponding to the "right" of a molecule containing the extracellular domain of CD40L. In some embodiments, as described above, constructs of chimeric proteins having one of the other configurations will contain the three nucleic acids such that the resulting translated chimeric protein has the desired configuration, e.g., a double inwardly oriented chimeric protein. Thus, in certain embodiments, the chimeric proteins of the invention are so modified.

[0043] CD172a (SIRPα)-Fc-CD40L chimeric protein In one embodiment, the chimeric protein is capable of simultaneously binding to the human CD172a (SIRPα) ligand and the human CD40 receptor, wherein the CD172a (SIRPα) ligand is CD47 and the CD40L receptor is CD40.

[0044] The chimeric protein has the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first and second domains, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L). In certain embodiments, the linker comprises at least one cysteine ​​residue capable of forming a disulfide bond.

[0045] The chimeric protein of the present disclosure has a first domain capable of sterically binding its ligand / receptor and / or a second domain capable of sterically binding its ligand / receptor. This means that there is sufficient overall flexibility in the chimeric protein and / or physical distance between the extracellular domain (or a portion thereof) and the rest of the chimeric protein such that the ligand / receptor binding domain of the extracellular domain is not sterically hindered from binding its ligand / receptor. This flexibility and / or physical distance (referred to herein as "slack") may typically be present in the extracellular domain(s), typically be present in the linker, and / or typically be present in the chimeric protein (as a whole). Alternatively or additionally, the chimeric protein may be modified by including one or more additional amino acid sequences (e.g., conjugated linkers described below) or synthetic linkers (e.g., polyethylene glycol (PEG) linkers) that provide the additional slack required to avoid steric hindrance.

[0046] In one embodiment, the chimeric protein of the invention comprises a variant of the extracellular domain of CD172a (SIRPα). By way of example, the variant is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or at least about 100%, or at least about 101%, or at least about 102%, or at least about 103%, or at least about 104%, or at least about 105%, or at least about 106%, or at least about 107%, or at least about 108%, or at least about 109%, or at least about 110%, or at least about 111%, or at least about 112%, or at least about 113%, or at least about 114%, or at least about 115%, or at least about 116%, or may have at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.

[0047] In one embodiment, the extracellular domain of CD172a (SIRPα) has the following amino acid sequence: EEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQWFRGAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSAPVVSGPAARATPQHTVSFTCESHGFSPRDITLKWFKNGNELSDFQTNVDPVGESVSYSIHSTAKVVLTREDVHSQVICEVAHVTLQGDPLRGTANLSETIRVPPTLEVTQQPVRAENQVNVTCQVRKFYPQRLQLTWLENGNVSRTETASTVTENKDGTYNWMSWLLVNVSAHRDDVKLTCQVEHDGQPAVSKSHDLKVSAHPKEQGSNTAAENTGSNERNIY (SEQ ID NO:57).

[0048] In one embodiment, the chimeric protein comprises a variant of the extracellular domain of CD172a (SIRPα). By way of example, the variant is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or at least about 100%, or at least about 101%, or at least about 102%, or at least about 103%, or at least about 104%, or at least about 105%, or at least about 106%, or at least about 107%, or at least about 108%, or at least about 109%, or at least about 110%, or at least about 111%, or at least about 112%, or at least about 113%, or at least about 114%, or at least about 115%, or at least about 116%, or at least about or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.

[0049] In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO:57.

[0050] Those skilled in the art may select variants of the known amino acid sequence of CD172a (SIRPα) by reference to, for example, the following documents: Hatherley et al., “Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47.”Mol Cell 31:266-277(2008);Hatherley et al.,“The Structure of the Macrophage Signal Regulatory Protein Alpha(Sirpalpha)Inhibitory Receptor Reveals a Binding Face Reminiscent of that Used by T Cell Receptors.” J Biol Chem 282:14567(2007);Hatherley et al.,“Structure of Signal-Regulatory Protein Alpha:A Link to Antigen Receptor Evolution.” J Biol Chem 284:26613(2009);Hatherley et al.,“Polymorphisms in the Human Inhibitory Signal-Regulatory Protein Alpha Do not Affect Binding to its Ligand Cd47.” J Biol Chem 289:10024(2014);Ring et. al., “Anti-SIRP alpha antibody immunotherapy enhances neutrophil and macrophage antitumor activity.” Proc Natl Acad Sci USA 114:E10578-E10585(2017) (each of which is incorporated by reference in its entirety).

[0051] In one embodiment, the chimeric protein of the invention comprises a variant of the extracellular domain of CD40L. By way of example, the variant is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or at least about 100%, or at least about 101%, or at least about 102%, or at least about 103%, or at least about 104%, or at least about 105%, or at least about 106%, or at least about 107%, or at least about 108%, or at least about 109%, or at least about 110%, or at least about 111%, or at least about 112%, or at least about 113%, or at least about 114%, or at least about 115%, or at least about 116%, or at least about 1 8%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.

[0052] In one embodiment, the extracellular domain of CD40L has the following amino acid sequence: HRRLDKIEDERNLHEDFVFMKTIQRCNTGERSLSLLNCEEIKSQFEGFVKDIMLNKEETKKENSFEMQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL (SEQ ID NO:58).

[0053] In one embodiment, the chimeric protein comprises a variant of the extracellular domain of CD40L. By way of example, the variant is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or at least about 100%, or at least about 101%, or at least about 102%, or at least about 103%, or at least about 104%, or at least about 105%, or at least about 106%, or at least about 107%, or at least about 108%, or at least about 109%, or at least about 110%, or at least about 111%, or at least about 112%, or at least about 113%, or at least about 114%, or at least about 115%, or at least about 116%, or at least about 117%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.

[0054] In an embodiment, the second domain of the chimeric protein comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:58. In an embodiment, the second domain of the chimeric protein comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:58. In an embodiment, the second domain of the chimeric protein comprises an amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:58. In an embodiment, the second domain of the chimeric protein comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:58. In an embodiment, the second domain of the chimeric protein comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:58. In an embodiment, the second domain of the chimeric protein comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO:58.

[0055] Those skilled in the art may select variants of the known amino acid sequence of CD40L by reference to, for example, the following documents: Karpusas et al., “2 A crystal structure of an extracellular fragment of human CD40 ligand.” Structure 3:1031-1039 (1995); Cytokine CD40 Ligand through a Subunit Fracture Mechanism.” ACS Chem Biol 6:636-647(2011);An et al.,“Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation.” J Biol Chem 286:11226-11235(2011);Karnell et al.,“A CD40L-targeting protein reduces autoantibodies and improves disease activity in “Patients with autoimmunity.” Sci Transl Med 11 (2019) (each publication is incorporated by reference in its entirety).

[0056] In an embodiment, the linker of the chimeric protein comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker of the chimeric protein comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker of the chimeric protein comprises an amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker of the chimeric protein comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker of the chimeric protein comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker of the chimeric protein comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

[0057] In one embodiment, a chimeric protein of the present disclosure comprises (1) a first domain comprising an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to SEQ ID NO:57; (b) a second domain comprising an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to SEQ ID NO:58; and (c) a linker comprising an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

[0058] In an embodiment, a chimeric protein of the present disclosure comprises (1) a first domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:57, (b) a second domain comprising an amino acid sequence at least 95% identical to SEQ ID NO:58, and (c) a linker comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, a chimeric protein of the present disclosure comprises (1) a first domain comprising an amino acid sequence at least 97% identical to SEQ ID NO:57, (b) a second domain comprising an amino acid sequence at least 97% identical to SEQ ID NO:58, and (c) a linker comprising an amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, a chimeric protein of the present disclosure comprises (1) a first domain comprising an amino acid sequence at least 98% identical to SEQ ID NO:57, (b) a second domain comprising an amino acid sequence at least 98% identical to SEQ ID NO:58, and (c) a linker comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, a chimeric protein of the present disclosure comprises (1) a first domain comprising an amino acid sequence at least 99% identical to SEQ ID NO:57, (b) a second domain comprising an amino acid sequence at least 99% identical to SEQ ID NO:58, and (c) a linker comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, a chimeric protein of the present disclosure comprises (1) a first domain comprising an amino acid sequence of SEQ ID NO:57, (b) a second domain comprising an amino acid sequence of SEQ ID NO:58, and (c) a linker comprising an amino acid sequence at least 95% identical to SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, a chimeric protein of the present disclosure comprises (1) a first domain comprising an amino acid sequence identical to SEQ ID NO:57, (b) a second domain comprising an amino acid sequence identical to SEQ ID NO:58, and (c) a linker comprising an amino acid sequence identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

[0059] In one embodiment, a CD172a (SIRPα)-Fc-CD40L chimeric protein of the present disclosure has the following amino acid sequence (the extracellular domain of CD172a (SIRPα) is shown in bold, the extracellular domain of CD40L is underlined, and the Fc domain is shown in italics: [ka]

[0060] The 792 amino acid sequence (not including the leader sequence) of the CD172a (SIRPα)-Fc-CD40L chimeric protein (SL-172154) is shown above. The CD172a (SIRPα)-Fc-CD40L chimeric protein exists as an oligomeric form characteristic. There are 17 cysteines in the amino acid sequence, 8 of which are likely disulfide pairs. Both N-linked and O-linked glycosylation have been identified.

[0061] In an embodiment, a chimeric protein of the present disclosure comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 potential N-glycosylation sites. In an embodiment, a chimeric protein of the present disclosure comprises at least 2 potential N-glycosylation sites. In an embodiment, a chimeric protein of the present disclosure comprises at least 4 potential N-glycosylation sites. In an embodiment, a chimeric protein of the present disclosure comprises at least 6 potential N-glycosylation sites. In an embodiment, a chimeric protein of the present disclosure comprises at least 8 potential N-glycosylation sites. In an embodiment, a chimeric protein of the present disclosure comprises at least 10 potential N-glycosylation sites. In an embodiment, a chimeric protein of the present disclosure comprises at least 1, 2, 3, 4, 5, 6, 7, or 8 potential O-glycosylation sites. In an embodiment, a chimeric protein of the present disclosure comprises at least 2 potential O-glycosylation sites. In an embodiment, a chimeric protein of the present disclosure comprises at least 4 potential O-glycosylation sites. In certain embodiments, a chimeric protein of the present disclosure comprises at least six potential O-glycosylation sites. In certain embodiments, a chimeric protein of the present disclosure comprises at least eight potential O-glycosylation sites. In certain embodiments, a chimeric protein of the present disclosure comprises at least two potential N-glycosylation sites and at least two potential O-glycosylation sites. In certain embodiments, a chimeric protein of the present disclosure comprises at least four potential N-glycosylation sites and at least four potential O-glycosylation sites. In certain embodiments, a chimeric protein of the present disclosure comprises at least six potential N-glycosylation sites and at least six potential O-glycosylation sites. In certain embodiments, a chimeric protein of the present disclosure comprises at least eight potential N-glycosylation sites and at least eight potential O-glycosylation sites. In certain embodiments, a chimeric protein of the present disclosure comprises at least ten potential N-glycosylation sites and at least eight potential O-glycosylation sites. In certain embodiments, the chimeric protein expressed in Chinese Hamster Ovary (CHO) cells is glycosylated.

[0062] There are 17 cysteines in the SL-172154 chimeric protein. In some embodiments, the SL-172154 chimeric protein has no disulfide bonds. In some embodiments, the SL-172154 chimeric protein has at least one, or at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine, or at least ten disulfide bonds. In some embodiments, the SL-172154 chimeric protein has at least one, or at least two interchain disulfide bonds. In some embodiments, the SL-172154 chimeric protein has at least one, or at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or eight interchain disulfide bonds. In some embodiments, the SL-172154 chimeric protein has a C350=C350 interchain disulfide bond. In some embodiments, the SL-172154 chimeric protein has a C353=C353 interchain disulfide bond. In some embodiments, the SL-172154 chimeric protein has a C153=C153 interchain disulfide bond. In some embodiments, the SL-172154 chimeric protein has a C25=C91 disulfide bond. In some embodiments, the SL-172154 chimeric protein has a C140=C198 disulfide bond. In some embodiments, the SL-172154 chimeric protein has a C243=C301 disulfide bond. In some embodiments, the SL-172154 chimeric protein has a C385=C445 disulfide bond. In some embodiments, the SL-172154 chimeric protein has a C491=C549 disulfide bond. In some embodiments, the SL-172154 chimeric protein has a C603=C615 disulfide bond.In some embodiments, the SL-172154 chimeric protein has a C709=C725 disulfide bond.In some embodiments, the SL-172154 chimeric protein has a C140=C243=C709 / C725 scrambled disulfide bond. In some embodiments, the SL-172154 chimeric protein has a C615(chain 1)=C615(chain 2) scrambled disulfide bond.

[0063] In some embodiments, a CD172a (SIRPα)-Fc-CD40L chimeric protein of the disclosure is encoded by the following nucleotide sequence (leader sequence shown in bold underlined font): [ka] [ka] In some embodiments, SEQ ID NO:60 encodes the precursor of a CD172a (SIRPα)-Fc-CD40L chimeric protein of the disclosure having the following amino acid sequence (leader sequence shown in italic font): [ka] The chimeric protein of SEQ ID NO:59 (also referred to herein as SL-172154) is a recombinant fusion glycoprotein comprising the extracellular domain of human CD172a (SIRPα) (PDCD1, CD272a), the central domain including the hinge-CH2-CH3 region of human immunoglobulin constant γ4 (inhibitory receptor SHPS-1, IgG4), and the extracellular domain of human CD40L (TNFSF5, TRAP, CD154). The linear configuration of SL-172154 is CD172a (SIRPα)-Fc-CD40L.

[0064] The predicted molecular weight of the monomeric chimeric protein of SEQ ID NO: 59 is 88.1 kDa. The predicted molecular weight of the glycosylated monomeric chimeric protein of SEQ ID NO: 59 is approximately 115 kDa.

[0065] The dual nature of the chimeric proteins disclosed herein, such as the CD172a (SIRPα)-Fc-CD40L chimeric proteins (e.g., SEQ ID NO:59 or SEQ ID NO:61), is designed to block the CD172a (SIRPα)-CD47 macrophage checkpoint, one of the key immunosuppressive pathways within the tumor microenvironment (TME).

[0066] Tumor cells may express CD47 on the cell surface, which can bind to CD172a (SIRPα) expressed by macrophages to inhibit the phagocytosis of tumor cells. Thus, CD172a (SIRPα)-Fc-CD40L chimeric proteins (e.g., SEQ ID NO: 59 or SEQ ID NO: 61) can bind to CD47 expressed on the surface of tumors, and the CD172a (SIRPα) domain of the CD172a (SIRPα)-Fc-CD40L chimeric proteins disclosed herein is intended to provide competitive inhibition of CD47 and replace the CD47 inhibitory signal with functionally trimerized / hexamerized CD40L, so that incoming T cells are co-stimulated by binding through their CD40 receptors, rather than inhibited by CD172a (SIRPα) interactions. In other words, the extracellular domains (ECDs) of CD172a (SIRPα) and CD40L are physically interconnected and localized in the TME, so that tumor-infiltrating T cells can recognize tumor antigens via the T cell receptor (TCR) and simultaneously be co-stimulated. Importantly, the ECDs of CD172a (SIRPα) and CD40L are physically interconnected and localized in the TME, so that tumor-infiltrating T cells can recognize tumor antigens via the T cell receptor and simultaneously be co-stimulated. By combining these, the inhibitory CD47 signal will be replaced by the co-stimulatory CD40L signal, enhancing the antitumor activity of T cells.

[0067] The three components of the chimeric proteins disclosed herein, including the CD172a (SIRPα)-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61), have unique properties that promote dimerization or oligomerization. The extracellular domain of CD172a (SIRPα) usually exists as a monomer and is not known to form higher order homomeric complexes. The central Fc domain contains cysteine ​​residues that can disulfide bond to form a dimeric structure. In an embodiment, the chimeric proteins disclosed herein, such as the CD172a (SIRPα)-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61), contain an S228P mutation in the hinge region of the Fc domain to prevent exchange of Fab arms. The CD40L domain is known to form homotrimeric complexes, which are stabilized by non-covalent electrostatic interactions. The chimeric proteins disclosed herein, such as CD172a(SIRPα)-Fc-CD40L chimeric proteins (e.g., SEQ ID NO:59 or SEQ ID NO:61), are expressed as continuous monomeric proteins by the production cell line, but the resulting monomeric proteins self-assemble into higher order species, hexamers (dimers of trimers), based on the combined influence of CD40L disulfide and charge-based interactions (forming trimers) and these attractive forces. The majority (>80%) of CD172a(SIRPα)-Fc-CD40L chimeric proteins (e.g., SEQ ID NO:59 or SEQ ID NO:61) are composed of hexamers and trimers with similar activity. Importantly, CD172a(SIRPα)-Fc-CD40L chimeric proteins (e.g., SEQ ID NO:59 or SEQ ID NO:61) are composed of hexamers and trimers and stimulate CD40 signaling in the absence of cross-linking by Fc receptors or any other cross-linking agents.The predicted tertiary structure of the CD172a (SIRPα)-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61) in monomeric and various oligomeric states based on disulfide (Fc) and charge-based (CD40L) interactions shows the visualization by electron microscopy of CD172a (SIRPα)-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61) hexamers (top two images) and CD172a (SIRPα)-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61) trimers (bottom two images). Thus, CD172a (SIRPα)-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61) forms trimers / hexamers and activates CD40 without the need for cross-linking. It is noteworthy that, unlike monoclonal antibodies, the functional activity of the CD172a (SIRPα)-Fc-CD40L chimeric protein (eg, SEQ ID NO: 59 or SEQ ID NO: 61) does not require cross-linking of Fc receptors.

[0068] In certain embodiments, the chimeric protein comprises a variant of the CD172a (SIRPα)-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61). By way of example, the variant may be at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or at least about 99%, or at least about 100%, or at least about 101%, or at least about 102%, or at least about 103%, or at least about 104%, or at least about 105%, or at least about 106%, or at least about 107%, or at least about 108%, or at least about 109%, or at least about 1109%, or at least about 1110%, or at least about 112%, or at least about 1 or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or at least about 99.2%, or at least about 99.4%, or at least about 99.6%, or at least about 99.8% sequence identity.

[0069] In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61.

[0070] In certain embodiments, the first domain is capable of binding to a CD172a (SIRPα) ligand.

[0071] In one embodiment, the first domain comprises substantially all of the extracellular domain of CD172a (SIRPα).

[0072] In certain embodiments, the second domain is capable of binding to the CD40 receptor.

[0073] In one embodiment, the second domain comprises substantially the entire extracellular domain of CD40L.

[0074] In certain embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from IgG4, e.g., human IgG4.

[0075] In an embodiment, the linker comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker comprises an amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

[0076] In an embodiment, the first domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain of the chimeric protein comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO:57.

[0077] In an embodiment, the second domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:58. In an embodiment, the second domain of the chimeric protein comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:58. In an embodiment, the second domain of the chimeric protein comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:58. In an embodiment, the second domain of the chimeric protein comprises an amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:58. In an embodiment, the second domain of the chimeric protein comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:58. In an embodiment, the second domain of the chimeric protein comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:58. In an embodiment, the second domain of the chimeric protein comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO:58.

[0078] In one embodiment, (a) the first domain comprises the amino acid sequence of SEQ ID NO:57, (b) the second domain comprises the amino acid sequence of SEQ ID NO:58, and (c) the linker comprises an amino acid sequence at least 95% identical to SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

[0079] In some embodiments, the chimeric protein further comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:5 and / or SEQ ID NO:7. In some embodiments, the chimeric protein further comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:5 and / or SEQ ID NO:7. In some embodiments, the chimeric protein further comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:5 and / or SEQ ID NO:7. In some embodiments, the chimeric protein further comprises the amino acid sequence of SEQ ID NO:5 and / or SEQ ID NO:7.

[0080] In certain embodiments, the chimeric protein comprises an amino acid sequence that is at least about 95% identical to SEQ ID NO:59 or SEQ ID NO:61, e.g., an amino acid sequence that is at least about 98% identical to SEQ ID NO:59 or SEQ ID NO:61, an amino acid sequence that is at least about 99% identical to SEQ ID NO:59 or SEQ ID NO:61, an amino acid sequence that is at least about 99.2% identical to SEQ ID NO:59 or SEQ ID NO:61, an amino acid sequence that is at least about 99.4% identical to SEQ ID NO:59 or SEQ ID NO:61, an amino acid sequence that is at least about 99.6% identical to SEQ ID NO:59 or SEQ ID NO:61, or an amino acid sequence that is at least about 99.8% identical to SEQ ID NO:59 or SEQ ID NO:61. In certain embodiments, the chimeric protein comprises the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61.

[0081] In any of the aspects and embodiments disclosed herein, the chimeric protein may comprise an amino acid sequence having one or more amino acid mutations compared to any of the protein sequences disclosed herein, hi an embodiment, the one or more amino acid mutations may be independently selected from a substitution, an insertion, a deletion, and a truncation.

[0082] In certain embodiments, the amino acid mutation is an amino acid substitution, which may include conservative and / or non-conservative substitutions. A "conservative substitution" may be made, for example, based on similarity in polarity, charge, size, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the amino acid residues involved. The 20 naturally occurring amino acids can be classified into six standard amino acid groups: (1) hydrophobic: Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr; Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that affect chain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe. As used herein, a "conservative substitution" is defined as the replacement of an amino acid with another amino acid listed within the same group of the six standard amino acid groups above. For example, the replacement of Asp with Glu retains one negative charge in the so modified polypeptide. Additionally, glycine and proline may be substituted for one another based on their ability to disrupt α-helices. As used herein, a "non-conservative substitution" is defined as the replacement of an amino acid with another amino acid listed in a different group of the six standard amino acid groups (1) to (6) above.

[0083] In certain embodiments, substitutions may also include non-classical amino acids (e.g., selenocysteine, pyrrolysine, N-formylmethionine, β-alanine, GABA and δ-aminolevulinic acid, 4-aminobenzoic acid (PABA), D-isomers of common amino acids, 2,4-diaminobutyric acid, α-aminoisobutyric acid, 4-aminobutyric acid, Abu, 2-aminobutyric acid, γ-Abu, ε-Ahx, 6-aminohexanoic acid, Aib, 2-aminoisobutyric acid, 3-aminopropionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosme, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β-alanine, fluoroamino acids, designer amino acids such as β-methyl amino acids, C α-methyl amino acids, N α-methyl amino acids, and common amino acid analogs).

[0084] Mutations can also be made in the nucleotide sequence of the chimeric protein by reference to the genetic code, including taking into account codon degeneracy.

[0085] In certain embodiments, the chimeric protein is capable of binding to a human ligand(s) / receptor(s).

[0086] In certain embodiments, each extracellular domain of the chimeric protein (or a variant thereof) has a K of about 1 nM to about 5 nM, e.g., about 1 nM, about 1.5 nM, about 2 nM, about 2.5 nM, about 3 nM, about 3.5 nM, about 4 nM, about 4.5 nM, or about 5 nM. D In certain embodiments, the chimeric protein binds to its cognate receptor or ligand with a K of about 5 nM to about 15 nM, e.g., about 5 nM, about 5.5 nM, about 6 nM, about 6.5 nM, about 7 nM, about 7.5 nM, about 8 nM, about 8.5 nM, about 9 nM, about 9.5 nM, about 10 nM, about 10.5 nM, about 11 nM, about 11.5 nM, about 12 nM, about 12.5 nM, about 13 nM, about 13.5 nM, about 14 nM, about 14.5 nM, or about 15 nM. D It binds to its cognate receptor or ligand at

[0087] In certain embodiments, each extracellular domain of the chimeric protein (or a variant thereof) has a K of about 1 μM, about 900 nM, about 800 nM, about 700 nM, about 600 nM, about 500 nM, about 400 nM, about 300 nM, about 200 nM, about 150 nM, about 130 nM, about 100 nM, about 90 nM, about 80 nM, about 70 nM, about 60 nM, about 55 nM, about 50 nM, about 45 nM, about 40 nM, about 35 nM, about 30 nM, about 25 nM, about 20 nM, about 15 nM, about 10 nM, or about 5 nM, or less than about 1 nM (e.g., as measured by surface plasmon resonance or biolayer interferometry). D and binds to its cognate receptor or ligand.

[0088] In certain embodiments, the chimeric protein has a K of about 1 nM to about 5 nM, e.g., about 1 nM, about 1.5 nM, about 2 nM, about 2.5 nM, about 3 nM, about 3.5 nM, about 4 nM, about 4.5 nM, or about 5 nM. D In certain embodiments, the chimeric protein binds to human CD47 with a K of about 3 nM, about 2 nM, about 1 nM, about 900 pM, about 800 pM, about 700 pM, about 600 pM, about 500 pM, about 400 pM, about 300 pM, about 200 pM, about 100 pM, about 90 pM, about 80 pM, about 70 pM, about 60 pM, about 55 pM, about 50 pM, about 45 pM, about 40 pM, about 35 pM, about 30 pM, about 25 pM, about 20 pM, about 15 pM, or about 10 pM, or less than about 1 pM (e.g., as measured by surface plasmon resonance or biolayer interferometry). D It binds to human CD47.

[0089] In certain embodiments, the chimeric protein has a K of about 1 nM, about 900 pM, about 800 pM, about 700 pM, about 600 pM, about 500 pM, about 400 pM, about 300 pM, about 200 pM, about 100 pM, about 90 pM, about 80 pM, about 70 pM, about 60 pM, about 55 pM, about 50 pM, about 45 pM, about 40 pM, about 35 pM, about 30 pM, about 25 pM, about 20 pM, about 15 pM, or about 10 pM, or less than about 1 pM (e.g., as measured by surface plasmon resonance or biolayer interferometry). D It binds to human CD40 at .

[0090] As used herein, a variant of an extracellular domain is capable of binding to a receptor / ligand of the native extracellular domain. For example, the variant may include one or more mutations in the extracellular domain that do not affect its binding affinity with its receptor / ligand, alternatively, one or more mutations in the extracellular domain may improve the binding affinity to the receptor / ligand, or one or more mutations in the extracellular domain may reduce the binding affinity to the receptor / ligand but do not completely eliminate binding. In an embodiment, one or more mutations are located outside the binding pocket where the extracellular domain interacts with its receptor / ligand. In an embodiment, one or more mutations are located inside the binding pocket where the extracellular domain interacts with its receptor / ligand, unless the mutation completely eliminates binding. Based on the knowledge of the skilled artisan and knowledge of the art of receptor-ligand binding, one will understand which mutations allow binding and which eliminate binding.

[0091] In certain embodiments, the chimeric protein has enhanced stability and protein half-life.

[0092] The chimeric protein of the present disclosure may comprise more than two extracellular domains. For example, the chimeric protein may comprise three, four, five, six, seven, eight, nine, ten, or more extracellular domains. As disclosed herein, the second extracellular domain may be separated from the third extracellular domain via a linker. Alternatively, the second extracellular domain may be directly linked to the third extracellular domain (e.g., via a peptide bond). In an embodiment, as disclosed herein, the chimeric protein comprises an extracellular domain that is directly linked and an extracellular domain that is indirectly linked via a linker.

[0093] Linker In certain embodiments, the chimeric protein comprises a linker.

[0094] In some embodiments, the linker comprises at least one cysteine ​​residue capable of forming a disulfide bond. At least one cysteine ​​residue can form a disulfide bond between a pair (or more) of chimeric proteins. Without wishing to be bound by theory, such disulfide bond formation contributes to maintaining the useful multimeric state of the chimeric protein. This allows for efficient production of the chimeric protein, which in turn provides the desired activity in vitro and in vivo.

[0095] In the chimeric proteins of the present disclosure, the linker is a polypeptide selected from a flexible amino acid sequence, an IgG hinge region, or an antibody sequence.

[0096] In some embodiments, the linker is derived from a natural multidomain protein or is an empirical linker, for example, as described in Chichili et al., Protein Sci. 22(2): 153-167 (2013); Chen et al., Adv Drug Deliv Rev. 65(10): 1357-1369 (2013), the entire contents of which are incorporated herein by reference. In some embodiments, the linker may be designed using linker design databases and computer programs, such as those described in Chen et al., Adv Drug Deliv Rev. 65(10): 1357-1369 (2013); and Crasto et al., Protein Eng. 13(5): 309-312 (2000), the entire contents of which are incorporated herein by reference.

[0097] In some embodiments, the linker comprises a polypeptide. In some embodiments, the polypeptide is less than about 500, 450, 400, 350, 300, 250, 200, 150, or 100 amino acids in length. For example, the linker can be less than about 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 amino acids in length.

[0098] In certain embodiments, the linker is flexible.

[0099] In certain embodiments, the linker is rigid.

[0100] In certain embodiments, the linker consists essentially of glycine and serine residues (e.g., about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or about 97%, or about 98%, or about 99%, or about 100% glycine and serine).

[0101] In certain embodiments, the linker comprises a hinge region of an antibody (e.g., IgG, IgA, IgD, and IgE, including subclasses (e.g., IgG1, IgG2, IgG3, and IgG4, and IgA1, and IgA2)). The hinge region found in IgG, IgA, IgD, and IgE class antibodies functions as a flexible spacer, allowing the Fab portion to move freely in space. In contrast to the constant region, the hinge domain is structurally diverse, differing in both sequence and length among immunoglobulin classes and subclasses. For example, the length and flexibility of the hinge region differs among IgG subclasses. The hinge region of IgG1 encompasses amino acids 216-231 and is freely flexible, so that the Fab fragment can rotate around its axis of symmetry and move within a sphere central to the first of the two inter-heavy chain disulfide bridges. IgG2 has a shorter hinge than IgG1, with 12 amino acid residues and four disulfide bridges. The hinge region of IgG2 lacks glycine residues, is relatively short, and contains a rigid polyproline double helix stabilized by an additional inter-heavy chain disulfide bridge. These properties limit the flexibility of the IgG2 molecule. IgG3 differs from other subclasses by its unique extended hinge region (approximately four times longer than the IgG1 hinge), which contains 62 amino acids (including 21 prolines and 11 cysteines) and forms a polyproline double helix that is not flexible. In IgG3, the Fab fragment is relatively far from the Fc fragment, which increases the flexibility of the molecule. The elongated hinge in IgG3 is also responsible for its high molecular weight compared to other subclasses. The hinge region of IgG4 is shorter than that of IgG1, and its flexibility is intermediate between IgG1 and IgG2. The flexibility of the hinge region has been reported to decrease in the order IgG3>IgG1>IgG4>IgG2. In certain embodiments, the linker is derived from human IgG4 and may contain one or more mutations to enhance dimer formation (including S228P) or FcRn binding.

[0102] According to crystallographic studies, immunoglobulin hinge regions can be functionally further subdivided into three regions: the upper hinge region, the core region, and the lower hinge region. See Shin et al., Immunological Reviews 130:87 (1992). The upper hinge region contains C H1 The upper hinge region includes the amino acids from the carboxyl terminus of the C to the first residue in the hinge that restricts movement, usually the first cysteine ​​residue that forms the interchain disulfide bond between the two heavy chains. The length of the upper hinge region correlates with the segmental plasticity of the antibody. The core hinge region contains the inter-heavy chain disulfide bridges, and the lower hinge region is H2 Binds to the amino terminus of the domain and H2 The core hinge region of wild-type human IgG1 contains the sequence CPPC (SEQ ID NO: 24), which when dimerized by disulfide bond formation results in a cyclic octapeptide that is believed to act as a pivot, thus providing flexibility. In certain embodiments, the linkers of the invention comprise one, two, or three of the upper hinge region, core region, and lower hinge region of any antibody (e.g., IgG, IgA, IgD, and IgE, including subclasses (e.g., IgG1, IgG2, IgG3, and IgG4, and IgA1 and IgA2)). The hinge region may also contain one or more glycosylation sites, which contain several structurally distinct types of sites for carbohydrate attachment. For example, IgA1 contains five glycosylation sites within a 17 amino acid segment of the hinge region, conferring resistance of the hinge region polypeptide to intestinal proteases, a property believed to be advantageous for secretory immunoglobulins. In certain embodiments, a linker of the present disclosure comprises one or more glycosylation sites.

[0103] In certain embodiments, the linker comprises an Fc domain of an antibody (eg, IgG, IgA, IgD, and IgE, including subclasses (eg, IgG1, IgG2, IgG3, and IgG4, and IgA1 and IgA2)).

[0104] In the chimeric proteins of the present disclosure, the linker comprises a hinge-CH2-CH3 Fc domain derived from IgG4. In certain embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from human IgG4. In certain embodiments, the linker comprises an amino acid sequence that is at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 1 to 3. In certain embodiments, the linker comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of any one of SEQ ID NOs: 1 to 3 (e.g., at least 95% identical to the amino acid sequence of SEQ ID NO: 2). In certain embodiments, the linker comprises one or more bonded linkers, such bonded linkers being independently selected from SEQ ID NOs: 4 to 50 (or variants thereof). In one embodiment, the linker comprises two or more linked linkers, each linked linker independently selected from SEQ ID NOs: 4-50 (or a variant thereof), and one linked linker is N-terminal to the hinge-CH2-CH3 Fc domain and the other linked linker is C-terminal to the hinge-CH2-CH3 Fc domain.

[0105] In one embodiment, the linker comprises a hinge-CH2-CH3 Fc domain derived from a human IgG1 antibody. In one embodiment, the Fc domain exhibits increased affinity and enhanced binding to the neonatal Fc receptor (FcRn). In one embodiment, the Fc domain comprises one or more mutations that increase affinity and enhance binding to FcRn. Without wishing to be bound by theory, it is believed that the increased affinity and enhanced binding to FcRn increases the in vivo half-life of the chimeric protein of the invention.

[0106] In some embodiments, the Fc domain in the linker comprises one or more amino acid substitutions at amino acid residues 250, 252, 254, 256, 308, 309, 311, 416, 428, 433, or 434 (according to Kabat numbering as in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), expressly incorporated herein by reference), or their equivalents. In some embodiments, the amino acid substitution at amino acid residue 250 is a substitution with glutamine. In some embodiments, the amino acid substitution at amino acid residue 252 is a substitution with tyrosine, phenylalanine, tryptophan, or threonine. In some embodiments, the amino acid substitution at amino acid residue 254 is a substitution with threonine. In some embodiments, the amino acid substitution at amino acid residue 256 is a substitution with serine, arginine, glutamine, glutamic acid, aspartic acid, or threonine. In some embodiments, the amino acid substitution at amino acid residue 308 is a substitution with threonine. In some embodiments, the amino acid substitution at amino acid residue 309 is a substitution with proline. In some embodiments, the amino acid substitution at amino acid residue 311 is a substitution with serine. In some embodiments, the amino acid substitution at amino acid residue 385 is a substitution with arginine, aspartic acid, serine, threonine, histidine, lysine, alanine, or glycine. In some embodiments, the amino acid substitution at amino acid residue 386 is a substitution with threonine, proline, aspartic acid, serine, lysine, arginine, isoleucine, or methionine. In some embodiments, the amino acid substitution at amino acid residue 387 is a substitution with arginine, proline, histidine, serine, threonine, or alanine. In certain embodiments, the amino acid substitution at amino acid residue 389 is with a proline, serine, or asparagine. In certain embodiments, the amino acid substitution at amino acid residue 416 is with a serine.In some embodiments, the amino acid substitution at amino acid residue 428 is with leucine. In some embodiments, the amino acid substitution at amino acid residue 433 is with arginine, serine, isoleucine, proline, or glutamine. In some embodiments, the amino acid substitution at amino acid residue 434 is with histidine, phenylalanine, or tyrosine.

[0107] In some embodiments, the Fc domain linker (e.g., comprising an IgG constant region) comprises one or more mutations, such as substitutions at amino acid residues 252, 254, 256, 433, 434, or 436 (according to Kabat numbering, as in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), expressly incorporated herein by reference). In some embodiments, the IgG constant region comprises a triple M252Y / S254T / T256E mutation or a YTE mutation. In some embodiments, the IgG constant region comprises a triple H433K / N434F / Y436H mutation or a KFH mutation. In some embodiments, the IgG constant region comprises a combination of YTE and KFH mutations.

[0108] In some embodiments, the linker comprises an IgG constant region comprising one or more mutations at amino acid residues 250, 253, 307, 310, 380, 428, 433, 434, and 435 (according to Kabat numbering as in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), expressly incorporated herein by reference). Exemplary mutations include T250Q, M428L, T307A, E380A, I253A, H310A, M428L, H433K, N434A, N434F, N434S, and H435A. In some embodiments, the IgG constant region comprises an M428L / N434S mutation or an LS mutation. In some embodiments, the IgG constant region comprises T250Q / M428L mutations or QL mutations. In some embodiments, the IgG constant region comprises N434A mutations. In some embodiments, the IgG constant region comprises T307A / E380A / N434A mutations or AAA mutations. In some embodiments, the IgG constant region comprises I253A / H310A / H435A mutations or IHH mutations. In some embodiments, the IgG constant region comprises H433K / N434F mutations. In some embodiments, the IgG constant region comprises a combination of M252Y / S254T / T256E and H433K / N434F mutations.

[0109] Additional exemplary mutations in IgG constant regions are described, for example, in Robbie, et al., Antimicrobial Agents and Chemotherapy 57(12):6147-6153(2013); Dall'Acqua et al., Journal Biol Chem 281(33):23514-24(2006); Dall'Acqua et al., Journal of Immunology 169:5171-80(2002); Ko et al. Nature 514:642-645(2014); Grevys et al. Journal of Immunology 194(11):5497-508(2015), and U.S. Patent No. 7,083,784, the entire contents of which are incorporated herein by reference.

[0110] An exemplary Fc stabilizing mutant is S228P. Exemplary Fc half-life extending mutants are T250Q, M428L, V308T, L309P, and Q311S, and a linker of the invention may comprise one, two, three, four, or five of these mutants.

[0111] In some embodiments, the chimeric protein binds to FcRn with high affinity. In some embodiments, the chimeric protein binds to FcRn with a K of about 1 nM to about 80 nM. D For example, the chimeric protein may bind to FcRn with a K of about 1 nM, about 2 nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, about 10 nM, about 15 nM, about 20 nM, about 25 nM, about 30 nM, about 35 nM, about 40 nM, about 45 nM, about 50 nM, about 55 nM, about 60 nM, about 65 nM, about 70 nM, about 71 nM, about 72 nM, about 73 nM, about 74 nM, about 75 nM, about 76 nM, about 77 nM, about 78 nM, about 79 nM, or about 80 nM. D In one embodiment, the chimeric protein can bind to FcRn with a K of about 9 nM. D In certain embodiments, the chimeric protein does not substantially bind to other Fc receptors that have effector function (i.e., other than FcRn).

[0112] In some embodiments, the Fc domain in the linker has an amino acid sequence of SEQ ID NO:1 (see Table 1 below), or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical thereto. In some embodiments, mutations are made to SEQ ID NO:1 to increase stability and / or half-life. For example, in some embodiments, the Fc domain in the linker comprises an amino acid sequence of SEQ ID NO:2 (see Table 1 below), or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical thereto. For example, in some embodiments, the Fc domain in the linker comprises an amino acid sequence of SEQ ID NO:3 (see Table 1 below), or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical thereto.

[0113] Further, one or more linking linkers may be used to connect the Fc domain (e.g., one of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical thereto) and the extracellular domain in the linker. For example, any one of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or a variant thereof may connect the extracellular domain disclosed herein and the Fc domain in the linker disclosed herein. Optionally, any one of SEQ ID NOs:4-50, or a variant thereof, is located between the extracellular domain disclosed herein and the Fc domain disclosed herein.

[0114] In certain embodiments, the chimeric protein of the present invention may include a variant of the binding linker disclosed in Table 1 below. For example, the linker is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, relative to the amino acid sequence of any one of SEQ ID NOs: 4-50. Or it may have at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.

[0115] In certain embodiments, the first and second attached linkers may be different, or they may be the same.

[0116] Without wishing to be bound by theory, the inclusion of a linker that comprises at least a portion of the Fc domain in the chimeric protein helps to avoid the formation of insoluble, potentially non-functional protein concatamers and / or aggregates due to the presence of cysteines within the Fc domain that can form disulfide bonds between the chimeric proteins.

[0117] In certain embodiments, the chimeric protein may include one or more attached linkers as disclosed herein, or may lack an Fc domain linker as disclosed herein.

[0118] In certain embodiments, the first and / or second attachment linker are independently selected from the amino acid sequences of SEQ ID NOs: 4-50 and are provided in Table 1 below: [Table 1-1] [Table 1-2] [Table 1-3]

[0119] In some embodiments, the conjugated linker comprises substantially glycine and serine residues (e.g., about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95%, or about 97%, or about 98%, or about 99%, or about 100% glycine and serine). For example, in some embodiments, the conjugated linker comprises (Gly4Ser) n In one embodiment, the conjugated linker sequence is GGSGGSGGGGSGGGGS (SEQ ID NO: 33). Additional exemplary conjugated linkers include LE, (EAAAK) n (n = 1 to 3) (SEQ ID NO: 36 to SEQ ID NO: 38), A(EAAAK) n A(n=2 to 5) (SEQ ID NO: 39 to SEQ ID NO: 42), A(EAAAK)4ALEA(EAAAK)4A (SEQ ID NO: 43), PAPAP (SEQ ID NO: 44), KESGSVSSEQLAQFRSLD (SEQ ID NO: 45), GSAGSAAGSGEF (SEQ ID NO: 46), and (XP) n(wherein X represents any amino acid, such as, for example, Ala, Lys, or Glu). In one embodiment, the bonded linker is GGS. In one embodiment, the bonded linker is the sequence (Gly) n In the sequence, n is any number from 1 to 100, for example, (Gly)8 (SEQ ID NO: 34) and (Gly)6 (SEQ ID NO: 35).

[0120] In certain embodiments, the bond linker is one or more of GGGSE (SEQ ID NO: 47), GSESG (SEQ ID NO: 48), GSEGS (SEQ ID NO: 49), GEGGSGEGSSGEGSSSEGGGSEGGGSEGGGSEGGS (SEQ ID NO: 50), and a bond linker with G, S, and E randomly spaced every 4 amino acid interval.

[0121] In one embodiment, the chimeric protein comprises a linked linker comprising the amino acid sequence of SEQ ID NO:5 and / or SEQ ID NO:7.

[0122] In one embodiment, when a chimeric protein comprises the extracellular domain (ECD) of CD172a (SIRPα), one binding linker preceding the Fc domain, a second binding linker following the Fc domain, and the ECD of CD40L, the chimeric protein may comprise the following structure: ECD of human CD172a (SIRPα) - Linker 1 - Fc domain - Linker 2 - ECD of human CD40L The combination of a first binding linker, an Fc domain linker, and a second binding linker is referred to herein as a "modular linker." In one embodiment, the chimeric protein comprises a modular linker as shown in Table 2. [Table 2-1] [Table 2-2]

[0123] In certain embodiments, the chimeric proteins of the invention may comprise variants of the modular linkers disclosed in Table 2 above. For example, the linker is at least about 60%, or at least about 61%, or at least about 62%, or at least about 63%, or at least about 64%, or at least about 65%, or at least about 66%, or at least about 67%, or at least about 68%, or at least about 69%, or at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, or at least about 100%, or at least about 101%, or at least about 102%, or at least about 103%, or at least about 104%, or at least about 105%, or at least about 106%, or at least about 107%, or at least about 108%, or at least about 109%, or at least about 110, or at least about 111, or at least about 112, or at least about 113, or at least about 114, or at least about 115, or at least about 116, or at least about or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, or at least about 86%, or at least about 87%, or at least about 88%, or at least about 89%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity.

[0124] In certain embodiments, the linker can be flexible, including but not limited to being highly flexible. In certain embodiments, the linker can be rigid, including but not limited to being a rigid alpha helix. Characteristics of exemplary bond linkers are shown in Table 3 below: [Table 3]

[0125] In certain embodiments, the linker may be functional. For example, but not limited to, the linker may function to improve the folding and / or stability, improve expression, improve pharmacokinetics, and / or improve biological activity of the chimeric protein of the present invention. In another example, the linker may function to target the chimeric protein to a particular cell type or location.

[0126] In certain embodiments, the chimeric protein includes only one attachment linker.

[0127] In certain embodiments, the chimeric protein lacks an attached linker.

[0128] In certain embodiments, the linker is a synthetic linker, such as polyethylene glycol (PEG).

[0129] In an embodiment, the chimeric protein has a first domain capable of sterically binding its ligand / receptor and / or a second domain capable of sterically binding its ligand / receptor. Thus, there is sufficient overall flexibility in the chimeric protein and / or physical distance between the extracellular domain (or a portion thereof) and the rest of the chimeric protein such that the ligand / receptor binding domain of the extracellular domain is not sterically hindered from binding its ligand / receptor. This flexibility and / or physical distance (referred to as "slack") may be typically present in the extracellular domain(s), typically present in the linker, and / or typically present in the chimeric protein (as a whole). Alternatively or additionally, an amino acid sequence (for example) may be added to one or more extracellular domains and / or linkers to provide the necessary slack to avoid steric hindrance. Any amino acid sequence that provides slack may be added. In an embodiment, the added amino acid sequence is the sequence (Gly) nwhere n is any number between 1 and 100. Additional examples of amino acid sequences that can be added include the linker attachments described in Tables 1 and 3. In some embodiments, a polyethylene glycol (PEG) linker may be added between the extracellular domain and the linker to provide the slack necessary to avoid steric hindrance. Such PEG linkers are well known in the art.

[0130] In an embodiment, a chimeric protein of the present disclosure comprises the extracellular domain of human CD172a (SIRPα) (or a variant thereof), a linker, and the extracellular domain of human CD40L (or a variant thereof). In an embodiment, the linker comprises a hinge-CH2-CH3 Fc domain derived from IgG1 or IgG4, e.g., human IgG1 or IgG4. Thus, in an embodiment, a chimeric protein of the present disclosure comprises the extracellular domain of human CD172a (SIRPα) (or a variant thereof), a linker comprising a hinge-CH2-CH3 Fc domain, and the extracellular domain of human CD40L (or a variant thereof). Such a chimeric protein may be referred to herein as "hCD172a (SIRPα)-Fc-CD40L" or "SL-172154".

[0131] Diseases, Treatments, and Mechanisms of Action One aspect of the disclosure is a method of treating cancer in a human subject. In an embodiment, the method comprises (i) administering to the human subject a first dose of a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L). In an embodiment, the background level and / or activity of cells in a biological sample taken from the subject prior to administration of the first dose is measured, and the marker is selected from one or more of CD80+ cells, CD8+ cells, Granzyme B+ cells, CD68+ cells, Ki67+ cells, and PD-L1+ immune cells. In some embodiments, the method further comprises (ii) administering to the human subject a second dose of the chimeric protein if the level and / or activity of the cells after administration is greater than the background level and / or activity of the cells, hi some embodiments, the second dose is administered at least about 48 hours after administration of the first dose.

[0132] In some embodiments, the biological sample is selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, ascites, tissue or fine needle biopsy sample, cell-containing body fluid, suspended nucleic acid, sputum, saliva, urine, cerebrospinal fluid, ascites, pleural fluid, feces, lymphatic fluid, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or washing, aspirate, scraping, bone marrow specimen, biopsy specimen, and surgical specimen. In some embodiments, the biological sample is a biopsy specimen or a surgical specimen. In some embodiments, the biological sample is a tumor biopsy specimen or a tumor surgical specimen. In some embodiments, the tumor biopsy specimen is from a tumor selected from ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN).

[0133] In some embodiments, the level and / or activity of cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof. In some embodiments, the level and / or activity of cells is measured by contacting the sample with an agent that specifically binds to one or more molecules selected from CD80, CD8, Granzyme B, CD68, Ki67, and PD-L1. In some embodiments, the agent that specifically binds to one or more molecules is an antibody or a fragment thereof. In some embodiments, the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof.

[0134] In one embodiment, the cell level and / or activity is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding one or more of CD80, CD8, Granzyme B, CD68, Ki67, and PD-L1. In one embodiment, the agent that specifically binds to one or more nucleic acids is a nucleic acid primer or probe.

[0135] One aspect of the disclosure is a method of treating cancer in a human subject. In an embodiment, the method comprises (i) administering to the human subject a first dose of a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L). In an embodiment, the background level and / or activity of B cells and / or CD40+ cells in a first biological sample taken from the subject prior to administration of the first dose is measured. In an embodiment, the level and / or activity of B cells and / or CD40+ cells N hours after administration is measured in a second biological sample taken from the subject after administration of the first dose. In some embodiments, N is a number between 1 and 24. In some embodiments, the level and / or activity of B cells and / or CD40+ cells N hours after administration is lower than background levels and / or activity of B cells and / or CD40+ cells. In some embodiments, the level and / or activity of B cells and / or CD40+ cells M days after administration is measured in a third biological sample obtained from the subject after administration of the first dose. In some embodiments, M is a number between 1 and 28. In some embodiments, the method further comprises (ii) administering a second dose of the chimeric protein to the human subject if the level and / or activity of B cells and / or CD40+ cells M days after administration is at least about 50% higher than the level and / or activity of B cells and / or CD40+ cells N hours after administration. In some embodiments, the second dose is administered at least about 48 hours after administration of the first dose.

[0136] In certain embodiments, N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1. In certain embodiments, M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2. In certain embodiments, N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1 and M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2.

[0137] In some embodiments, the level and / or activity of B cells and / or CD40+ cells N hours after administration is greater than the background level and / or activity of B cells and / or CD40+ cells. In some embodiments, the level and / or activity of B cells and / or CD40+ cells N hours after administration is less than the background level and / or activity of B cells and / or CD40+ cells. In some embodiments, the level and / or activity of B cells and / or CD40+ cells N hours after administration is within about 10%, about 20%, about 30%, or about 40% of the background level and / or activity of B cells and / or CD40+ cells.

[0138] In some embodiments, the first biological sample, the second biological sample, and the third biological sample are independently selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, peritoneal fluid, tissue or fine needle biopsy sample, cell-containing body fluid, suspended nucleic acid, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymphatic fluid, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or washing, aspirate, scrape, bone marrow specimen, biopsy specimen, and surgical specimen. In some embodiments, the first biological sample, the second biological sample, and the third biological sample are blood.

[0139] In some embodiments, the level and / or activity of B cells and / or CD40+ cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof. In some embodiments, the level and / or activity of B cells and / or CD40+ cells is measured by contacting the sample with an agent that specifically binds to CD40 and / or a B cell marker. In some embodiments, the B cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45R, CD86, CD95, IgM, IgD, and CD40. In some embodiments, the agent that specifically binds to one or more molecules is an antibody or a fragment thereof. In some embodiments, the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof. In some embodiments, the level and / or activity of B cells and / or CD40+ cells is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding CD40 and / or a B cell marker. In certain embodiments, the B cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45R, CD86, CD95, IgM, IgD, and CD40. In certain embodiments, the agent that specifically binds to one or more nucleic acids is a nucleic acid primer or probe.

[0140] One aspect of the disclosure is a method of treating cancer in a human subject. In an embodiment, the method comprises (i) administering to the human subject a first dose of a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L). In an embodiment, the background amount and / or activity of a cytokine selected from CCL2, CXCL9, CXCL10, IFNα, IL15, IL23, IL-12, MCP-1, MIP-1β, MIP-1α, and MDC is measured in a first biological sample obtained from the subject prior to administration of the first dose. In some embodiments, the amount and / or activity of the cytokine is measured in a second biological sample taken from the subject after administration of the first dose N hours after administration. In some embodiments, N is a number between 1 and 24. In some embodiments, the amount and / or activity of the cytokine N hours after administration is higher than the background amount and / or activity of the cytokine. In some embodiments, the amount and / or activity of the cytokine is measured M days after administration in a third biological sample taken from the subject after administration of the first dose, where M is a number between 1 and 28. In some embodiments, the method further comprises (ii) administering a second dose of the chimeric protein to the human subject if the amount and / or activity of the cytokine M days after administration is at least about 30% lower than the amount and / or activity of the cytokine N hours after administration. In some embodiments, the second dose is administered at least about 48 hours after administration of the first dose.

[0141] One aspect of the disclosure is a method of treating cancer in a human subject. In an embodiment, the method includes (i) administering to the human subject a first dose of a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L). In an embodiment, a background level of cells in a pre-administration biological sample taken from the subject prior to administration of the first dose is measured, and the marker is selected from one or more of CD80+ cells, CD8+ cells, Granzyme B+ cells, CD68+ cells, Ki67+ cells, and PD-L1+ immune cells. In some embodiments, the method further comprises administering a second dose of the chimeric protein to the human subject when the level of the cells after administration is higher than background levels of the cells, hi some embodiments, the second dose is administered at least about 48 hours after administration of the first dose.

[0142] In some embodiments, the biological sample is selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, peritoneal fluid, tissue or fine needle biopsy sample, cell-containing body fluid, suspended nucleic acid, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymphatic fluid, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or washing, aspirate, scraping, bone marrow specimen, biopsy specimen, and surgical specimen. In some embodiments, the biological sample is a biopsy specimen or a surgical specimen. In some embodiments, the biological sample is a tumor biopsy specimen or a tumor surgical specimen. In some embodiments, the tumor biopsy specimen or tumor surgical specimen is derived from a tumor selected from ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN).

[0143] In some embodiments, the level and / or activity of cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof. In some embodiments, the level and / or activity of cells is measured by contacting the sample with an agent that specifically binds to one or more molecules selected from CD80, CD8, Granzyme B, CD68, Ki67, and PD-L1. In some embodiments, the agent that specifically binds to one or more molecules is an antibody or a fragment thereof. In some embodiments, the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof. In some embodiments, the level and / or activity of cells is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding one or more of CD80, CD8, Granzyme B, CD68, Ki67, and PD-L1. In some embodiments, the agent that specifically binds to one or more nucleic acids is a nucleic acid primer or a probe.

[0144] One aspect of the disclosure is a method of treating cancer in a human subject. In an embodiment, the method comprises (i) administering to the human subject a first dose of a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L). In an embodiment, the background level and / or activity of B cells and / or CD40+ cells in a first biological sample taken from the subject prior to administration of the first dose is measured. In an embodiment, the level and / or activity of B cells and / or CD40+ cells N hours after administration is measured in a second biological sample taken from the subject after administration of the first dose. In some embodiments, N is a number between 1 and 24. In some embodiments, the level and / or activity of B cells and / or CD40+ cells N hours after administration is lower than background levels and / or activity of B cells and / or CD40+ cells. In some embodiments, the level and / or activity of B cells and / or CD40+ cells M days after administration is measured in a third biological sample obtained from the subject after administration of the first dose. In some embodiments, M is a number between 1 and 28. In some embodiments, the method further comprises (ii) administering a second dose of the chimeric protein to the human subject if the level and / or activity of B cells and / or CD40+ cells M days after administration is at least about 50% higher than the level and / or activity of B cells and / or CD40+ cells N hours after administration. In some embodiments, the second dose is administered at least about 48 hours after administration of the first dose.

[0145] In certain embodiments, N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1. In certain embodiments, M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2. In certain embodiments, N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1 and M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2.

[0146] In some embodiments, the level and / or activity of B cells and / or CD40+ cells N hours after administration is greater than the background level and / or activity of B cells and / or CD40+ cells. In some embodiments, the level and / or activity of B cells and / or CD40+ cells N hours after administration is less than the background level and / or activity of B cells and / or CD40+ cells. In some embodiments, the level and / or activity of B cells and / or CD40+ cells N hours after administration is within about 10%, about 20%, about 30%, or about 40% of the background level and / or activity of B cells and / or CD40+ cells.

[0147] In some embodiments, the first biological sample, the second biological sample, and the third biological sample are independently selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, peritoneal fluid, tissue or fine needle biopsy sample, cell-containing body fluid, suspended nucleic acid, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymphatic fluid, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or washing, aspirate, scrape, bone marrow specimen, biopsy specimen, and surgical specimen. In some embodiments, the first biological sample, the second biological sample, and the third biological sample are blood.

[0148] In some embodiments, the level and / or activity of B cells and / or CD40+ cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof. In some embodiments, the level and / or activity of B cells and / or CD40+ cells is measured by contacting the sample with an agent that specifically binds to CD40 and / or a B cell marker. In some embodiments, the B cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45R, CD86, CD95, IgM, IgD, and CD40. In some embodiments, the agent that specifically binds to one or more molecules is an antibody or a fragment thereof. In some embodiments, the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof. In some embodiments, the level and / or activity of B cells and / or CD40+ cells is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding CD40 and / or a B cell marker. In certain embodiments, the B cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45R, CD86, CD95, IgM, IgD, and CD40. In certain embodiments, the agent that specifically binds to one or more nucleic acids is a nucleic acid primer or probe.

[0149] One aspect of the disclosure is a method of treating cancer in a human subject. In an embodiment, the method comprises (i) administering to the human subject a first dose of a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L). In an embodiment, the background amount and / or activity of a cytokine selected from CCL2, CXCL9, CXCL10, IFNα, IL15, IL23, IL-12, MCP-1, MIP-1β, MIP-1α, and MDC is measured in a first biological sample obtained from the subject prior to administration of the first dose. In some embodiments, the amount and / or activity of the cytokine is measured N hours later in a second biological sample taken from the subject after administration of the first dose. In some embodiments, N is a number between 1 and 24. In some embodiments, the amount and / or activity of the cytokine N hours after administration is higher than the background amount and / or activity of the cytokine. In some embodiments, the amount and / or activity of the cytokine is measured M days later in a third biological sample taken from the subject after administration of the first dose. In some embodiments, M is a number between 1 and 28. In some embodiments, the method further comprises (ii) administering a second dose of the chimeric protein to the human subject if the amount and / or activity of the cytokine M days after administration is at least about 30% lower than the amount and / or activity of the cytokine N hours after administration. In some embodiments, the second dose is administered at least about 48 hours after administration of the first dose.

[0150] In certain embodiments, N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1. In certain embodiments, M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2. In certain embodiments, N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1 and M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2.

[0151] In some embodiments, the amount and / or activity N hours after administration of the cytokine is greater than the background amount and / or activity of the cytokine. In some embodiments, the amount and / or activity N hours after administration of the cytokine is less than the background amount and / or activity of the cytokine. In some embodiments, the amount and / or activity N hours after administration of the cytokine is within about 10%, about 20%, about 30%, or about 40% of the background amount and / or activity of the cytokine.

[0152] In some embodiments, the first biological sample, the second biological sample, and the third biological sample are independently selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, peritoneal fluid, tissue or fine needle biopsy sample, cell-containing body fluid, suspended nucleic acid, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymphatic fluid, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or washing, aspirate, scrape, bone marrow specimen, biopsy specimen, and surgical specimen. In some embodiments, the first biological sample, the second biological sample, and the third biological sample are blood.

[0153] In some embodiments, the amount and / or activity of a cytokine is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof. In some embodiments, the amount and / or activity of a cytokine is measured by contacting a sample with an agent that specifically binds to the cytokine. In some embodiments, the agent that specifically binds to one or more molecules is an antibody or a fragment thereof. In some embodiments, the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof. In some embodiments, the amount and / or activity of a cytokine is measured by contacting a sample with an agent that specifically binds to one or more nucleic acids encoding the cytokine. In some embodiments, the agent that specifically binds to one or more nucleic acids is a nucleic acid primer or a probe.

[0154] The chimeric proteins disclosed herein, including CD172a (SIRPα)-Fc-CD40L chimeric proteins (e.g., SEQ ID NO: 59 or SEQ ID NO: 61), are used in methods to treat both advanced solid tumors and advanced lymphomas. These tumor types include melanoma, non-small cell lung cancer (squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma), urothelial carcinoma, renal cell carcinoma, squamous cell cervical carcinoma, gastric or gastroesophageal junction adenocarcinoma, anal squamous cell carcinoma, head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, and high-frequency microsatellite instability or mismatch repair deficient solid tumors other than central nervous system (CNS) tumors. Other tumors of interest include Hodgkin's lymphoma (HL), diffuse large B-cell lymphoma, acute myeloid leukemia (AML), and high-risk myelodysplastic syndromes (HR-MDS).

[0155] In some embodiments, the cancer comprises an advanced solid tumor (localized and / or metastatic). In some embodiments, the human subject is afflicted with cancer and the cancer to be treated is characterized by the presence of macrophages in the tumor microenvironment and / or the presence of tumor cells in the tumor that are CD47+ cells. In some embodiments, administration of a SIRPα-Fc-CD40L chimeric protein blocks "don't eat me" signals and / or stimulates "eat me" signals in tumor cells. In some embodiments, treatment with a SIRPα-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61) stimulates macrophages to phagocytose tumor cells and effectively presents tumor antigens of the phagocytosed tumor cells to T cells.

[0156] In some embodiments, the cancer is a solid cancer. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is a metastatic cancer. In some embodiments, the cancer is a hematological cancer. In some embodiments, the cancer expresses CD47.

[0157] In some embodiments, the cancer comprises advanced lymphoma. In some embodiments, the cancer comprises acute myeloid leukemia (AML). In some embodiments, the cancer comprises p53 mutant AML. In some embodiments, the cancer comprises high-risk myelodysplastic syndrome (HR-MDS).

[0158] Aspects of the present disclosure provide a method of treating cancer, the method comprising administering to a subject in need thereof an effective amount of a chimeric protein, e.g., in a pharmaceutical composition, as disclosed herein.

[0159] In many cases, it is desirable to enhance immunostimulatory signaling to boost an immune response, for example to enhance an anti-tumor immune response in a patient.

[0160] In an embodiment, the chimeric protein of the present disclosure comprises the extracellular domain of human CD172a (SIRPα), which prevents, blocks, reduces, inhibits, and / or hides the transmission of immunosuppressive signals from cancer cells that are trying to avoid being detected and / or destroyed, and the extracellular domain of human CD40L, which enhances, increases, and / or stimulates the transmission of immunostimulatory signals to anti-cancer immune cells. Thus, the simultaneous binding of the extracellular domain of CD172a (SIRPα) to its ligand / receptor and the binding of the extracellular domain of CD40L to its receptor prevents the transmission of immunosuppressive signals from cancer cells and stimulates the immune activity of immune system cells. In other words, the chimeric protein of the present disclosure can treat cancer through two different mechanisms.

[0161] In an embodiment, the disclosure relates to the treatment or prevention of cancer and / or tumors, e.g., cancer and / or tumors. As disclosed elsewhere herein, in an embodiment, the treatment of cancer includes modulating the immune system with the chimeric proteins of the invention to promote an increase or activation of immune stimulatory signals. In an embodiment, the method reduces the amount or activity of regulatory T cells (Tregs) compared to untreated subjects or subjects treated with antibodies against CD172a (SIRPα), CD40L, and / or their respective ligands or receptors. In an embodiment, the method increases the priming of effector T cells in the subject's draining lymph nodes compared to untreated subjects or subjects treated with antibodies against CD172a (SIRPα), CD40L, and / or their respective ligands or receptors. In an embodiment, the method causes an overall decrease in immune suppressive cells and a shift to a more inflammatory tumor environment compared to untreated subjects or subjects treated with antibodies against CD172a (SIRPα), CD40L, and / or their respective ligands or receptors.

[0162] In some embodiments, the chimeric proteins of the invention can be used in methods that can or include modulating the magnitude of an immune response, e.g., modulating the level of effector output. In some embodiments, for example, when used to treat cancer, the chimeric proteins of the invention alter the degree of immune stimulation compared to immune inhibition, increasing the amplitude of T cell responses, including, but not limited to, stimulating increased levels of cytokine production, proliferation, or potential to kill targets. In some embodiments, the patient's T cells are activated and / or stimulated by the chimeric protein, allowing the activated T cells to sequester and / or secrete cytokines.

[0163] Cancer or tumor refers to the unregulated proliferation of cells and / or abnormal increase in cell survival rate and / or inhibition of apoptosis that interferes with the normal functioning of the body's organs and systems. It includes benign and malignant cancers, polyps, hyperplasias, and dormant tumors or micrometastases. It also includes cells with abnormal proliferation that are not prevented by the immune system (e.g., virus-infected cells). Cancer may be a primary cancer or a metastatic cancer. A primary cancer may be an area of ​​cancer cells at the site of origin that becomes clinically detectable, which may be a primary tumor. In contrast, a metastatic cancer may be the spread of disease from one organ or part to another non-adjacent organ or part. Metastatic cancer is caused by cancer cells that have acquired the ability to penetrate and invade normal tissues surrounding the local area, forming new tumors that may be local metastases. Cancer may also be caused by cancer cells that have acquired the ability to penetrate the walls of lymphatic and / or blood vessels, after which the cancer cells may circulate via the bloodstream to other parts and tissues of the body (thus becoming circulating tumor cells). Cancer may result from processes such as lymphatic or hematogenous spread. Cancer may also be caused by tumor cells coming to rest at another site and re-infiltrating the blood vessels or walls to continue to grow, eventually forming another clinically detectable tumor. The cancer may be this new tumor or it may be a metastatic (or secondary) tumor.

[0164] Cancer may be caused by metastasized tumor cells, and may be a secondary tumor or a metastatic tumor. The cells of the tumor may resemble the cells of the original tumor. For example, if breast cancer or colon cancer metastasizes to the liver, the secondary tumor will be present in the liver, but will be composed of abnormal breast cells or colon cells, not abnormal liver cells. Thus, the tumor in the liver may be metastatic breast cancer or metastatic colon cancer, but not liver cancer.

[0165] Cancer can originate from any tissue. Cancer can be of melanoma, colon, breast, or prostate origin, and therefore may consist of cells that were originally skin, colon, breast, or prostate tissue, respectively. Cancer can also be a hematological malignancy, which can be leukemia or lymphoma. Cancer can invade tissues such as liver, lung, bladder, or intestine.

[0166] In some embodiments, the chimeric protein is used to treat a subject with a treatment-refractory cancer. In some embodiments, the chimeric protein is used to treat a subject who is refractory to one or more immunomodulatory agents. For example, in some embodiments, the chimeric protein is used to treat a subject who does not respond to treatment or whose disease progresses after about 12 weeks of treatment. For example, in some embodiments, the subject is refractory to one or more CD172a (SIRPα) and / or CD47 agents, including, for example, magrolimab (5F9), Hu5F9-G4, CC-90002, Ti-061, SRF231, TTI-621, TTI-622, or ALX148-refractory patients. For example, in some embodiments, the subject is refractory to an anti-CTLA-4 agent, such as, for example, an ipilimumab (YERVOY)-refractory patient (e.g., a melanoma patient). Thus, in certain embodiments, the present disclosure provides cancer treatments that provide relief to patients who are non-responsive to a variety of treatments, including monotherapy with one or more immunomodulatory agents.

[0167] In an embodiment, the present disclosure provides chimeric proteins that target cells or tissues in the tumor microenvironment. In an embodiment, the cells or tissues in the tumor microenvironment express one or more targets or binding partners of the chimeric protein. Tumor microenvironment refers to the cellular environment in which a tumor resides, including cells, secreted proteins, physiological small molecules, and blood vessels. In an embodiment, the cells or tissues in the tumor microenvironment are one or more of the following: tumor vasculature, tumor-infiltrating lymphocytes, fibroblastic reticular cells, endothelial progenitor cells (EPCs), cancer-associated fibroblasts, pericytes, other stromal cells, components of the extracellular matrix (ECM), dendritic cells, antigen-presenting cells, T cells, regulatory T cells, macrophages, neutrophils, and other immune cells located in the vicinity of the tumor. In an embodiment, the chimeric proteins of the present invention target cancer cells. In an embodiment, the cancer cells express one or more targets or binding partners of the chimeric protein.

[0168] The activation of regulatory T cells is critically influenced by costimulatory and co-inhibitory signals. Two major families of costimulatory molecules include the B7 and tumor necrosis factor (TNF) families. These molecules bind to receptors on T cells that belong to the CD28 or TNF receptor families, respectively. Many well-defined co-inhibitors and their receptors belong to the B7 and CD28 families.

[0169] In certain embodiments, an immunostimulatory signal refers to a signal that enhances an immune response. For example, in oncology, such a signal may enhance anti-tumor immunity. For example, but not limited to, an immunostimulatory signal may be identified by directly stimulating the proliferation, cytokine production, killing activity, or phagocytic activity of white blood cells. For example, the chimeric protein may directly stimulate the proliferation and cytokine production of individual T cell subsets. Another example includes direct stimulation of immunosuppressive cells via receptors that inhibit the activity of such immunosuppressive cells. This includes, for example, stimulation of CD4+FoxP3+ regulatory T cells, which reduces the ability of regulatory T cells to suppress the proliferation of conventional CD4+ or CD8+ T cells. In another example, this includes stimulation of CD40 on the surface of antigen-presenting cells, which causes activation of antigen-presenting cells, including enhanced ability of those cells to present antigens in the context of appropriate natural costimulatory molecules, including those in the B7 or TNF superfamily. In another example, the chimeric protein causes activation of lymphoid cells and / or production of proinflammatory cytokines or chemokines, which may further stimulate an immune response within the tumor.

[0170] In certain embodiments, the chimeric proteins of the invention can be used in methods that can or require enhancing, restoring, promoting, and / or stimulating immune regulation. In certain embodiments, the chimeric proteins of the invention described herein restore, promote, and / or stimulate the activity or activation of one or more immune cells against tumor cells, including, but not limited to, T cells, cytotoxic T lymphocytes, T helper cells, natural killer (NK) cells, natural killer T (NKT) cells, anti-tumor macrophages (e.g., M1 macrophages), B cells, and dendritic cells. In certain embodiments, the chimeric proteins of the present invention enhance, restore, promote, and / or stimulate T cell activity and / or activation, including activating and / or stimulating one or more T cell intrinsic signals, including, by way of non-limiting examples, pro-survival signals, autocrine or paracrine growth signals; p38 MAPK-, ERK-, STAT-, JAK-, AKT-, or PI3K-mediated signals; anti-apoptotic signals, and / or signals that promote and / or are required for one or more of pro-inflammatory cytokine production, or T cell migration, or T cell tumor infiltration.

[0171] In some embodiments, the chimeric proteins of the invention can cause or can be used in methods that require the expansion of one or more of T cells (including, but not limited to, cytotoxic T lymphocytes, T helper cells, and natural killer T (NKT) cells), B cells, natural killer (NK) cells, natural killer T (NKT) cells, dendritic cells, monocytes, and macrophages (e.g., one or more of M1 and M2) to a tumor or tumor microenvironment. In some embodiments, the chimeric proteins enhance the recognition of tumor antigens by CD8+ T cells, particularly T cells infiltrating the tumor microenvironment. In some embodiments, the chimeric proteins of the invention induce CD19 expression and / or increase the number of CD19-positive cells (e.g., CD19-positive B cells). In some embodiments, the chimeric proteins of the invention induce IL-15Rα expression and / or increase the number of IL-15Rα-positive cells (e.g., IL-15Rα-positive dendritic cells).

[0172] In an embodiment, the chimeric proteins of the present invention can be used in methods that can inhibit and / or cause or require a reduction in immune suppressive cells (e.g., myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), tumor-associated neutrophils (TANs), M2 macrophages, and tumor-associated macrophages (TAMs)), particularly within the tumor and / or tumor microenvironment (TME). In an embodiment, the treatment can alter the ratio of M1 to M2 macrophages in the tumor site and / or TME in favor of M1 macrophages. In an embodiment, the SIRPα-Fc-CD40L chimeric protein inhibits / reduces / eliminates the delivery of "don't eat me" signals to tumor cells via Sipr1a / CD47. In an embodiment, the SIRPα-Fc-CD40L chimeric protein increases the likelihood that the tumor will be attacked by the subject's immune system. In an embodiment, the SIRPα-Fc-CD40L chimeric protein increases the likelihood that the tumor will be attacked by the subject's innate immune system. In one embodiment, the SIRPα-Fc-CD40L chimeric protein increases the likelihood that the tumor will be attacked by the subject's adaptive immune system. In one embodiment, the SIRPα-Fc-CD40L chimeric protein can suppress / reduce / eliminate binding of CD47 overexpressed on tumors to SIRPα expressed on phagocytes, allowing phagocytic removal of cancer cells and / or immunogenic processing of tumor antigens by macrophages and / or dendritic cells. In one embodiment, administration of the SIRPα-Fc-CD40L chimeric protein blocks the "don't eat me" signal of tumor cells and / or stimulates the "eat me" signal. In one embodiment, treatment with the SIRPα-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61) stimulates macrophages to phagocytose tumor cells and effectively presents tumor antigens of the phagocytosed tumor cells to T cells.

[0173] In some embodiments, the chimeric proteins of the present invention may increase serum levels of various cytokines, including, but not limited to, one or more of IFNγ, TNFα, IL-2, IL-4, IL-5, IL-9, IL-10, IL-13, IL-17A, IL-17F, and IL-22. In some embodiments, the chimeric proteins of the present invention may enhance IL-2, IL-4, IL-5, IL-10, IL-13, IL-17A, IL-22, or IFNγ in the serum of a treated subject. In some embodiments, the chimeric proteins of the present invention do not increase serum levels of a particular cytokine. In some embodiments, the chimeric proteins of the present invention do not increase serum levels of IL-6 and / or TNFα in the serum. In some embodiments, the chimeric proteins of the present invention do not increase serum levels of f IL-6 and / or TNFα in the serum of a treated subject. In certain embodiments, the chimeric proteins of the invention do not increase serum levels of IL-6 and / or TNFα in the serum of a treated subject, but do increase the levels of other cytokines, including but not limited to CCL2, IL-8, and CXCL9, in the serum of a treated subject. Detection of such cytokine responses can provide a method for determining optimal dosing regimens for a given chimeric protein.

[0174] In the chimeric proteins of the present disclosure, the chimeric proteins can increase or prevent a decrease in subpopulations of CD4+ and / or CD8+ T cells.

[0175] In the chimeric proteins of the present disclosure, the chimeric proteins can enhance tumor killing activity by T cells.

[0176] In one embodiment, the chimeric protein activates T cells in a human subject when bound to the CD40L domain of the chimeric protein; (a) prevents one or more tumor cells from transmitting immunosuppressive signals when bound to a first domain of the chimeric protein; (b) achieves a quantifiable cytokine response in the peripheral blood of the subject; and / or (c) reduces tumor growth in a subject in need thereof compared to subjects treated with a CD40 agonistic antibody and / or a CD47 blocking antibody.

[0177] In certain embodiments, the chimeric proteins of the present invention inhibit, block, and / or reduce cell death of anti-tumor CD8+ and / or CD4+ T cells, or stimulate, induce, and / or enhance cell death of tumor-inducing T cells. T cell exhaustion is a state of T cell dysfunction characterized by progressive loss of proliferation and effector function, leading to clonal deletion. Thus, tumor-inducing T cells refer to a state of T cell dysfunction that occurs during many chronic infections, inflammatory diseases, and cancers. This dysfunction is defined by insufficient proliferation and / or effector function, persistent expression of inhibitory receptors, and transcriptional status that differ from functional effector or memory T cells. Exhaustion prevents optimal control of infection and tumors. Exemplary tumor-inducing T cells include, but are not limited to, Tregs, CD4+ and / or CD8+ T cells expressing one or more checkpoint inhibitory receptors, Th2 cells, and Th17 cells. Checkpoint inhibitory receptors refer to receptors expressed on immune cells that prevent or inhibit unregulated immune responses. In contrast, anti-tumor CD8+ and / or CD4+ T cells refer to T cells that are capable of mounting an immune response against a tumor.

[0178] In one embodiment, the chimeric proteins of the present invention can increase the ratio of effector T cells to regulatory T cells and can be used in methods involving the same. Exemplary effector T cells include ICOS + Effector T cells, cytotoxic T cells (e.g., αβ TCR, CD3 + , CD8 + , CD45RO+ ), CD4 + Effector T cells (e.g., αβ TCR, CD3 + , CD4 + , CCR7 + , CD62L high, IL - 7R / CD127 + ), CD8 + Effector T cells (e.g., αβ TCR, CD3 + , CD8 + , CCR7 + , CD62L high, IL - 7R / CD127 + ); effector memory T cells (e.g., CD62L low, CD44 + , TCR, CD3 + , I.L. - 7R / CD127 + , IL-15R + , CCR7 low), central memory T cells (e.g., CCR7 + , CD62L + , CD27 + , or CCR7 high, CD44 + , CD62L high, TCR, CD3 + , IL-7R / CD127 + , IL-15R + );CD62L + Effector T cells, early effector memory T cells (CD27 + CD62L - ) and late effector memory T cells (CD27 - CD62L - ) (TemE and TemL, respectively) + Effector memory T cells (TEM); CD127 ( + )CD25(low / -) effector T cells;CD127( - )CD25( - ) Effector T cells; CD8 + Stem cell memory effector cells (TSCM) (e.g., CD44(low)CD62L(high)CD122(high)sca( + )); TH1 effector T cells (e.g., CXCR3 + , CXCR6 +, and CCR5 + , or αβ TCR, CD3 + , CD4 + , IL-12R + , IFNγR + , CXCR3 + ), TH2 effector T cells (e.g., CCR3 + , CCR4 + , and CCR8 + ; or αβ TCR, CD3 + , CD4 + , IL-4R + , IL-33R + , CCR4 + , IL-17RB + , CRTH2 + ); TH9 effector T cells (e.g., αβ TCR, CD3 + , CD4 + ); TH17 effector T cells (e.g., αβ TCR, CD3 + , CD4 + , IL-23R + , CCR6 + , IL-1R + );CD4 + CD45RO + CCR7 + Effector T cells, CD4 + CD45RO + CCR7( - ) effector T cells; and effector T cells that secrete IL-2, IL-4, and / or IFN-γ. Exemplary regulatory T cells include ICOS + Regulatory T cells, CD4 + CD25 + FOXP3 + Regulatory T cells, CD4 + CD25 + Regulatory T cells, CD4 + CD25 - Regulatory T cells, CD4 + CD25 hyperregulatory T cells, TIM-3 + CD172a (SIRPα) + Regulatory T cell, lymphocyte activation gene-3 (LAG-3) + Regulatory T cells, CTLA-4 / CD152+ Regulatory T cells, Neuropilin-1 (Nrp-1) + Regulatory T cells, CCR4 + CCR8 + Regulatory T cells, CD62L (L-selectin) + Regulatory T cells, CD45RB low regulatory T cells, CD127 low regulatory T cells, LRRC32 / GARP + Regulatory T cells, CD39 + Regulatory T cells, GITR + Regulatory T cells, LAP + Regulatory T cell, 1B11 + Regulatory T cells, BTLA + Regulatory T cells, type 1 regulatory T cells (Tr1 cells), T helper type 3 (Th3) cells, regulatory cells of natural killer T cell phenotype (NKTreg), CD8 + Regulatory T cells, CD8 + CD28 - These include regulatory T cells and / or regulatory T cells that secrete IL-10, IL-35, TGF-β, TNF-α, Galectin-1, IFN-γ, and / or MCP1.

[0179] In certain embodiments, the chimeric protein of the invention induces an expansion of effector T cells (eg, CD4+CD25- T cells).

[0180] In certain embodiments, the chimeric protein causes a depletion of regulatory T cells (eg, CD4+CD25+ T cells).

[0181] In some embodiments, the chimeric protein generates a memory response that can, for example, prevent recurrence or protect the animal from recurrence and / or prevent metastasis or reduce the likelihood of metastasis. Thus, animals treated with the chimeric protein can attack tumor cells and / or prevent tumor development when rechallenged after initial treatment with the chimeric protein. Thus, the chimeric proteins of the present disclosure stimulate both active tumor destruction and also immune recognition of tumor antigens, which are essential for programming a memory response that can prevent recurrence.

[0182] In some embodiments, the chimeric protein can cause activation of antigen-presenting cells. In some embodiments, the chimeric protein can enhance the antigen-presenting capacity of antigen-presenting cells.

[0183] In certain embodiments, the chimeric proteins of the invention can be used in methods that include, transiently stimulating effector T cells for greater than about 12 hours, about 24 hours, about 48 hours, about 72 hours, or about 96 hours, or about one week, or about two weeks. In certain embodiments, the transient stimulation of effector T cells occurs substantially in the patient's bloodstream, or in specific tissues / locations including, for example, lymphoid tissues such as bone marrow, lymph nodes, spleen, thymus, mucosa-associated lymphoid tissue (MALT), non-lymphoid tissues, or the tumor microenvironment.

[0184] In the chimeric proteins of the present disclosure, the chimeric proteins of the present invention unexpectedly exhibit a slow dissociation rate (Kd or K off) which in some embodiments results in an unexpectedly long interaction between the receptor and the ligand and vice versa. Such an effect allows for a longer positive signaling effect, e.g., an increase or activation of an immune stimulatory signal. For example, the chimeric proteins of the present invention, e.g., through long dissociation rate binding, allow for sufficient signaling to cause immune cell proliferation, allow for anti-tumor attack, allow for sufficient signaling to cause stimulatory signals, e.g., release of cytokines.

[0185] The chimeric proteins of the present invention can form stable synapses between cells. Stable synapses of cells (e.g., between cells carrying negative signals) promoted by the chimeric proteins provide a spatial orientation favorable for tumor regression, such as positioning T cells to attack tumor cells and / or sterically preventing tumor cells from delivering negative signals, including negative signals beyond those masked by the chimeric proteins of the present invention. In one embodiment, this is achieved by reducing the serum half-life (t 1 / 2 ) compared to longer on-target (e.g., intratumoral) t 1 / 2 Such properties may have the combined advantage of reducing off-target toxicity associated with systemic distribution of the chimeric protein.

[0186] In certain embodiments, the chimeric protein can provide a sustained immunomodulatory effect.

[0187] Due to the ability to enhance site-specific interactions of two immunotherapeutic agents, the chimeric proteins of the invention provide synergistic therapeutic effects (e.g., antitumor effects). In certain embodiments, the chimeric proteins of the invention offer the potential to reduce off-site and / or systemic toxicity.

[0188] In some embodiments, the chimeric proteins of the present invention exhibit enhanced safety profiles. In some embodiments, the chimeric proteins of the present invention exhibit reduced toxicity. For example, administration of the chimeric proteins of the present invention may reduce one or more of the side effects, such as diarrhea, inflammation (e.g., intestinal), and weight loss, that occur after administration of an antibody directed to the ligand(s) / receptor(s) targeted by the extracellular domain of the chimeric proteins of the present invention. In some embodiments, the chimeric proteins of the present invention improve safety without sacrificing efficacy, compared to an antibody directed to the ligand(s) / receptor(s) targeted by the extracellular domain of the chimeric proteins of the present invention.

[0189] In certain embodiments, the chimeric proteins of the present invention reduce side effects, e.g., GI complications, compared to current immunotherapies, e.g., antibodies directed to the ligand(s) / receptor(s) targeted by the extracellular domain of the chimeric proteins of the present invention. Exemplary GI complications include abdominal pain, loss of appetite, autoimmune effects, constipation, cramps, dehydration, diarrhea, feeding problems, fatigue, flatulence, fluid in the abdomen or ascites, gastrointestinal (GI) endotoxicosis, GI mucositis, inflammatory bowel disease, irritable bowel syndrome (IBS-D and IBS-C), nausea, pain, stool or urinary changes, ulcerative colitis, vomiting, weight gain due to fluid retention, and / or weakness.

[0190] Pharmaceutical Compositions Aspects of the present disclosure include pharmaceutical compositions comprising a therapeutically effective amount of the chimeric proteins disclosed herein.

[0191] Any of the chimeric proteins disclosed herein may be used in a pharmaceutical composition.

[0192] In some embodiments, the chimeric proteins disclosed herein are provided as a sterile frozen solution in a vial or as a sterile liquid solution in a vial. A pharmaceutical product comprising a chimeric protein disclosed herein is sterile filtered and contains a formulated chimeric protein solution disclosed herein, filled into a 10 mL disposable glass vial stoppered with a Flurotec® rubber stopper and sealed with an aluminum flip-off seal. In some embodiments, the chimeric proteins disclosed herein are formulated at about 10 mg / mL to about 30 mg / mL, e.g., about 20 mg / mL, in about 30 mM to about 70 mM L-histidine, e.g., about 50 mM L-histidine, and about 125 mM to about 400 mM sucrose, e.g., about 250 mM sucrose, in water for injection. In some embodiments, each vial contains about 1 mL of pharmaceutical product or about 20 mg of a chimeric protein disclosed herein.

[0193] The chimeric proteins disclosed herein, including CD172a (SIRPα)-Fc-CD40L chimeric proteins (e.g., SEQ ID NO: 59 or SEQ ID NO: 61), may have sufficiently basic functional groups capable of reacting with inorganic or organic acids, or carboxyl groups capable of reacting with inorganic or organic bases, to form pharma- ceutically acceptable salts. As is well known in the art, pharma- ceutically acceptable acid addition salts are formed from pharma- ceutically acceptable acids. Such salts include, for example, pharma- ceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2-19 (1977), and The Handbook of Pharmaceutical Salts; Properties, Selection, and Use. P.H. Stahl and C.G. Wermuth (eds.), Verlag, Zurich (Switzerland) 2002, which are incorporated herein by reference in their entirety.

[0194] In certain embodiments, the compositions disclosed herein are in the form of a pharma- ceutically acceptable salt.

[0195] Further, any chimeric protein disclosed herein can be administered to a subject as a composition comprising a pharma- ceutically acceptable carrier or vehicle, e.g., a component of a pharmaceutical composition. Such pharmaceutical compositions can optionally contain a suitable amount of a pharma- ceutical acceptable excipient to provide a suitable form for administration. The pharmaceutical excipient can be a liquid, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. The pharmaceutical excipient can be, for example, saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizer, thickening agent, lubricant, and coloring agents can be used. In certain embodiments, the pharma- ceutical acceptable excipient is sterile when administered to a subject. Water is a useful excipient when any agent disclosed herein is administered intravenously. Saline solutions and aqueous solutions of dextrose and glycerol can also be used as liquid excipients, particularly for infusion solutions. Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, etc. Any of the agents disclosed herein, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

[0196] In certain embodiments, a composition disclosed herein, e.g., a pharmaceutical composition, is resuspended in a saline buffer (including but not limited to TBS, PBS, etc.).

[0197] In some embodiments, the chimeric protein may be conjugated and / or fused to another drug to extend half-life or otherwise improve pharmacodynamic and pharmacokinetic properties. In some embodiments, the chimeric protein may be fused or conjugated to one or more of PEG, XTEN (e.g., as rPEG), polysialic acid (POLYXEN), albumin (e.g., human serum albumin or HAS), elastin-like protein (ELP), PAS, HAP, GLK, CTP, transferrin, etc. In some embodiments, each individual chimeric protein is fused to one or more of the drugs described in Strohl, BioDrugs 29(4):215-239(2015), the entire contents of which are incorporated herein by reference.

[0198] The present disclosure includes the disclosed chimeric proteins in various formulations of pharmaceutical compositions. Any chimeric protein disclosed herein may be in the form of a solution, suspension, emulsion, drip, tablet, pill, pellet, capsule, liquid-containing capsule, powder, sustained release formulation, suppository, emulsion, aerosol, spray, suspension, or other form suitable for use. DNA or RNA constructs encoding the protein sequence may also be used. In some embodiments, the composition is in the form of a capsule (see, for example, U.S. Patent No. 5,698,155). Other examples of suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed. 1995), which is incorporated herein by reference.

[0199] If necessary, the pharmaceutical composition containing the chimeric protein may also contain a solubilizing agent. Also, as is known in the art, the drug may be delivered in a suitable vehicle or delivery device. The composition for administration may optionally contain a local anesthetic, such as lignocaine, to reduce pain at the injection site.

[0200] Pharmaceutical compositions containing the chimeric protein of the present disclosure may be conveniently provided in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing the therapeutic agent into association with a carrier which constitutes one or more accessory ingredients. In general, pharmaceutical compositions are prepared by bringing the therapeutic agent into association uniformly and intimately with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulation (e.g., wet or dry granulation, powder blending, etc., followed by tableting using conventional methods known in the art).

[0201] In certain embodiments, any of the chimeric proteins disclosed herein are formulated in accordance with routine procedures as pharmaceutical compositions adapted for the methods of administration disclosed herein.

[0202] Administration, Dosage, and Treatment Regimens One aspect of the present disclosure is a method for evaluating the efficacy of a cancer treatment in a subject suffering from cancer and in need of the cancer treatment. In an embodiment, the method includes (i) obtaining a biological sample taken from a subject receiving a first dose of a chimeric protein. In an embodiment, the chimeric protein has a general structure of N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L). In an embodiment, the background level and / or activity of cells in the biological sample taken from the subject prior to administration of the first dose is measured. In some embodiments, the cells are selected from one or more of CD80+ cells, CD8+ cells, Granzyme B+ cells, CD68+ cells, Ki67+ cells, and PD-L1+ immune cells. In some embodiments, the method further comprises (ii) measuring the post-administration level and / or activity of the cells in the biological sample. In some embodiments, the method further comprises (iii) determining that the chimeric protein is efficacious if the post-administration level and / or activity of the cells is higher than the background level and / or activity of the cells. In some embodiments, the biological sample is a tumor biopsy or tumor surgical specimen. In some embodiments, the level and / or activity of the cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

[0203] One aspect of the present disclosure is a method for selecting a subject for a cancer treatment. In an embodiment, the method includes (i) obtaining a biological sample from a subject receiving a first dose of a chimeric protein. In an embodiment, the chimeric protein has a general structure of N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L). In an embodiment, the background level and / or activity of cells in the biological sample from the subject prior to administration of the first dose is measured. In some embodiments, the cells are selected from one or more of CD80+ cells, CD8+ cells, Granzyme B+ cells, CD68+ cells, Ki67+ cells, and PD-L1+ immune cells. In some embodiments, the method further comprises (ii) measuring the post-administration level and / or activity of the cells in the biological sample. In some embodiments, the method further comprises (iii) selecting the subject for treatment with the chimeric protein if the post-administration level and / or activity of the cells is higher than the background level and / or activity of the cells. In some embodiments, the biological sample is a tumor biopsy or tumor surgical specimen. In some embodiments, the level and / or activity of the cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

[0204] In some embodiments, the biological sample is selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, peritoneal fluid, tissue or fine needle biopsy sample, cell-containing body fluid, suspended nucleic acid, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymphatic fluid, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or washing, aspirate, scraping, bone marrow specimen, biopsy specimen, and surgical specimen. In some embodiments, the biological sample is a biopsy specimen or a surgical specimen. In some embodiments, the biological sample is a tumor biopsy specimen or a tumor surgical specimen. In some embodiments, the tumor biopsy specimen or tumor surgical specimen is derived from a tumor selected from ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN).

[0205] In some embodiments, the level and / or activity of cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof. In some embodiments, the level and / or activity of cells is measured by contacting the sample with an agent that specifically binds to one or more molecules selected from CD80, CD8, Granzyme B, CD68, Ki67, and PD-L1. In some embodiments, the agent that specifically binds to one or more molecules is an antibody or a fragment thereof. In some embodiments, the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof. In some embodiments, the level and / or activity of cells is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding one or more of CD80, CD8, Granzyme B, CD68, Ki67, and PD-L1. In some embodiments, the agent that specifically binds to one or more nucleic acids is a nucleic acid primer or a probe.

[0206] One aspect of the present disclosure is a method for evaluating the efficacy of a cancer treatment in a subject suffering from cancer and in need of the cancer treatment. In an embodiment, the method includes (i) obtaining a first biological sample taken from a subject receiving a first dose of a chimeric protein. In an embodiment, the chimeric protein has a general structure of N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L). In an embodiment, the method further includes measuring the background level and / or activity of B cells and / or CD40+ cells in the first biological sample. In some embodiments, the method further comprises (iii) obtaining a second biological sample from the subject N hours after the administration, where N is a number between 1 and 24. In some embodiments, the method further comprises measuring the level and / or activity of B cells and / or CD40+ cells in the second biological sample N hours after the administration. In some embodiments, the method further comprises (iv) obtaining a third biological sample from the subject M days after the administration, where M is a number between 1 and 28. In some embodiments, the method further comprises measuring the level and / or activity of B cells and / or CD40+ cells in the third biological sample M days after the administration. In one embodiment, the method further includes (v) determining that the chimeric protein is effective if the level and / or activity of B cells and / or CD40+ cells N hours after administration is lower than the background level and / or activity of B cells and / or CD40+ cells and / or if the level and / or activity of B cells and / or CD40+ cells M days after administration is at least about 50% higher than the level and / or activity of B cells and / or CD40+ cells N hours after administration.

[0207] One aspect of the present disclosure is a method for selecting a subject for treatment with a cancer therapy. In an embodiment, the method includes (i) obtaining a first biological sample from a subject receiving a first dose of a chimeric protein. In an embodiment, the chimeric protein has a general structure of N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L). In an embodiment, the method further includes measuring background levels and / or activity of B cells and / or CD40+ cells in the first biological sample. In an embodiment, the method further includes (iii) obtaining a second biological sample from the subject N hours after administration, where N is a number between 1 and 24. In some embodiments, the method further comprises measuring the level and / or activity of B cells and / or CD40+ cells in the second biological sample N hours after administration. In some embodiments, the method further comprises (iv) obtaining a third biological sample from the subject M days after administration, where M is a number between 1 and 28. In some embodiments, the method further comprises measuring the level and / or activity of B cells and / or CD40+ cells in the third biological sample M days after administration. In some embodiments, the method further comprises (v) selecting the subject for treatment with the chimeric protein if the level and / or activity of B cells and / or CD40+ cells N hours after administration is lower than background level and / or activity of B cells and / or CD40+ cells and / or if the level and / or activity of B cells and / or CD40+ cells M days after administration is at least about 50% higher than the level and / or activity of B cells and / or CD40+ cells N hours after administration.

[0208] In certain embodiments, N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1. In certain embodiments, M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2. In certain embodiments, N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1 and M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2.

[0209] In some embodiments, the level and / or activity of B cells and / or CD40+ cells N hours after administration is greater than the background level and / or activity of B cells and / or CD40+ cells. In some embodiments, the level and / or activity of B cells and / or CD40+ cells N hours after administration is less than the background level and / or activity of B cells and / or CD40+ cells. In some embodiments, the level and / or activity of B cells and / or CD40+ cells N hours after administration is within about 10%, about 20%, about 30%, or about 40% of the background level and / or activity of B cells and / or CD40+ cells.

[0210] In some embodiments, the first biological sample, the second biological sample, and the third biological sample are independently selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, peritoneal fluid, tissue or fine needle biopsy sample, cell-containing body fluid, suspended nucleic acid, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymphatic fluid, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or washing, aspirate, scrape, bone marrow specimen, biopsy specimen, and surgical specimen. In some embodiments, the first biological sample, the second biological sample, and the third biological sample are blood.

[0211] In some embodiments, the level and / or activity of B cells and / or CD40+ cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof. In some embodiments, the level and / or activity of B cells and / or CD40+ cells is measured by contacting the sample with an agent that specifically binds to CD40 and / or a B cell marker. In some embodiments, the B cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45R, CD86, CD95, IgM, IgD, and CD40. In some embodiments, the agent that specifically binds to one or more molecules is an antibody or a fragment thereof. In some embodiments, the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof. In some embodiments, the level and / or activity of B cells and / or CD40+ cells is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding CD40 and / or a B cell marker. In certain embodiments, the B cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45R, CD86, CD95, IgM, IgD, and CD40. In certain embodiments, the agent that specifically binds to one or more nucleic acids is a nucleic acid primer or probe.

[0212] One aspect of the present disclosure is a method for evaluating the efficacy of a cancer treatment in a subject suffering from cancer and in need of the cancer treatment. In an embodiment, the method includes (i) obtaining a first biological sample taken from a subject receiving a first dose of a chimeric protein. In an embodiment, the chimeric protein has a general structure of N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L). In an embodiment, the method further includes (ii) measuring the background amount and / or activity of a cytokine in the first biological sample. In some embodiments, the cytokine is selected from CCL2, CXCL9, CXCL10, IFNα, IL15, IL23, IL-12, MCP-1, MIP-1β, MIP-1α, and MDC. In some embodiments, the method further comprises (iii) obtaining a second biological sample from the subject N hours after administration, where N is a number between 1 and 24. In some embodiments, the method further comprises measuring the amount and / or activity of the cytokine in the second biological sample N hours after administration. In some embodiments, the method further comprises (iv) obtaining a third biological sample from the subject M days after administration, where M is a number between 1 and 28. In some embodiments, the method further comprises measuring the amount and / or activity of the cytokine in the third biological sample M days after administration. In one embodiment, the method further includes (v) determining that the chimeric protein is effective if the amount and / or activity of the cytokine N hours after administration is greater than the background amount and / or activity of the cytokine and / or if the amount and / or activity of the cytokine M days after administration is at least about 50% lower than the amount and / or activity of the cytokine N hours after administration.

[0213] One aspect of the present disclosure is a method for selecting a subject for treatment with a cancer therapy. In an embodiment, the method includes (i) obtaining a first biological sample from a subject receiving a first dose of a chimeric protein. In an embodiment, the chimeric protein has a general structure of N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L). In an embodiment, the method further includes (ii) measuring the background amount and / or activity of a cytokine in the first biological sample. In some embodiments, the cytokine is selected from CCL2, CXCL9, CXCL10, IFNα, IL15, IL23, IL-12, MCP-1, MIP-1β, MIP-1α, and MDC. In some embodiments, the method further comprises (iii) obtaining a second biological sample from the subject N hours after administration, where N is a number between 1 and 24. In some embodiments, the method further comprises measuring the amount and / or activity of the cytokine in the second biological sample N hours after administration. In some embodiments, the method further comprises (iv) obtaining a third biological sample from the subject M days after administration, where M is a number between 1 and 28. In some embodiments, the method further comprises measuring the amount and / or activity of the cytokine in the third biological sample M days after administration. In one embodiment, the method further includes (v) selecting the subject for treatment with the chimeric protein if the amount and / or activity of the cytokine N hours after administration is greater than the background amount and / or activity of the cytokine and / or if the amount and / or activity of the cytokine M days after administration is at least about 50% lower than the amount and / or activity of the cytokine N hours after administration.

[0214] In certain embodiments, N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1. In certain embodiments, M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2. In certain embodiments, N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1 and M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2.

[0215] In some embodiments, the amount and / or activity N hours after administration of the cytokine is greater than the background amount and / or activity of the cytokine. In some embodiments, the amount and / or activity N hours after administration of the cytokine is less than the background amount and / or activity of the cytokine. In some embodiments, the amount and / or activity N hours after administration of the cytokine is within about 10%, about 20%, about 30%, or about 40% of the background amount and / or activity of the cytokine. In some embodiments, the first biological sample, the second biological sample, and the third biological sample are independently selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, ascites, tissue or fine needle biopsy samples, cell-containing fluids, suspended nucleic acids, sputum, saliva, urine, cerebrospinal fluid, ascites, pleural fluid, feces, lymph, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or lavage fluid, aspirate, scraping, bone marrow specimen, biopsy specimen, and surgical specimen. In certain embodiments, the first biological sample, the second biological sample, and the third biological sample are blood.

[0216] In some embodiments, the amount and / or activity of a cytokine is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof. In some embodiments, the amount and / or activity of a cytokine is measured by contacting a sample with an agent that specifically binds to the cytokine. In some embodiments, the agent that specifically binds to one or more molecules is an antibody or a fragment thereof. In some embodiments, the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof. In some embodiments, the amount and / or activity of a cytokine is measured by contacting a sample with an agent that specifically binds to one or more nucleic acids encoding the cytokine. In some embodiments, the agent that specifically binds to one or more nucleic acids is a nucleic acid primer or a probe.

[0217] In some embodiments, the first dose of the chimeric protein ranges from about 0.03 mg / kg to 10 mg / kg, hi some embodiments, the first dose is about 0.003, or about 0.01, or about 0.03, or about 0.1, or about 0.3, or about 1, or about 2, or about 3, or about 4, or about 6, or about 8, or about 10 mg / kg.

[0218] In an embodiment, the method of any aspect disclosed herein further comprises a second dose of chimeric protein. In an embodiment, the second dose is administered at least about 3 days, or at least about 4 days, or at least about 5 days, or at least about 6 days, or at least about 7 days, or at least about 8 days, or at least about 9 days, or at least about 10 days, or at least about 14 days, or at least about 21 days, or at least about 28 days after administration of the first dose. In an embodiment, the second dose of chimeric protein is in the range of about 0.03 mg / kg to 10 mg / kg. In an embodiment, the second dose is about 0.003, or about 0.01, or about 0.03, or about 0.1, or about 0.3, or about 1, or about 2, or about 3, or about 4, or about 6, or about 8, or about 10 mg / kg.

[0219] In an embodiment, the method of any aspect disclosed herein further comprises a second dose of chimeric protein. In an embodiment, the second dose is administered at least about 3 days, or at least about 4 days, or at least about 5 days, or at least about 6 days, or at least about 7 days, or at least about 8 days, or at least about 9 days, or at least about 10 days, or at least about 14 days, or at least about 21 days, or at least about 28 days after administration of the first dose. In an embodiment, the second dose of chimeric protein is in the range of about 0.03 mg / kg to 10 mg / kg. In an embodiment, the second dose is about 0.003, or about 0.01, or about 0.03, or about 0.1, or about 0.3, or about 1, or about 2, or about 3, or about 4, or about 6, or about 8, or about 10 mg / kg.

[0220] In some embodiments, the first domain is capable of binding to a CD172a (SIRPα) ligand. In some embodiments, the first domain comprises substantially all of the extracellular domain of CD172a (SIRPα). In some embodiments, the first domain comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:57.

[0221] In some embodiments, the second domain is capable of binding to the CD40 receptor. In some embodiments, the second domain comprises substantially the entire extracellular domain of CD40L. In some embodiments, the second domain comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:58.

[0222] In certain embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from IgG4. In certain embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from human IgG4. In certain embodiments, the linker comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

[0223] In one embodiment, (a) the first domain comprises the amino acid sequence of SEQ ID NO:57, (b) the second domain comprises the amino acid sequence of SEQ ID NO:58, and (c) the linker comprises an amino acid sequence at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In one embodiment, the chimeric protein further comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:7. In one embodiment, the chimeric protein further comprises the amino acid sequences of SEQ ID NO:5 and SEQ ID NO:7.

[0224] In an embodiment, the chimeric protein comprises an amino acid sequence at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In an embodiment, the chimeric protein comprises an amino acid sequence at least about 99% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In an embodiment, the chimeric protein comprises an amino acid sequence at least about 99.2% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In an embodiment, the chimeric protein comprises an amino acid sequence at least about 99.4% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In an embodiment, the chimeric protein comprises an amino acid sequence at least about 99.6% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In an embodiment, the chimeric protein comprises an amino acid sequence at least about 99.8% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In an embodiment, the chimeric protein comprises the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61.

[0225] In some embodiments, the human subject is afflicted with or suspected to be afflicted with advanced solid tumors or lymphomas. In some embodiments, the human subject is afflicted with or suspected to be afflicted with a cancer selected from ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN). In some embodiments, the subject has failed one or more platinum-based therapies. In some embodiments, the human subject is unable to receive platinum therapy. In some embodiments, the human subject has not received concurrent chemotherapy, immunotherapy, biological therapy, or hormonal therapy, and / or the human subject has received, is resistant to, or is ineligible for standard therapy, and / or there is no approved therapy for the cancer that is considered standard of care.

[0226] In some embodiments, the chimeric proteins disclosed herein are provided as a sterile frozen solution at a concentration of about 20 mg / mL and a total volume of about 1 mL, optionally in a 10 mL glass vial. In some embodiments, the chimeric proteins disclosed herein are administered by intravenous infusion (IV) after dilution with normal saline. The starting dose, dose escalation scheme, and dose schedule of certain embodiments are provided below.

[0227] In some embodiments, the dose of the chimeric protein administered is at least 0.0001 mg / kg, for example, about 0.0001 mg / kg to about 10 mg / kg. In some embodiments, the dose of the chimeric protein administered is at least about 0.3 mg / kg, for example, at least about 0.3 mg / kg, or about 1.0 mg / kg, or about 2 mg / kg, or about 3, about 4 mg / kg, or about 6 mg / kg, or about 8 mg / kg, or about 10 mg / kg. In some embodiments, the dose of the chimeric protein administered is at least about 1 mg / kg, for example, at least about 1.0 mg / kg, or about 2 mg / kg, or about 3, about 4 mg / kg, or about 6 mg / kg, or about 8 mg / kg, or about 10 mg / kg. In certain embodiments, the dose of the SIRPα-Fc-CD40L chimeric protein is higher than the tolerated dose of certain other therapeutic agents (e.g., anti-CD47 antibodies or SIRPαFc fusion proteins) because it is not limited by the effects of anemia or other cytopenias. Moreover, in certain embodiments, low-dose priming is not required.

[0228] In some embodiments, administration is intravenous. In some embodiments, administration is intratumoral. In some embodiments, administration is by injection. In some embodiments, administration is by infusion. In some embodiments, administration is by intravenous infusion. In some embodiments, administration is by intratumoral injection.

[0229] In some embodiments, the chimeric protein is administered at an initial dose (e.g., any one of about 0.0001, about 0.001, about 0.003, about 0.01, about 0.03, about 0.1, about 0.3, about 1, about 2, about 3, about 4, about 6, about 8, or about 10 mg / kg) and the chimeric protein is administered in one or more subsequent doses. In some embodiments, the about one or more subsequent doses have a dose of one or more of about 0.0001, about 0.001, about 0.003, about 0.01, about 0.03, about 0.1, about 0.3, about 1, about 2, about 3, about 4, about 6, about 8, and about 10 mg / kg.

[0230] In certain embodiments, the initial dose and / or the subsequent doses are at or less than the maximum tolerated dose.

[0231] In one embodiment, the dose is escalated in logarithmic increments between one or more subsequent doses, for example, from 0.0001 mg / kg to 0.001 mg / kg, from 0.001 mg / kg to 0.01 mg / kg, and from 0.01 mg / kg to 0.1 mg / kg.

[0232] In one embodiment, the dose is escalated between one or more subsequent doses in about half-log increments, for example, from 0.001 mg / kg to 0.003 mg / kg and from 0.003 mg / kg to 0.01 mg / kg.

[0233] In some embodiments, the human subject has failed one or more platinum-based therapies and is optionally ineligible to receive platinum therapy, in some embodiments, the human subject has not received concurrent chemotherapy, immunotherapy, biologic therapy, or hormonal therapy, and / or the human subject has received, is resistant to, or is ineligible for standard therapy, and / or there is no approved therapy for the cancer that is considered a standard of care.

[0234] In certain embodiments, the initial dose is lower than the dose for at least one of the subsequent doses, eg, each of the subsequent doses.

[0235] In certain embodiments, the initial dose is the same as the dose for at least one of the subsequent doses, eg, each of the subsequent doses.

[0236] In one embodiment, the chimeric protein is administered at least about once a month.

[0237] In one embodiment, the chimeric protein is administered at least about twice a month.

[0238] In one embodiment, the chimeric protein is administered at least about three times per month.

[0239] In certain embodiments, the chimeric protein is initially administered once a week for three weeks, followed by administration of the chimeric protein once every three weeks or once every four weeks.

[0240] In some embodiments, the chimeric protein is administered once a week for an initial period of three weeks, and then about twice a month. For example, the chimeric protein is administered once a week for an initial period of three weeks, and then about once every two weeks.

[0241] In some embodiments, the chimeric protein is administered at least about four times per month. For example, the chimeric protein is administered about once per week. In some embodiments, the chimeric protein is administered once per week (once every seven days). In some embodiments, the chimeric protein is administered once every two weeks.

[0242] In an embodiment, administration of the SIRPα-Fc-CD40L chimeric protein does not cause anemia or other cytopenias in the patient. In an embodiment, administration does not cause lysis of RBCs. In an embodiment, administration of the SIRPα-Fc-CD40L chimeric protein is less likely to cause anemia or other cytopenias than, for example, an anti-CD47 antibody. In an embodiment, the dose of the SIRPα-Fc-CD40L chimeric protein is higher than the tolerated dose of certain other therapeutic agents (e.g., anti-CD47 antibodies or SIRPαFc fusion proteins) because it is not limited by the effects of anemia or other cytopenias. Furthermore, in an embodiment, low-dose priming is not required.

[0243] Another advantage of the SIRPα-Fc-CD40L chimeric protein (e.g., SEQ ID NO: 59 or SEQ ID NO: 61) is that it does not cause anemia or other cytopenias in patients despite targeting. This is because, as shown herein, the SIRPα-Fc-CD40L chimeric protein does not cause RBC lysis, even though CD47 / SIRPα interactions play an important role in lysis of red blood cells. Thus, the methods of the present invention are less likely to cause anemia or other cytopenias than, for example, anti-CD47 antibodies.

[0244] The chimeric protein may be administered intravenously by intravenous infusion or by bolus injection into the bloodstream. The chimeric protein may be administered intravenously by intravenous infusion to patients with advanced ovarian, fallopian tube, or primary peritoneal cancer.

[0245] The chimeric protein may be administered by intratumoral injection. In some embodiments, the therapeutic dose of intratumoral administration is equivalent to or less than the therapeutic dose of intravenous infusion. In some embodiments, the therapeutic dose of intratumoral administration is equivalent to the therapeutic dose of intravenous infusion. In some embodiments, the therapeutic dose of intratumoral administration is less than the therapeutic dose of intravenous infusion. In some embodiments, the therapeutic dose of intratumoral administration for patients suffering from advanced or metastatic CSCC and HNSCC.

[0246] In certain embodiments, the chimeric proteins of the present invention allow for a dual effect with fewer side effects than those seen with conventional immunotherapies (e.g., treatment with one or more of OPDIVO, KEYTRUDA, YERVOY, and TECENTRIQ). For example, the chimeric proteins of the present invention reduce or prevent commonly observed immune-related adverse events affecting various tissues and organs, including the skin, gastrointestinal tract, kidneys, peripheral and central nervous systems, liver, lymph nodes, eyes, pancreas, and endocrine system, such as hypophysitis, colitis, hepatitis, interstitial pneumonitis, rashes, and rheumatic diseases.

[0247] Forms suitable for intravenous administration include, for example, solutions, suspensions, dispersions, emulsions, etc. They can also be prepared in the form of sterile solid compositions (e.g., lyophilized compositions) that can be dissolved or suspended in a sterile injectable medium immediately before use. They may contain, for example, suspending or dispersing agents known in the art.

[0248] The dose and administration schedule of any chimeric protein disclosed herein may depend on a variety of parameters, including, but not limited to, the disease being treated, the general health of the subject, and the discretion of the administrating physician.

[0249] In one aspect, the disclosure relates to a method of treating cancer in a human subject in need thereof, the method comprising administering to the human subject an effective amount of a chimeric protein having the general structure: N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first and second domains, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), and the step of administering comprises biphasic administration. In an embodiment, the first and second phases each independently comprise an administration frequency of about twice a week to about once every two months. In an embodiment, the linker comprises at least one cysteine ​​residue capable of forming a disulfide bond. In some embodiments, the chimeric protein exhibits a linear dose response, for example, in the dose range of about 0.3 mg / kg to about 3 mg / kg, or about 0.5 mg / kg to about 3 mg / kg, or about 0.7 mg / kg to about 3 mg / kg, or about 1 mg / kg to about 3 mg / kg, or about 1.5 mg / kg to about 3 mg / kg, or about 2 mg / kg to about 3 mg / kg, or about 2.5 mg / kg to about 3 mg / kg, or about 0.3 mg / kg to about 2.5 mg / kg, or about 0.3 mg / kg to about 2 mg / kg, or about 0.3 mg / kg to about 1.5 mg / kg, or about 0.3 mg / kg to about 1.0 mg / kg, or about 0.3 mg / kg to about 0.5 mg / kg. In some embodiments, the chimeric protein does not exhibit a bell-shaped dose response.

[0250] In some embodiments, the dosing frequency of the first phase is the same as the dosing frequency of the second phase, while in other embodiments, the dosing frequency of the first phase is different from the dosing frequency of the second phase.

[0251] In some embodiments, the administration frequency in the first phase is selected from about every 3 days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about every 7 weeks, about every 8 weeks, and about every 2 months. In some embodiments, the administration frequency in the first phase is selected from about every 3 days to about every 10 days, about every 1 week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks, about every 5 weeks to about every 7 weeks, about every 6 weeks to about every 8 weeks, and about every 6 weeks to about every 2 months.

[0252] In some embodiments, the administration frequency in the second phase is selected from about every 3 days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about every 7 weeks, about every 8 weeks, and about every 2 months. In some embodiments, the administration frequency in the second phase is selected from about every 3 days to about every 10 days, about every 1 week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks, about every 5 weeks to about every 7 weeks, about every 6 weeks to about every 8 weeks, and about every 6 weeks to about every 2 months.

[0253] In one embodiment, the administration frequency in the first phase is selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, or about every 10 days to about every 3 weeks, and the administration frequency in the second phase is selected from about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, or about every 4 weeks to about every 6 weeks.

[0254] Additionally or alternatively, in some embodiments, the first and second stages each independently last from about 2 days to about 12 months. In some embodiments, the first stage lasts from about 2 weeks to about 2 months, and the second stage lasts from about 2 weeks to about 12 months. In some embodiments, the first stage lasts from about 2 weeks to about 1 month, and the second stage lasts from about 2 weeks to about 12 months. In some embodiments, the first stage lasts from about 2 weeks to about 1 month, and the second stage lasts from about 4 weeks to about 12 months.

[0255] Additionally or alternatively, in some embodiments, the effective amounts of the first, second, and third stages are each independently comprised between about 0.01 mg / kg and about 10 mg / ml. In some embodiments, the effective amounts of the first, second, and third stages are each independently selected from about 0.03 mg / kg, about 0.1 mg / kg, about 0.3 mg / kg, about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, and any ranges including and / or between any two of the foregoing values. In some embodiments, the effective amounts of the first, second, and third stages are each independently selected from about 0.01 mg / kg to about 0.1 mg / kg, about 0.03 mg / kg to about 0.3 mg / kg, about 0.1 mg / kg to about 1 mg / kg, about 0.3 mg / kg to about 3 mg / kg, and about 1 mg / kg to about 10 mg / kg. In some embodiments, the effective amounts in the first, second, and third stages are the same. In some embodiments, the effective amounts in the first, second, and third stages are different. In some embodiments, the effective amount in the first stage is higher than the effective amount in the second stage. In some embodiments, the effective amount in the first stage is about 0.03 mg / kg to about 0.3 mg / kg, about 0.1 mg / kg to about 1 mg / kg, about 0.3 mg / kg to about 3 mg / kg, or about 1 mg / kg to about 10 mg / kg, and the effective amount in the second stage is about 0.01 mg / kg to about 0.1 mg / kg, about 0.03 mg / kg to about 0.3 mg / kg, about 0.1 mg / kg to about 1 mg / kg, about 0.3 mg / kg to about 3 mg / kg, or about 1 mg / kg to about 10 mg / kg.

[0256] In certain embodiments, the chimeric protein disclosed herein is a human CD172a (SIRPα)-Fc-CD40L chimeric protein.

[0257] In one aspect, the disclosure relates to a method of treating cancer in a human subject in need thereof, the method comprising administering to the human subject an effective amount of a chimeric protein having the general structure: N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first and second domains, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), the administering step comprising a first cycle, a second cycle, and a third cycle. In an embodiment, the linker comprises at least one cysteine ​​residue capable of forming a disulfide bond. In an embodiment, the first cycle, the second cycle, and the third cycle each independently comprise an administration frequency of about twice a week to about once every two months. In some embodiments, the dosing frequency of the first cycle, the dosing frequency of the second cycle, and the dosing frequency of the third cycle are the same. In some embodiments, the dosing frequency of the first cycle, the dosing frequency of the second cycle, and the dosing frequency of the third cycle are different. In some embodiments, the dosing frequency of the first cycle is selected from about every 3 days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about every 7 weeks, about every 8 weeks, and about every 2 months. In some embodiments, the chimeric protein exhibits a linear dose response, for example, in the dose range of about 0.3 mg / kg to about 3 mg / kg, or about 0.5 mg / kg to about 3 mg / kg, or about 0.7 mg / kg to about 3 mg / kg, or about 1 mg / kg to about 3 mg / kg, or about 1.5 mg / kg to about 3 mg / kg, or about 2 mg / kg to about 3 mg / kg, or about 2.5 mg / kg to about 3 mg / kg, or about 0.3 mg / kg to about 2.5 mg / kg, or about 0.3 mg / kg to about 2 mg / kg, or about 0.3 mg / kg to about 1.5 mg / kg, or about 0.3 mg / kg to about 1.0 mg / kg, or about 0.3 mg / kg to about 0.5 mg / kg. In some embodiments, the chimeric protein does not exhibit a bell-shaped dose response.

[0258] In one embodiment, the administration frequency of the first cycle is selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks, about every 5 weeks to about every 7 weeks, about every 6 weeks to about every 8 weeks, and about every 6 weeks to about every 2 months. In one embodiment, the administration frequency of the second cycle is selected from about every 3 days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about every 7 weeks, about every 8 weeks, and about every 2 months. In one embodiment, the administration frequency of the second cycle is selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks, about every 5 weeks to about every 7 weeks, about every 6 weeks to about every 8 weeks, and about every 6 weeks to about every 2 months. In one embodiment, the administration frequency of the third cycle is selected from about every 3 days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about every 7 weeks, about every 8 weeks, and about every 2 months. In one embodiment, the administration frequency of the third cycle is selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks, about every 5 weeks to about every 7 weeks, about every 6 weeks to about every 8 weeks, and about every 6 weeks to about every 2 months. In one embodiment, the administration frequency of the first cycle is selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, and about every 10 days to about every 3 weeks, and the administration frequency of the second cycle is selected from about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, and about every 4 weeks to about every 6 weeks.

[0259] Additionally or alternatively, in some embodiments, the first cycle, the second cycle, and the third cycle each independently last from about 2 days to about 12 months. In some embodiments, the first cycle lasts from about 2 weeks to about 2 months, and the second cycle lasts from about 2 weeks to about 12 months. In some embodiments, the first cycle lasts from about 2 weeks to about 2 months, the second cycle lasts from about 2 weeks to about 12 months, and the third cycle lasts from about 2 weeks to about 6 months.

[0260] Additionally or alternatively, in some embodiments, the effective amounts of the first, second, and third cycles are each independently comprised between about 0.01 mg / kg and about 10 mg / ml. In some embodiments, the effective amounts of the first, second, and third cycles are each independently selected from about 0.03 mg / kg, about 0.1 mg / kg, about 0.3 mg / kg, about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, and any ranges therebetween including any two of the foregoing values. In some embodiments, the effective amounts of the first, second, and third cycles are each independently selected from about 0.01 mg / kg to about 0.1 mg / kg, about 0.03 mg / kg to about 0.3 mg / kg, about 0.1 mg / kg to about 1 mg / kg, about 0.3 mg / kg to about 3 mg / kg, and about 1 mg / kg to about 10 mg / kg.

[0261] In some embodiments, the effective amounts of the first, second, and third cycles are the same. In other embodiments, the effective amounts of the first, second, and third cycles are different. In some embodiments, the effective amount of the first cycle is higher than the effective amount of the second cycle. In other embodiments, the effective amount of the first cycle is lower than the effective amount of the second cycle. In yet other embodiments, the effective amount of the first cycle and the effective amount of the second cycle are the same.

[0262] In certain embodiments, the effective amount for the first cycle is about 0.03 mg / kg to about 0.3 mg / kg, about 0.1 mg / kg to about 1 mg / kg, about 0.3 mg / kg to about 3 mg / kg, or about 1 mg / kg to about 10 mg / kg, and the effective amount for the second cycle is about 0.01 mg / kg to about 0.1 mg / kg, about 0.03 mg / kg to about 0.3 mg / kg, about 0.1 mg / kg to about 1 mg / kg, about 0.3 mg / kg to about 3 mg / kg, or about 1 mg / kg to about 10 mg / kg.

[0263] In certain embodiments, the chimeric protein disclosed herein is a human CD172a (SIRPα)-Fc-CD40L chimeric protein.

[0264] In one aspect, the disclosure relates to a method of treating cancer in a human subject in need thereof, the method comprising administering to the human subject an effective amount of a chimeric protein having the general structure: N-terminus-(a)-(b)-(c)-C-terminus according to a dosing regimen, where (a) is a first domain comprising an extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first and second domains, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising an extracellular domain of human CD40 ligand (CD40L), the dosing regimen comprising administering at a frequency ranging from about every 3 days to about every 2 months. In certain embodiments, the linker comprises at least one cysteine ​​residue capable of forming a disulfide bond. In some embodiments, the dosing schedule is selected from about every 3 days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about every 7 weeks, about every 8 weeks, and about every 2 months. In some embodiments, the dosing schedule is selected from about every week, about every 10 days, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about every 7 weeks, about every 8 weeks, and about every 2 months. In some embodiments, the dosing schedule is about every 2 weeks, about every 3 weeks, or about every 4 weeks.

[0265] In one aspect, the disclosure relates to a method of treating cancer in a human subject in need of such treatment, the method comprising administering to the human subject an effective amount of a chimeric protein having the general structure: N-terminus-(a)-(b)-(c)-C-terminus, according to a dosing regimen selected from about every 3 days to about every 10 days, about every week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks, about every 5 weeks to about every 7 weeks, about every 6 weeks to about every 8 weeks, and about every 6 weeks to about every 2 months, wherein (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), and (b) is a linker flanking the first and second domains, the linker comprising a hinge-CH2-CH3 and (c) a second domain comprising the extracellular domain of human CD40 ligand (CD40L). In certain embodiments, the linker comprises at least one cysteine ​​residue capable of forming a disulfide bond. In certain embodiments, the dosing regimen is about once a week to about once every two weeks, about every 10 days to about every three weeks, or about every two weeks to about every four weeks. In some embodiments, the chimeric protein exhibits a linear dose response, for example, in the dose range of about 0.3 mg / kg to about 3 mg / kg, or about 0.5 mg / kg to about 3 mg / kg, or about 0.7 mg / kg to about 3 mg / kg, or about 1 mg / kg to about 3 mg / kg, or about 1.5 mg / kg to about 3 mg / kg, or about 2 mg / kg to about 3 mg / kg, or about 2.5 mg / kg to about 3 mg / kg, or about 0.3 mg / kg to about 2.5 mg / kg, or about 0.3 mg / kg to about 2 mg / kg, or about 0.3 mg / kg to about 1.5 mg / kg, or about 0.3 mg / kg to about 1.0 mg / kg, or about 0.3 mg / kg to about 0.5 mg / kg. In some embodiments, the chimeric protein does not exhibit a bell-shaped dose response.

[0266] In some embodiments of any of the aspects disclosed herein, the first domain is capable of binding to a CD172a (SIRPα) ligand. In certain embodiments, the first domain comprises substantially all of the extracellular domain of CD172a (SIRPα). In certain embodiments, the second domain is capable of binding to a CD40 receptor. In certain embodiments, the second domain comprises substantially the entire extracellular domain of CD40L. In certain embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derived from IgG4, e.g., human IgG4. In certain embodiments, the linker comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In certain embodiments, the linker comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In certain embodiments, the linker comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the first domain comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain comprises an amino acid sequence at least 96% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:57. In an embodiment, the first domain comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO:57.

[0267] In some embodiments of any of the aspects disclosed herein, the second domain comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:58. In some embodiments of any of the aspects disclosed herein, the second domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:58. In some embodiments of any of the aspects disclosed herein, the second domain comprises an amino acid sequence at least 96% identical to the amino acid sequence of SEQ ID NO:58. In some embodiments of any of the aspects disclosed herein, the second domain comprises an amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:58. In some embodiments of any of the aspects disclosed herein, the second domain comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:58. In some embodiments of any of the aspects disclosed herein, the second domain comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:58. In some embodiments of any of the aspects disclosed herein, the second domain comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO: 58. In an embodiment, (a) the first domain comprises the amino acid sequence of SEQ ID NO: 57, (b) the second domain comprises the amino acid sequence of SEQ ID NO: 58, and (c) the linker comprises an amino acid sequence at least 95% identical to SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

[0268] In some embodiments, the chimeric protein further comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:7. In some embodiments, the chimeric protein further comprises the amino acid sequences of SEQ ID NO:5 and SEQ ID NO:7. In some embodiments, the chimeric protein comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to SEQ ID NO:59 or SEQ ID NO:61. In some embodiments, the chimeric protein comprises an amino acid sequence at least 95% identical to SEQ ID NO:59 or SEQ ID NO:61. In some embodiments, the chimeric protein comprises an amino acid sequence at least 96% identical to SEQ ID NO:59 or SEQ ID NO:61. In some embodiments, the chimeric protein comprises an amino acid sequence at least 97% identical to SEQ ID NO:59 or SEQ ID NO:61. In some embodiments, the chimeric protein comprises an amino acid sequence at least 98% identical to SEQ ID NO:59 or SEQ ID NO:61. In some embodiments, the chimeric protein comprises an amino acid sequence at least 99% identical to SEQ ID NO:59 or SEQ ID NO:61. In certain embodiments, the chimeric protein comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In certain embodiments, the chimeric protein comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In certain embodiments, the chimeric protein comprises an amino acid sequence that is at least about 99% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61.

[0269] Additionally or alternatively, in some embodiments, the chimeric protein comprises an amino acid sequence that is at least about 99.2% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In some embodiments, the chimeric protein comprises an amino acid sequence that is at least about 99.4% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In some embodiments, the chimeric protein comprises an amino acid sequence that is at least about 99.6% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In some embodiments, the chimeric protein comprises an amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In some embodiments, the chimeric protein comprises an amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In some embodiments, the human subject has undergone, is resistant to, or is ineligible for, a standard of care treatment, and / or there is no approved treatment for cancer that is considered a standard of care treatment.

[0270] In one aspect, the disclosure relates to a method of promoting lymphocyte migration from peripheral blood to secondary lymphoid organs (e.g., lymph nodes and spleen) in a human subject in need of treatment, the method comprising administering to the human subject an effective amount of a chimeric protein having the general structure: N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first and second domains, the linker comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L).

[0271] In some embodiments of any of the aspects disclosed herein, the human subject is not receiving concomitant chemotherapy, immunotherapy, biologic therapy, or hormonal therapy.

[0272] In one aspect, the disclosure relates to a chimeric protein for use in the method of any of the embodiments disclosed herein.

[0273] In one aspect, the disclosure relates to a chimeric protein comprising an amino acid sequence at least about 98% identical to SEQ ID NO: 59 or SEQ ID NO: 61. In an embodiment, the chimeric protein comprises an amino acid sequence at least about 99% identical to SEQ ID NO: 59 or SEQ ID NO: 61. In an embodiment, the chimeric protein comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61.

[0274] The administration frequency in the first stage and the administration frequency in the second stage may be the same or different. In one embodiment, the administration frequency in the first stage and the administration frequency in the second stage are each independently selected from about every 3 days, about twice a week, about every week, about every 10 days, about twice every 3 weeks, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every month, about every 5 weeks, about every 6 weeks, about every 7 weeks, about every 8 weeks, and about every 2 months. In one embodiment, the administration frequency in the first stage is selected from about every 3 days to about every 10 days, about every 1 week to about every 2 weeks, about every 10 days to about every 3 weeks, about every 2 weeks to about every 4 weeks, about every 3 weeks to about every 5 weeks, about every 4 weeks to about every 6 weeks, about every 5 weeks to about every 7 weeks, about every 6 weeks to about every 8 weeks, and about every 6 weeks to about every 2 months.

[0275] In one embodiment, the first stage and the second stage each independently last for about 2 days to about 12 months. For example, in one embodiment, the first stage lasts for about 2 weeks to about 2 months, and the second stage lasts for about 2 weeks to about 12 months. In one embodiment, the first stage lasts for about 2 weeks to about 1 month, and the second stage lasts for about 2 weeks to about 12 months. In one embodiment, the first stage lasts for about 2 weeks to about 1 month, and the second stage lasts for about 4 weeks to about 12 months.

[0276] The effective amounts of the first, second, and third stages may be the same or different. In some embodiments, the effective amounts of the first, second, and third stages each independently comprise about 0.01 mg / kg to about 10 mg / ml. In some embodiments, the effective amount of the first stage is about 0.03 mg / kg to about 0.3 mg / kg, about 0.1 mg / kg to about 1 mg / kg, about 0.3 mg / kg to about 3 mg / kg, or about 1 mg / kg to about 10 mg / kg, and the effective amount of the second stage is about 0.01 mg / kg to about 0.1 mg / kg, about 0.03 mg / kg to about 0.3 mg / kg, about 0.1 mg / kg to about 1 mg / kg, about 0.3 mg / kg to about 3 mg / kg, or about 1 mg / kg to about 10 mg / kg. In certain embodiments, the chimeric protein disclosed herein is a human CD172a (SIRPα)-Fc-CD40L chimeric protein.

[0277] In certain embodiments, the human CD172a (SIRPα)-Fc-CD40L chimeric protein can provide a sustained immunomodulatory effect.

[0278] In an embodiment, the linker comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker comprises an amino acid sequence at least 96% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In an embodiment, the linker comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

[0279] In certain embodiments, the linker comprises a hinge-CH2-CH3 Fc domain from an IgG. In certain embodiments, the linker comprises a hinge-CH2-CH3 Fc domain from an IgG selected from IgG1 and IgG4. In certain embodiments, the linker comprises a hinge-CH2-CH3 Fc domain from human IgG1 or human IgG4. In certain embodiments, the linker comprises a hinge-CH2-CH3 Fc domain from IgG4. In certain embodiments, the hinge-CH2-CH3 Fc domain is from human IgG4.

[0280] Additionally or alternatively, in certain embodiments, the extracellular domain of human signal-regulatory protein alpha (CD172a(SIRPα)) comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:57. In certain embodiments, the extracellular domain of human signal-regulatory protein alpha (CD172a(SIRPα)) comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:57. In certain embodiments, the extracellular domain of human signal-regulatory protein alpha (CD172a(SIRPα)) comprises an amino acid sequence at least 96% identical to the amino acid sequence of SEQ ID NO:57. In embodiments, the extracellular domain of human signal-regulatory protein alpha (CD172a(SIRPα)) comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:57. In certain embodiments, the extracellular domain of human signal-regulatory protein alpha (CD172a(SIRPα)) comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:57. In one embodiment, the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)) comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO:57.

[0281] Additionally or alternatively, in certain embodiments, the extracellular domain of human CD40 ligand (CD40L) comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO:58. In certain embodiments, the extracellular domain of human CD40 ligand (CD40L) comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:58. In certain embodiments, the extracellular domain of human CD40 ligand (CD40L) comprises an amino acid sequence at least 96% identical to the amino acid sequence of SEQ ID NO:58. In certain embodiments, the extracellular domain of human CD40 ligand (CD40L) comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:58. In certain embodiments, the extracellular domain of human CD40 ligand (CD40L) comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:58. In certain embodiments, the extracellular domain of human CD40 ligand (CD40L) comprises an amino acid sequence identical to the amino acid sequence of SEQ ID NO:58.

[0282] Additionally or alternatively, in certain embodiments, the human CD172a (SIRPα)-Fc-CD40L chimeric protein comprises an amino acid sequence at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identical to SEQ ID NO:59 or SEQ ID NO:61. In certain embodiments, the human CD172a (SIRPα)-Fc-CD40L chimeric protein comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In certain embodiments, the human CD172a (SIRPα)-Fc-CD40L chimeric protein comprises an amino acid sequence at least 96% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In certain embodiments, the human CD172a (SIRPα)-Fc-CD40L chimeric protein comprises an amino acid sequence at least 97% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:61. In one embodiment, the human CD172a (SIRPα)-Fc-CD40L chimeric protein comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61. In one embodiment, the human CD172a (SIRPα)-Fc-CD40L chimeric protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61. In one embodiment, the human CD172a (SIRPα)-Fc-CD40L chimeric protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 61.

[0283] In one aspect, the disclosure relates to a method of treating cancer in a human subject, comprising: (i) administering to the human subject a chimeric protein having the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first and second domains, the linker comprising at least one cysteine ​​residue capable of forming a disulfide bond and / or comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L); and (ii) administering a second therapeutic agent. In one embodiment, the chimeric protein is administered at a dose of about 0.0001 mg / kg to about 10 mg / kg. In certain embodiments, the dose of the chimeric protein administered is at least about 0.3 mg / kg, e.g., at least about 0.3 mg / kg, or about 1.0 mg / kg, or about 2 mg / kg, or about 3, about 4 mg / kg, or about 6 mg / kg, or about 8 mg / kg, or about 10 mg / kg. In certain embodiments, the dose of the chimeric protein administered is at least about 1 mg / kg, e.g., at least about 1.0 mg / kg, or about 2 mg / kg, or about 3, about 4 mg / kg, or about 6 mg / kg, or about 8 mg / kg, or about 10 mg / kg. In some embodiments, the chimeric protein exhibits a linear dose response, for example, in the dose range of about 0.3 mg / kg to about 3 mg / kg, or about 0.5 mg / kg to about 3 mg / kg, or about 0.7 mg / kg to about 3 mg / kg, or about 1 mg / kg to about 3 mg / kg, or about 1.5 mg / kg to about 3 mg / kg, or about 2 mg / kg to about 3 mg / kg, or about 2.5 mg / kg to about 3 mg / kg, or about 0.3 mg / kg to about 2.5 mg / kg, or about 0.3 mg / kg to about 2 mg / kg, or about 0.3 mg / kg to about 1.5 mg / kg, or about 0.3 mg / kg to about 1.0 mg / kg, or about 0.3 mg / kg to about 0.5 mg / kg. In some embodiments, the chimeric protein does not exhibit a bell-shaped dose response.

[0284] In one embodiment, administration of the chimeric protein results in a receptor occupancy (RO) of CD47 on leukocytes that is at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, compared to the RO before administration of the chimeric protein, a second subject not administered the chimeric protein, and / or an external control. In certain embodiments, administration of the chimeric protein results in an RO of CD47 on B cells that is at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, compared to the RO before administration of the chimeric protein, a second subject not administered the chimeric protein, and / or an external control. In certain embodiments, administration of the chimeric protein increases the amount or activity of one or more of IL-12, MCP-1, MIP-1β, MIP-1α, and MDC%, compared to the RO before administration of the chimeric protein, a second subject not administered the chimeric protein, and / or an external control.

[0285] In one aspect, the disclosure relates to a method of treating cancer in a human subject, comprising administering to a subject in need of treatment a chimeric protein of the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first and second domains, the linker comprising at least one cysteine ​​residue capable of forming a disulfide bond and / or comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L), and the subject is undergoing or has undergone treatment with a second therapeutic agent. In certain embodiments, the chimeric protein is administered at a dose of about 0.0001 mg / kg to about 10 mg / kg. In certain embodiments, the dose of the chimeric protein administered is at least about 0.3 mg / kg, e.g., at least about 0.3 mg / kg, or about 1.0 mg / kg, or about 2 mg / kg, or about 3, about 4 mg / kg, or about 6 mg / kg, or about 8 mg / kg, or about 10 mg / kg. In certain embodiments, the dose of the chimeric protein administered is at least about 1 mg / kg, e.g., at least about 1.0 mg / kg, or about 2 mg / kg, or about 3, about 4 mg / kg, or about 6 mg / kg, or about 8 mg / kg, or about 10 mg / kg. In some embodiments, the chimeric protein exhibits a linear dose response, for example, in the dose range of about 0.3 mg / kg to about 3 mg / kg, or about 0.5 mg / kg to about 3 mg / kg, or about 0.7 mg / kg to about 3 mg / kg, or about 1 mg / kg to about 3 mg / kg, or about 1.5 mg / kg to about 3 mg / kg, or about 2 mg / kg to about 3 mg / kg, or about 2.5 mg / kg to about 3 mg / kg, or about 0.3 mg / kg to about 2.5 mg / kg, or about 0.3 mg / kg to about 2 mg / kg, or about 0.3 mg / kg to about 1.5 mg / kg, or about 0.3 mg / kg to about 1.0 mg / kg, or about 0.3 mg / kg to about 0.5 mg / kg. In some embodiments, the chimeric protein does not exhibit a bell-shaped dose response.

[0286] In one aspect, the disclosure relates to a method of treating cancer in a human subject comprising administering to a subject in need of treatment a second anti-cancer therapeutic, the subject being or having been treated with a chimeric protein of the general structure N-terminus-(a)-(b)-(c)-C-terminus, where (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)), (b) is a linker flanking the first and second domains, the linker comprising at least one cysteine ​​residue capable of forming a disulfide bond and / or comprising a hinge-CH2-CH3 Fc domain, and (c) is a second domain comprising the extracellular domain of human CD40 ligand (CD40L). In certain embodiments, the chimeric protein is administered at a dose of about 0.0001 mg / kg to about 10 mg / kg. In some embodiments, the chimeric protein exhibits a linear dose response, for example, in the dose range of about 0.3 mg / kg to about 3 mg / kg, or about 0.5 mg / kg to about 3 mg / kg, or about 0.7 mg / kg to about 3 mg / kg, or about 1 mg / kg to about 3 mg / kg, or about 1.5 mg / kg to about 3 mg / kg, or about 2 mg / kg to about 3 mg / kg, or about 2.5 mg / kg to about 3 mg / kg, or about 0.3 mg / kg to about 2.5 mg / kg, or about 0.3 mg / kg to about 2 mg / kg, or about 0.3 mg / kg to about 1.5 mg / kg, or about 0.3 mg / kg to about 1.0 mg / kg, or about 0.3 mg / kg to about 0.5 mg / kg. In some embodiments, the chimeric protein does not exhibit a bell-shaped dose response.

[0287] In some embodiments, the chimeric protein is administered prior to the second therapeutic agent. In some embodiments, the second therapeutic agent is administered prior to the chimeric protein. In some embodiments, the second therapeutic agent and the chimeric protein are administered substantially together.

[0288] In some embodiments, the second therapeutic agent is selected from an antibody and a chemotherapeutic agent. In some embodiments, the antibody is capable of antibody-dependent cellular cytotoxicity (ADCC). In some embodiments, the antibody is selected from cetuximab, rituximab, obinutuzumab, Hul4.18K322A, Hu3F8, dinituximab, and trastuzumab. In some embodiments, the antibody is capable of antibody-dependent cellular phagocytosis (ADCP). In some embodiments, the antibody is selected from cetuximab, daratumumab, rituximab, and trastuzumab. In some embodiments, the antibody is capable of binding to a molecule selected from carcinoembryonic antigen (CEA), EGFR, HER-2, epithelial cell adhesion molecule (EpCAM), human epithelial mucin-1, CD20, CD30, CD38, CD40, and CD52. In some embodiments, the antibody is capable of binding to EGFR. In some embodiments, the antibody is selected from Mab A13, AMG595, cetuximab (Erbitux, C225), panitumumab (ABX-EGF, Vectibix), depatuxizumab (ABT806), depatuxizumab, mafodotin, durigotuzumab (MEHD7945A, RG7597), futuximab (Sym004), GC1118, imgatuzumab (GA201), matuzumab (EMD72000), necitumumab (Portrazza), nimotuzumab (h-R3), anitumumab (Vectibix, ABX-EGF), zalutumumab, humMR1, and tomzotuximab. In some embodiments, the antibody is cetuximab.

[0289] In some embodiments, the chemotherapeutic agent is an anthracycline. In some embodiments, the anthracycline is selected from doxorubicin, daunorubicin, epirubicin, and idarubicin, and pharma- ceutically acceptable salts, acids, or derivatives thereof. In some embodiments, the chemotherapeutic agent is doxorubicin.

[0290] In certain embodiments, the dose of chimeric protein administered is at least about 0.0001 mg / kg, e.g., from about 0.0001 mg / kg to about 10.0 mg / kg. The chimeric protein may be administered at an initial dose (e.g., at one of about 0.0001, about 0.001, about 0.003, about 0.01, about 0.03, about 0.1, about 0.3, about 1, about 2, about 3, about 4, about 6, or about 10.0 mg / kg), and the chimeric protein is administered in one or more subsequent doses (e.g., at one or more of about 0.0001, about 0.001, about 0.003, about 0.01, about 0.03, about 0.1, about 0.3, about 1, about 2, about 3, about 4, about 6, about 8, and about 10 mg / kg). In some embodiments, the dose of the chimeric protein administered is at least about 0.3 mg / kg, e.g., at least about 0.3 mg / kg, or about 1.0 mg / kg, or about 2 mg / kg, or about 3, about 4 mg / kg, or about 6 mg / kg, or about 8 mg / kg, or about 10 mg / kg. In some embodiments, the dose of the chimeric protein administered is at least about 1 mg / kg, e.g., at least about 1.0 mg / kg, or about 2 mg / kg, or about 3, about 4 mg / kg, or about 6 mg / kg, or about 8 mg / kg, or about 10 mg / kg. In some embodiments, the initial dose is less than the dose of at least one of the subsequent doses (e.g., each of the subsequent doses), or the initial dose is the same as the dose of at least one of the subsequent doses (e.g., each of the subsequent doses). In some embodiments, the initial dose and / or the subsequent dose is at or less than the maximum tolerated dose. In certain embodiments, the chimeric protein is administered at least about once a month, e.g., at least about twice a month, at least about three times a month, and at least about four times a month. In certain embodiments, the chimeric protein is administered once a week for an initial period of three weeks, and then the chimeric protein is administered about once every three weeks or once every four weeks, or alternatively, the chimeric protein is administered once a week for an initial period of three weeks, and then the chimeric protein is administered about twice a month, e.g., once a week for three weeks, and then the chimeric protein is administered about once every two weeks.

[0291] In some embodiments, the cancer comprises an advanced solid tumor (localized and / or metastatic) or lymphoma. In some embodiments, the cancer is selected from ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN). In some embodiments, the cancer comprises an advanced solid tumor (localized and / or metastatic) or advanced lymphoma. EXAMPLES

[0292] The examples herein are presented to illustrate the advantages and usefulness of the present technology, and to further assist those skilled in the art in preparing or using the chimeric proteins of the present technology. The examples herein are also presented to more fully describe the preferred aspects of the present technology. The examples should not be interpreted in any way as limiting the scope of the present technology, which is defined by the appended claims. These examples may include or incorporate any of the variations, aspects, or embodiments of the present technology described above. Each of the variations, aspects, or embodiments described above may further include or incorporate any or all other variations, aspects, or embodiments of the present technology.

[0293] Example 1: Phase 1 clinical trial of SIRPα-Fc-CD40L chimeric protein (SL-172154) This first-in-human Phase 1 dose-escalation study is currently evaluating SL-172154 as monotherapy in subjects with platinum-resistant ovarian cancer. The primary objectives of the study are to evaluate safety and identify the maximum tolerated or maximum administered dose of SL-172154. Secondary objectives of the study are to identify the dose and schedule (i.e., recommended phase 2 dose [RP2D]), characterize PK and immunogenicity, and evaluate antitumor activity according to RECIST v1.1 for solid tumors. Exploratory objectives are to assess receptor occupancy of SIRPα and CD40 on PBMCs and investigate pharmacodynamic (PD) effects in blood and tumors.

[0294] Planned dose escalation is a half-log increase (Figure 1). At least three subjects will be enrolled at successive dose levels (DL) to assess for dose-limiting toxicity (DLT) during the first cycle of treatment. Subjects will receive SL-172154 intravenously (IV) according to Schedule 1 or Schedule 2 until disease progression, unacceptable toxicity, or withdrawal of consent. 10 mg / kg is currently enrolling.

[0295] The main inclusion criteria were: Locally advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer. Refractory to existing therapy(ies) and platinum-ineligible. Subjects with homologous recombination deficiency-positive disease must have previously received a PARPi with or without bevacizumab. 18 years or older ECOG performance status 0 or 1 Measurable disease per RECIST v1.1 The main exclusion criteria were: Failure to first-line platinum therapy, defined as progression during or within one month of upfront platinum therapy Prior treatment with anti-CD47 or anti-SIRPα targeted agents or CD40 agonists. History of autoimmune disease or active pneumonia Concomitant use of systemic corticosteroids or other immunosuppressants

[0296] Subject characteristics are shown in Table 4. [Table 4]

[0297] Fifteen subjects, median age 67 years (range 33-79 years) with a median of 5 prior systemic therapies (range 2-7), were treated with IV SL-172154 across 4 dose levels on 2 schedules. Thirteen of the 15 subjects had an ECOG PS of 1 at baseline. Six subjects were treated on schedule 1 (days 1, 8, 15, 29, every 2 weeks) at doses of 0.1 mg / kg (n=3) and 0.3 mg / kg (n=3). Nine subjects were treated on schedule 2 (weekly) at doses of 0.3 mg / kg (n=3), 1.0 mg / kg (n=3), and 3.0 mg / kg (n=3). Most of the subjects had primary ovarian cancer (n=9; 60%), FIGO stage IV (n=9; 60%), high-grade disease (n=11; 73%), and histologic evidence of serous carcinoma (n=11; 73%), as shown in Table 1. Adverse events are listed in Table 5. [Table 5]

[0298] No DLTs were observed with SL-172154 at doses ranging from 0.1 mg / kg to 3.0 mg / kg on any schedule. Fifteen subjects (100%) experienced adverse events (AEs) during treatment. The most common AEs (all causalities) occurring in ≥3 subjects were fatigue, infusion reactions (IRRs), nausea, diarrhea, decreased appetite, dehydration, and pruritus (Table 2). Fourteen (93%) subjects had treatment-related AEs (TRAEs). The most common TRAEs occurring in ≥2 subjects were IRRs (n=8; 53%), fatigue (n=7; 47%), nausea (n=4; 27%), decreased appetite (n=3; 20%), chills (n=2; 13%), diarrhea (n=2; 13%), and dyspnea (n=2, 13%). No TRAEs of grade ≥G3 were reported. Eight (53%) subjects had infusion reactions (IRRs) at the 0.3 mg / kg (n=3), 1.0 mg / kg (n=2), and 3.0 mg / kg (n=3) doses; one IRR event was G3 and considered attributable to iron infusion, 14 IRRs were G2 in severity, and two IRRs were G1 in severity. The IRRs were manageable with premedication and did not prevent completion of IV dosing or lead to discontinuation of SL-172154. Thirteen (87%) subjects discontinued SL-172154, including 12 due to radiological or clinical progression and one who elected to discontinue treatment.

[0299] Figure 3 shows tumor response and duration of treatment. Among the 14 subjects with post-baseline scans evaluating efficacy, the best responses were as follows: - SD, n=4 -PD, n=9 - NE, n=1 (subject had SD but did not meet the protocol-specified minimum interval for SD) - 1 subject (3 mg / kg) did not reach the first on-treatment disease assessment at Week 8.

[0300] Pharmacokinetics: ·Maximum concentration (C max ) and the area under the curve extrapolated from time 0 to infinity (AUC inf) increased disproportionately with increasing dose. Clearance decreased with increasing dose. PK appeared to be biphasic at 1.0 and 3.0 mg / kg. The loss phase of the curve was not fully characterized at the doses tested.

[0301] Figures 4A-D show reproducible increases in serum cytokines following repeated dosing of SL-172154. Plasma was prepared from subject blood draws at the indicated times. Cytokine levels were measured using a multiplex ECL ELISA method, and cytokines at selected dose levels are shown. The proinflammatory chemokines CCL2 (MCP-1) (Figure 4A), CCL4 (MIP-1β) (Figure 4B), CCL3 (MIP-1α) (Figure 4C), and CCL22 (MDC) (Figure 4D) showed dose-dependent increases in plasma levels at all measurements following infusion. These increases were of equal duration and magnitude across all infusion intervals.

[0302] Figures 5A and 5B show a dose-dependent and reproducible increase in serum IL-12. Figure 5A shows subject levels of interleukin 12 (IL-12), a mediator of TH1 proinflammatory responses, over time, which is representative of the cyclic effector cytokine responses observed in study subjects. Figure 5B shows the median response (horizontal bar) upon the first infusion, which appears preliminarily to be dose-dependent.

[0303] Figures 6A and 6B show that SL-172154 preferentially binds to CD47 on leukocytes but not RBCs. Figure 6A shows CD47 receptor occupancy (RO) on both red blood cells (RBCs) and white blood cells (WBCs, white blood cells) as assessed by fluorescence-activated cell sorting (FACS) analysis using whole blood. One hour post-infusion on cycle 1, day 1 (C1D1), the median CD47 RO on leukocytes (horizontal bar) is approximately 80%. Figure 6B shows that CD47 RO on erythrocytes is less than 5% at all dose levels.

[0304] Figures 7A-C show that SL-172154 stimulates B cell margination and activation in a dose-dependent manner. B cells represent a large pool of circulating immune cells expressing high levels of CD40. A fluorescence-activated cell sorting (FACS) panel was designed to examine CD40 receptor occupancy as well as activation and maturation status. With C1D1, nearly all (~80%) CD40+ B cells marginate, i.e., are released from the circulation, within 1 h after infusion. Figure 7A shows that the median frequency of marginating cells increases in a dose-dependent manner (horizontal bars). Receptor engagement is ~100% at all dose levels (data not shown). Figure 7B shows that the median B cell frequency returns to pre-infusion levels by the next infusion, maintaining a cyclical pattern of release and return with each infusion cycle. Figure 7C shows that returning B cells display an increase in the costimulatory marker CD86 and maturation marker CD95, suggesting that SL-172154 can induce a phenotypic change. Similarly, CD14+ monocytes marginate, i.e., exit the circulation within 1 h after infusion, returning to pre-infusion levels by the next infusion, maintaining a cyclical pattern of entry and exit from the circulation with each infusion cycle. The observed margination pattern is driven primarily by CD86+ classical and non-classical monocytes (data not shown).

[0305] Figures 8A and 8B show distinct profiles of TNFα and interleukin-6 (IL-6) in comparison to CD40 mAb. Figure 8A shows the induction of TNFα at various doses of CP-870,893 (left panel) or SL-172154 (right panel). Figure 8B shows the induction of IL-6 at various doses of CP-870,893 (left panel) or SL-172154 (right panel). Data for CP-870,893 are taken from Vonderheide et al., J Clin Oncol 25:876-883 (2007). These results, in particular, show that SL-172154 does not induce TNFα and interleukin-6 (IL-6) in comparison to CD40 mAb. Dose-limiting toxicity (DLT) is believed to be due to cytokine release syndrome (CRS), which limits dose escalation of CD40 agonist mAbs. Interestingly, no significant increase in TNFα and IL-6 has been observed with SL-172154. As a result, SL-172154 is currently administered at a dose 10 times higher than CP-870,893.

[0306] Figures 9A and 9B show that SL-172154 induces innate immune responses in the tumor microenvironment (TME). Figure 9A shows immunohistochemistry analysis of biopsy samples from patient A before and after administration of SL-172154. Monocytes were detected by staining for CD68, a protein highly expressed in monocytic cells. Figure 9B shows upregulation of activation markers CD40 and MHC class II in the TME in tumor biopsies after treatment with SL-172154 compared to pre-treatment biopsies.

[0307] Figure 10A and Figure 10B show that SL-172154 induces adaptive immune responses in the tumor microenvironment (TME). Figure 9A shows CD8+ cells, granzyme B+ cells, CD68+ cells, and Ki67+ cells in biopsy samples from patient A before and after administration of SL-172154. Compared to the pre-treatment biopsy sample, the post-treatment biopsy sample had increased CD8+ cells, granzyme B+ cells, CD68+ cells, and Ki67+ cells. Figure 9B is a graph comparing the tumor proportion score (TPS) and combined positive score (CPS). Induction of PD-L1 in immune cells is a result of the activation of CD8+ T cells.

[0308] These results suggest that SL-172154 was well tolerated with no DLTs or evidence of anemia, thrombocytopenia, liver dysfunction, cytokine release syndrome, or pneumonitis. Dose escalation will continue at 10 mg / kg. Preliminary PK parameters for SL-172154 suggest target-mediated pharmacokinetics via receptor binding. At the doses tested, high receptor occupancy of SL-172154 on CD47+ leukocytes was observed with minimal binding to RBCs. SL-172154 binding to CD40+ B cells and monocytes resulted in rapid activation and margination following infusion. Cyclic increases in innate and adaptive serum cytokines were consistent with CD40 receptor binding and activation. There was no increase in IL-6 or TNFα and no evidence of a bell-shaped dose response. SL-172154 was well tolerated at doses that saturate both CD40 and CD47, with evidence of on-target PD activity that has not yet plateaued, justifying further dose escalation. Without wishing to be bound by theory, these results further indicate that SL-172154 induces both innate and adaptive immune responses in the tumor microenvironment (TME).

[0309] Figure 11 shows the planned clinical development strategy for SL-172154, including trials of SL-172154 monotherapy in ovarian cancer, SL-172154 + liposomal doxorubicin combination therapy in ovarian cancer, SL-172154 + azacitidine + venetoclax combination therapy in AML, SL-172154 + azacitidine combination therapy in HR-MDS, and SL-172154 + azacitidine combination therapy in TP53 mutant AML.

[0310] Example 2: Increased expression of CD80 in tumors following administration of SIRPα-Fc-CD40L chimeric protein (SL-172154) SL-172154 was administered intratumorally to ovarian cancer patients. Tumor biopsies were taken from the patients before and after administration of SL-172154. Biopsies were analyzed to determine CD80 expression in the tumors. As shown in FIG. 12, biopsies taken after administration of SL-172154 showed increased abundance of CD80+ cells and / or CD80 expression in tumors after administration of SL-172154, compared to biopsies taken before administration of SL-172154.

[0311] Incorporation by Reference All patents and publications referenced herein are hereby incorporated by reference in their entirety.

[0312] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein should be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior invention.

[0313] All headings used herein are for organizational purposes only and are not intended to limit the disclosure in any manner The contents of any individual section may be equally applicable to all sections.

[0314] Equivalent While the invention has been disclosed in relation to specific embodiments thereof, it is capable of further modifications, and it is to be understood that this application is generally intended to cover any variations, uses, or adaptations of the invention in accordance with the principles of the invention, including such departures from the disclosure as are known or within the practice in the art to which this invention pertains and which may be applicable to the essential features described above, as well as departures from the disclosure as will fall within the scope of the appended claims.

[0315] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described specifically herein which equivalents are intended to be encompassed within the scope of the following claims.

Claims

1. 1. A method for treating cancer in a human subject, the method comprising: (i) the general structure N-terminus-(a)-(b)-(c)-C-terminus, During the ceremony, (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)); (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain; (c) administering to the human subject a first dose of a chimeric protein having said general structure, wherein a second domain comprises the extracellular domain of human CD40 ligand (CD40L); wherein a background level of cells is measured in a pre-administration biological sample obtained from the subject prior to administration of the first dose, the cells being selected from one or more of CD80+ cells, CD8+ cells, Granzyme B+ cells, CD68+ cells, Ki67+ cells, and PD-L1+ immune cells; (ii) if the level of the cells after administration is higher than the background level of the cells, administering to the human subject a second dose of the chimeric protein; The method, wherein the second dose is administered at least about 48 hours after administration of the first dose.

2. 2. The method of claim 1, wherein the biological sample is selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, peritoneal fluid, tissue or fine needle biopsy sample, cell-containing body fluids, suspended nucleic acid, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymphatic fluid, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or lavage fluid, aspirate, scraping, bone marrow specimen, biopsy specimen, and surgical specimen.

3. 3. The method of claim 2, wherein the biological sample is a biopsy or a surgical specimen, optionally wherein the biological sample is a tumor biopsy or a tumor surgical specimen.

4. 4. The method of claim 3, wherein the tumor biopsy or tumor surgical specimen is from a tumor selected from ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN).

5. The method of any one of claims 1 to 4, wherein the level of said cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

6. 6. The method of claim 5, wherein the level of said cells is measured by contacting said sample with an agent that specifically binds to one or more of CD80, CD8, Granzyme B, CD68, Ki67, and PD-L1.

7. The method of claim 6 , wherein the agent that specifically binds to the one or more molecules is an antibody or a fragment thereof.

8. The method of claim 7, wherein the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof.

9. 6. The method of claim 5, wherein the level of said cells is measured by contacting said sample with an agent that specifically binds to one or more nucleic acids encoding one or more of CD80, CD8, Granzyme B, CD68, Ki67, and PD-L1.

10. The method of claim 9, wherein the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe.

11. 1. A method for treating cancer in a human subject, the method comprising: (i) the general structure N-terminus-(a)-(b)-(c)-C-terminus, During the ceremony, (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)); (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain; (c) administering to the human subject a first dose of a chimeric protein having said general structure, wherein a second domain comprises the extracellular domain of human CD40 ligand (CD40L); wherein background levels and / or activity of B cells and / or CD40+ cells in a first biological sample from the subject prior to administration of the first dose is measured; a second biological sample obtained from the subject following administration of the first dose is obtained, the level and / or activity of B cells and / or CD40+ cells being measured N hours after administration, where N is a number between 1 and 24, and the level and / or activity of B cells and / or CD40+ cells N hours after administration is lower than a background level and / or activity of B cells and / or CD40+ cells; measuring the level and / or activity of B cells and / or CD40+ cells in a third biological sample obtained from the subject following administration of the first dose M days after administration, where M is a number between 1 and 28; (ii) administering to the human subject a second dose of the chimeric protein if the level and / or activity of B cells and / or CD40+ cells M days after said administration is at least about 50% greater than the level and / or activity of B cells and / or CD40+ cells N hours after said administration; The method, wherein the second dose is administered at least about 48 hours after administration of the first dose.

12. N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1; and / or 12. The method of claim 11, wherein M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2.

13. N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1; and 12. The method of claim 11, wherein M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2.

14. 14. The method of any one of claims 11 to 13, wherein the level and / or activity of B cells and / or CD40+ cells N hours after said administration is higher than the background level and / or activity of said B cells and / or CD40+ cells.

15. 14. The method of any one of claims 11 to 13, wherein the level and / or activity of B cells and / or CD40+ cells N hours after said administration is lower than the background level and / or activity of said B cells and / or CD40+ cells.

16. 14. The method of any one of claims 11 to 13, wherein the level and / or activity of B cells and / or CD40+ cells N hours after said administration is within about 10%, about 20%, about 30%, or about 40% of the background level and / or activity of said B cells and / or CD40+ cells.

17. 12. The method of claim 11, wherein the first biological sample, the second biological sample, and the third biological sample are independently selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, peritoneal fluid, tissue or fine needle biopsy sample, cell-containing bodily fluids, suspended nucleic acid, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymphatic fluid, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or lavage fluid, aspirate, scraping, bone marrow specimen, biopsy specimen, and surgical specimen.

18. 20. The method of claim 17, wherein the first biological sample, the second biological sample, and the third biological sample are blood.

19. 19. The method of any one of claims 11 to 18, wherein the level and / or activity of B cells and / or CD40+ cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

20. 20. The method of claim 19, wherein the level and / or activity of B cells and / or CD40+ cells is measured by contacting the sample with an agent that specifically binds to CD40 and / or a B cell marker.

21. 21. The method of claim 20, wherein the B cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45R, CD86, CD95, IgM, IgD, and CD40.

22. 22. The method of claim 20 or claim 21, wherein the agent that specifically binds to the one or more molecules is an antibody or a fragment thereof.

23. 23. The method of claim 22, wherein the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof.

24. 20. The method of claim 19, wherein the level and / or activity of B cells and / or CD40+ cells is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding CD40 and / or a B cell marker.

25. 25. The method of claim 24, wherein the B cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45R, CD86, CD95, IgM, IgD, and CD40.

26. 26. The method of claim 24 or claim 25, wherein the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe.

27. 1. A method for treating cancer in a human subject, the method comprising: (i) the general structure N-terminus-(a)-(b)-(c)-C-terminus, During the ceremony, (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)); (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain; (c) administering to the human subject a first dose of a chimeric protein having said general structure, wherein a second domain comprises the extracellular domain of human CD40 ligand (CD40L); wherein a background amount and / or activity of a cytokine selected from CCL2, CXCL9, CXCL10, IFNα, IL15, IL23, IL-12, MCP-1, MIP-1β, MIP-1α, and MDC is measured in a first biological sample taken from the subject prior to administration of the first dose; a second biological sample taken from the subject following administration of the first dose is examined to determine the amount and / or activity of the cytokine N hours after administration, where N is a number between 1 and 24, and the amount and / or activity of the cytokine N hours after administration is greater than a background amount and / or activity of the cytokine; the amount and / or activity of the cytokine is measured in a third biological sample taken from the subject after administration of the first dose M days after administration, where M is a number between 1 and 28; (ii) administering to the human subject a second dose of the chimeric protein if the amount and / or activity of the cytokine M days after said administration is at least about 30% lower than the amount and / or activity of the cytokine N hours after said administration; The method, wherein the second dose is administered at least about 48 hours after administration of the first dose.

28. N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1; and / or 28. The method of claim 27, wherein M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2.

29. N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1; and 28. The method of claim 27, wherein M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2.

30. The method of any one of claims 27 to 29, wherein the amount and / or activity of said cytokine N hours after said administration is higher than the background amount and / or activity of said cytokine.

31. The method of any one of claims 27 to 29, wherein the amount and / or activity of said cytokine N hours after said administration is lower than the background amount and / or activity of said cytokine.

32. 30. The method of any one of claims 27 to 29, wherein the amount and / or activity of the cytokine N hours after the administration is within about 10%, about 20%, about 30%, or about 40% of the background amount and / or activity of the cytokine.

33. 28. The method of claim 27, wherein the first biological sample, the second biological sample, and the third biological sample are independently selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, peritoneal fluid, tissue or fine needle biopsy sample, cell-containing bodily fluids, suspended nucleic acid, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymphatic fluid, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or lavage fluid, aspirate, scraping, bone marrow specimen, biopsy specimen, and surgical specimen.

34. 34. The method of claim 33, wherein the first biological sample, the second biological sample, and the third biological sample are blood.

35. The method according to any one of claims 27 to 34, wherein the amount and / or activity of said cytokine is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

36. 36. The method of claim 35, wherein the amount and / or activity of the cytokine is measured by contacting the sample with an agent that specifically binds to the cytokine.

37. 37. The method of claim 36, wherein the agent that specifically binds to the one or more molecules is an antibody or a fragment thereof, optionally wherein the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof.

38. 36. The method of claim 35, wherein the amount and / or activity of the cytokine is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding the cytokine.

39. 39. The method of claim 38, wherein the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe.

40. 40. The method of any one of claims 1-39, wherein the second dose is administered at least about 3 days, or at least about 4 days, or at least about 5 days, or at least about 6 days, or at least about 7 days, or at least about 8 days, or at least about 9 days, or at least about 10 days, or at least about 14 days, or at least about 21 days, or at least about 28 days after administration of the first dose.

41. 1. A method for assessing the efficacy of a cancer treatment in a subject in need of treatment, the subject having cancer, the method comprising: (i) obtaining a biological sample from the subject receiving a first dose of a chimeric protein; wherein the chimeric protein is having the general structure N-terminus-(a)-(b)-(c)-C-terminus, During the ceremony, (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)); (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain; (c) a second domain comprising the extracellular domain of human CD40 ligand (CD40L); a background level and / or activity of cells in a biological sample obtained from the subject prior to administration of the first dose is measured, the cells being selected from one or more of CD80+ cells, CD8+ cells, Granzyme B+ cells, CD68+ cells, Ki67+ cells, and PD-L1+ immune cells; (ii) measuring the level and / or activity of said cells in said biological sample following administration; and (iii) determining that the chimeric protein is effective if the level and / or activity of the cells after administration is higher than the background level and / or activity of the cells.

42. 1. A method for selecting a subject for treatment with a cancer therapy, comprising: (i) obtaining a biological sample from the subject receiving a first dose of a chimeric protein; wherein the chimeric protein is having the general structure N-terminus-(a)-(b)-(c)-C-terminus, During the ceremony, (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)); (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain; (c) a second domain comprising the extracellular domain of human CD40 ligand (CD40L); a background level and / or activity of cells in a biological sample obtained from the subject prior to administration of the first dose is measured, the cells being selected from one or more of CD80+ cells, CD8+ cells, Granzyme B+ cells, CD68+ cells, Ki67+ cells, and PD-L1+ immune cells; (ii) measuring the level and / or activity of said cells in said biological sample following administration; and (iii) selecting the subject for treatment with the chimeric protein if the level and / or activity of the cells after the administration is higher than the background level and / or activity of the cells.

43. 43. The method of claim 41 or claim 42, wherein the biological sample is selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, peritoneal fluid, tissue or fine needle biopsy sample, cell-containing body fluids, suspended nucleic acid, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, stool, lymphatic fluid, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or lavage fluid, aspirate, scraping, bone marrow specimen, biopsy specimen, and surgical specimen.

44. 44. The method of claim 43, wherein the biological sample is a biopsy sample or a surgical specimen.

45. 45. The method of claim 44, wherein the biological sample is a tumor biopsy or a tumor surgical specimen.

46. 46. ​​The method of claim 45, wherein the tumor biopsy or tumor surgical specimen is from a tumor selected from ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN).

47. 47. The method of any one of claims 41 to 46, wherein the levels of said cells are measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

48. 48. The method of claim 47, wherein the level of said cells is measured by contacting said sample with an agent that specifically binds to one or more molecules selected from CD80, CD8, Granzyme B, CD68, Ki67, and PD-L1.

49. 49. The method of claim 48, wherein the agent that specifically binds to the one or more molecules is an antibody or a fragment thereof.

50. 50. The method of claim 49, wherein the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof.

51. 48. The method of claim 47, wherein the level of said cells is measured by contacting said sample with an agent that specifically binds to one or more nucleic acids encoding one or more of CD80, CD8, Granzyme B, CD68, Ki67, and PD-L1.

52. 52. The method of claim 51, wherein the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe.

53. 1. A method for assessing the efficacy of a cancer treatment in a subject in need of treatment, the subject having cancer, the method comprising: (i) obtaining a first biological sample taken from the subject receiving a first dose of a chimeric protein; wherein the chimeric protein is having the general structure N-terminus-(a)-(b)-(c)-C-terminus, During the ceremony, (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)); (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain; (c) a second domain comprising the extracellular domain of human CD40 ligand (CD40L); (ii) measuring the background level and / or activity of B cells and / or CD40+ cells in said first biological sample; and (iii) obtaining a second biological sample from the subject N hours after administration, where N is a number between 1 and 24, and measuring the level and / or activity of B cells and / or CD40+ cells in the second biological sample N hours after administration; (iv) obtaining a third biological sample from the subject M days after the administration, where M is a number between 1 and 28, and measuring the level and / or activity of B cells and / or CD40+ cells in the third biological sample M days after the administration; (v) determining that the chimeric protein is effective if the level and / or activity of B cells and / or CD40+ cells N hours after the administration is lower than the background level and / or activity of B cells and / or CD40+ cells and / or if the level and / or activity of B cells and / or CD40+ cells M days after the administration is at least about 50% higher than the level and / or activity of B cells and / or CD40+ cells N hours after the administration.

54. 1. A method for selecting a subject for treatment with a cancer therapy, comprising: (i) obtaining a biological sample taken from the subject receiving a first dose of a chimeric protein; wherein the chimeric protein is having the general structure N-terminus-(a)-(b)-(c)-C-terminus, During the ceremony, (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)); (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain; (c) a second domain comprising the extracellular domain of human CD40 ligand (CD40L); (ii) measuring the background level and / or activity of B cells and / or CD40+ cells in said first biological sample; and (iii) obtaining a second biological sample from the subject N hours after administration, where N is a number between 1 and 24, and measuring the level and / or activity of B cells and / or CD40+ cells in the second biological sample N hours after administration; (iv) obtaining a third biological sample from the subject M days after the administration, where M is a number between 1 and 28, and measuring the level and / or activity of B cells and / or CD40+ cells in the third biological sample M days after the administration; (v) selecting the subject for treatment with the chimeric protein if the level and / or activity of B cells and / or CD40+ cells N hours after the administration is lower than background level and / or activity of B cells and / or CD40+ cells and / or if the level and / or activity of B cells and / or CD40+ cells M days after the administration is at least about 50% higher than the level and / or activity of B cells and / or CD40+ cells N hours after the administration.

55. N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1; and / or 55. The method of claim 53 or claim 54, wherein M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2.

56. N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1; and 55. The method of claim 53 or claim 54, wherein M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2.

57. 57. The method of any one of claims 53 to 56, wherein the level and / or activity of B cells and / or CD40+ cells N hours after said administration is higher than the background level and / or activity of said B cells and / or CD40+ cells.

58. 57. The method of any one of claims 53 to 56, wherein the level and / or activity of B cells and / or CD40+ cells N hours after said administration is lower than the background level and / or activity of said B cells and / or CD40+ cells.

59. 57. The method of any one of claims 53-56, wherein the level and / or activity of B cells and / or CD40+ cells N hours after said administration is within about 10%, about 20%, about 30%, or about 40% of the background level and / or activity of said B cells and / or CD40+ cells.

60. 55. The method of claim 53 or claim 54, wherein the first biological sample, the second biological sample, and the third biological sample are independently selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, peritoneal fluid, tissue or fine needle biopsy sample, cell-containing body fluids, suspended nucleic acid, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymphatic fluid, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or lavage fluid, aspirate, scraping, bone marrow specimen, biopsy specimen, and surgical specimen.

61. 61. The method of claim 60, wherein the first biological sample, the second biological sample, and the third biological sample are blood.

62. 62. The method of any one of claims 53 to 61, wherein the level and / or activity of B cells and / or CD40+ cells is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

63. 63. The method of claim 62, wherein the level and / or activity of B cells and / or CD40+ cells is measured by contacting the sample with an agent that specifically binds to CD40 and / or a B cell marker.

64. 64. The method of claim 63, wherein the B cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45R, CD86, CD95, IgM, IgD, and CD40.

65. 65. The method of claim 63 or claim 64, wherein the agent that specifically binds to the one or more molecules is an antibody or a fragment thereof.

66. 66. The method of claim 65, wherein the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof.

67. 63. The method of claim 62, wherein the level and / or activity of B cells and / or CD40+ cells is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding CD40 and / or a B cell marker.

68. 68. The method of claim 67, wherein the B cell marker is selected from CD19, CD20, CD24, CD27, CD34, CD38, CD45R, CD86, CD95, IgM, IgD, and CD40.

69. 69. The method of claim 67 or claim 68, wherein the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe.

70. 1. A method for assessing the efficacy of a cancer treatment in a subject in need of treatment, the subject having cancer, the method comprising: (i) obtaining a first biological sample taken from the subject receiving a first dose of a chimeric protein; wherein the chimeric protein is having the general structure N-terminus-(a)-(b)-(c)-C-terminus, During the ceremony, (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)); (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain; (c) a second domain comprising the extracellular domain of human CD40 ligand (CD40L); (ii) measuring the background amount and / or activity of a cytokine selected from CCL2, CXCL9, CXCL10, IFNα, IL15, IL23, IL-12, MCP-1, MIP-1β, MIP-1α, and MDC in the first biological sample; (iii) obtaining a second biological sample taken from the subject N hours after administration, where N is a number between 1 and 24, and measuring the amount and / or activity of the cytokine in the second biological sample N hours after administration; (iv) obtaining a third biological sample taken from the subject M days after administration, where M is a number between 1 and 28, and measuring the amount and / or activity of the cytokine in the third biological sample M days after administration; (v) determining that the chimeric protein is effective if the amount and / or activity of the cytokine N hours after the administration is higher than the background amount and / or activity of the cytokine, and / or if the amount and / or activity of the cytokine M days after the administration is at least about 50% lower than the amount and / or activity of the cytokine N hours after the administration.

71. 1. A method for selecting a subject for treatment with a cancer therapy, comprising: (i) obtaining a biological sample taken from the subject receiving a first dose of a chimeric protein; wherein the chimeric protein is having the general structure N-terminus-(a)-(b)-(c)-C-terminus, During the ceremony, (a) is a first domain comprising the extracellular domain of human signal regulatory protein alpha (CD172a (SIRPα)); (b) is a linker flanking the first domain and the second domain, the linker comprising a hinge-CH2-CH3 Fc domain; (c) a second domain comprising the extracellular domain of human CD40 ligand (CD40L); (ii) measuring the background amount and / or activity of a cytokine selected from CCL2, CXCL9, CXCL10, IFNα, IL15, IL23, IL-12, MCP-1, MIP-1β, MIP-1α, and MDC in the first biological sample; (iii) obtaining a second biological sample taken from the subject N hours after administration, where N is a number between 1 and 24, and measuring the amount and / or activity of the cytokine in the second biological sample N hours after administration; (iv) obtaining a third biological sample taken from the subject M days after administration, where M is a number between 1 and 28, and measuring the amount and / or activity of the cytokine in the third biological sample M days after administration; (v) selecting the subject for treatment with the chimeric protein if the amount and / or activity of the cytokine N hours after the administration is higher than the background amount and / or activity of the cytokine and / or if the amount and / or activity of the cytokine M days after the administration is at least about 50% lower than the amount and / or activity of the cytokine N hours after the administration.

72. N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1; and / or 72. The method of claim 70 or claim 71, wherein M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2.

73. N is less than 12, or less than 8, or less than 6, or less than 4, or less than 3, or less than 2, or less than 1; and 72. The method of claim 70 or claim 71, wherein M is less than 21, or less than 14, or less than 12, or less than 10, or less than 8, or less than 6, or less than 4, or less than 2.

74. 74. The method of any one of claims 70 to 73, wherein the amount and / or activity of said cytokine N hours after said administration is higher than the background amount and / or activity of said cytokine.

75. 74. The method of any one of claims 70 to 73, wherein the amount and / or activity of said cytokine N hours after said administration is lower than the background amount and / or activity of said cytokine.

76. 74. The method of any one of claims 70-73, wherein the amount and / or activity of the cytokine N hours after the administration is within about 10%, about 20%, about 30%, or about 40% of the background amount and / or activity of the cytokine.

77. 72. The method of claim 70 or claim 71, wherein the first biological sample, the second biological sample, and the third biological sample are independently selected from blood, plasma, serum, blood cells, tears, tears, bone marrow, peritoneal fluid, tissue or fine needle biopsy sample, cell-containing body fluids, suspended nucleic acid, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymphatic fluid, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, lavage or lavage fluid, aspirate, scraping, bone marrow specimen, biopsy specimen, and surgical specimen.

78. 78. The method of claim 77, wherein the first biological sample, the second biological sample, and the third biological sample are blood.

79. 79. The method of any one of claims 70 to 78, wherein the amount and / or activity of the cytokine is measured by RNA sequencing, immunohistochemical staining, Western blotting, intracellular Western, immunofluorescence staining, ELISA, and fluorescence activated cell sorting (FACS), or a combination thereof.

80. 80. The method of claim 79, wherein the amount and / or activity of the cytokine is measured by contacting the sample with an agent that specifically binds to the cytokine.

81. 81. The method of claim 80, wherein the agent that specifically binds to the one or more molecules is an antibody or a fragment thereof.

82. 82. The method of claim 81, wherein the antibody is a recombinant antibody, a monoclonal antibody, a polyclonal antibody, or a fragment thereof.

83. 80. The method of claim 79, wherein the amount and / or activity of the cytokine is measured by contacting the sample with an agent that specifically binds to one or more nucleic acids encoding the cytokine.

84. 84. The method of claim 83, wherein the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe.

85. 85. The method of any one of claims 1-84, wherein the first dose of the chimeric protein ranges from about 0.03 mg / kg to 10 mg / kg.

86. 86. The method of claim 85, wherein the first dose is about 0.003, or about 0.01, or about 0.03, or about 0.1, or about 0.3, or about 1, or about 2, or about 3, or about 4, or about 6, or about 8, or about 10 mg / kg.

87. The method of any one of claims 41-86, further comprising administering a second dose of the chimeric protein.

88. 88. The method of claim 87, wherein the second dose is administered at least about 3 days, or at least about 4 days, or at least about 5 days, or at least about 6 days, or at least about 7 days, or at least about 8 days, or at least about 9 days, or at least about 10 days, or at least about 14 days, or at least about 21 days, or at least about 28 days after administration of the first dose.

89. 89. The method of claim 87 or claim 88, wherein the second dose of the chimeric protein ranges from about 0.03 mg / kg to 10 mg / kg.

90. 90. The method of any one of claims 87-89, wherein the second dose is about 0.003, or about 0.01, or about 0.03, or about 0.1, or about 0.3, or about 1, or about 2, or about 3, or about 4, or about 6, or about 8, or about 10 mg / kg.

91. The method of any one of claims 1 to 90, wherein the first domain is capable of binding to a CD172a (SIRPα) ligand.

92. The method of any one of claims 1 to 91, wherein the first domain comprises substantially all of the extracellular domain of CD172a (SIRPα).

93. The method of any one of claims 1 to 92, wherein the second domain is capable of binding to the CD40 receptor.

94. The method of any one of claims 1 to 93, wherein the second domain comprises substantially all of the extracellular domain of CD40L.

95. 95. The method of any one of claims 1 to 94, wherein the linker comprises a hinge-CH2-CH3 Fc domain derived from IgG4.

96. 96. The method of claim 95, wherein the linker comprises a hinge-CH2-CH3 Fc domain derived from human IgG4.

97. 97. The method of any one of claims 1 to 96, wherein the linker comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:

3.

98. 98. The method of any one of claims 1 to 97, wherein the first domain comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:

57.

99. 99. The method of any one of claims 1 to 98, wherein the second domain comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:

58.

100. (a) the first domain comprises the amino acid sequence of SEQ ID NO:57; (b) the second domain comprises the amino acid sequence of SEQ ID NO:58; (c) the linker comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:

3.

101. The method of any one of claims 1 to 100, wherein the chimeric protein further comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:

7.

102. The method of any one of claims 1 to 101, wherein the chimeric protein further comprises the amino acid sequences of SEQ ID NO:5 and SEQ ID NO:

7.

103. 103. The method of any one of claims 1 to 102, wherein the chimeric protein comprises an amino acid sequence that is at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:

61.

104. The method of claim 103, wherein the chimeric protein comprises an amino acid sequence that is at least about 99% identical to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:

61.

105. The method of claim 103 or claim 104, wherein the chimeric protein comprises one, or two, or three, or four, or five, or six, or seven, or eight amino acid mutations with respect to the amino acid sequence of SEQ ID NO:59 or SEQ ID NO:

61.

106. 106. The method of any one of claims 1 to 105, wherein the human subject is afflicted with or suspected of being afflicted with an advanced solid tumor or lymphoma.

107. 107. The method of any one of claims 1 to 106, wherein the human subject is afflicted with or suspected of afflicting with a cancer selected from ovarian cancer, fallopian tube cancer, peritoneal cancer, cutaneous squamous cell carcinoma (CSCC), and squamous cell carcinoma of the head and neck (SCCHN).

108. The method of any one of claims 1 to 107, wherein the human subject has failed one or more platinum-based therapies.

109. The method of claim 108, wherein the human subject is ineligible for further platinum therapy.

110. The method of any one of claims 1 to 108, wherein the human subject is ineligible for platinum therapy.

111. 101. The method of any one of claims 1 to 100, wherein the human subject has not received concomitant chemotherapy, immunotherapy, biological therapy or hormonal therapy, and / or the human subject has received, is resistant to or is ineligible for standard therapy, and / or there is no approved therapy for the cancer that is considered a standard treatment.